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ABSTRACT 
 
Dendritic cells (DCs) are antigen-presenting cells crucial for the initiation and coordination of 
primary adaptive immune responses. Immature DCs (iDCs) express low levels of MHC class II 
and co-stimulatory molecules such as CD80, CD86, and CD40, with high phagocytic capacity 
and limited ability to induce antigen-specific T cell activation. DC maturation is associated 
with up-regulation of co-stimulatory molecules and cytokine production, rendering the DCs 
competent in T cell activation and the elicitation of an immune response. DC function and 
co-stimulatory receptor gene expression are known to be regulated by intracellular redox 
status, NF-B and MAPKs signalling pathways. 
Intracellular reactive oxygen species (ROS) levels influence DC maturation and function. The 
transcription factor, Nrf2, is essential for maintaining intracellular redox homeostasis. In 
response to oxidative stress, Nrf2 induces the transcription of a set of cytoprotective and 
antioxidant genes, including heme oxygenase-1 (HO-1), that are required for detoxification 
of xenobiotics and their reactive metabolites and the nullification of oxidative insult.  
It is now emerging that Nrf2, and its gene product, HO-1, play pivotal roles in regulation of 
immune responses. However, the key signalling mechanisms involved in Nrf2 and HO-1-
mediated altered DC function has not been fully elucidated and requires further 
investigation. In addition, the role of ROS in the absence of Nrf2 or HO-1 activity, in DC 
activation and function has not been investigated. 
Using immature bone marrow-derived DCs (iDCs) from Nrf2+/+ and Nrf2-/-  mice, we 
demonstrate in the first part of the work presented in this thesis, that Nrf2 deficiency in 
iDCs resulted in increased ROS levels, enhanced iDCs co-stimulatory receptor expression, 
and increased iDC-mediated antigen-specific CD8 T cell stimulatory capacity in response to 
an antigenic peptide. 
Using antioxidant vitamins to reset ROS levels in Nrf2-/- iDCs, we show that elevated ROS 
was not responsible for the altered phenotype and function of these DCs. Additionally, using 
appropriate pharmacological inhibitors, we demonstrate that the altered Nrf2-/- iDC  
 
ii 
 
 
 
phenotype and function did not require NF-B, ERK or JNK activity but was dependent on 
p38MAPK-CREB/ATF1 activity. 
Based on these experimental results, we conclude that Nrf2 regulates DC maturation and 
function by modulating intracellular signalling pathways independent of intracellular ROS 
levels. 
In the second part of the study, we demonstrate that inhibition of HO-1 activity in iDCs 
resulted in DCs with raised intracellular ROS levels, a mature phenotype, impaired 
phagocytic and endocytic function, and increased capacity to stimulate antigen-specific CD8 
T cells. Interestingly, our results reveal that the increased ROS levels following HO-1 
inhibition did not underlie the changes in phenotype and functions observed in these iDCs. 
Importantly, we show that the p38MAPK-CREB/ATF1 pathway was involved in the mediation 
of the phenotypic and functional changes arising from HO-1 inhibition. Furthermore, up-
regulation of HO-1 activity rendered iDCs refractory to lipopolysaccharide-induced 
activation of p38MAPK-CREB/ATF1 pathway and DC maturation. Finally, we demonstrate 
that treatment of iDC with the HO-1 substrate, heme, recapitulated the effects that result 
from HO-1 inhibition. Based on these experimental results, we conclude that HO-1 regulates 
DC maturation and function by modulating the p38MAPK-CREB/ATF1 signalling axis. 
Collectively, the work described in this thesis highlights the importance of the redox 
regulators, Nrf2 and HO-1, in controlling DC immune functions. This work supports the basis 
for utilisation of Nrf2 and HO-1 as potential molecular targets for pharmacological 
intervention in disease states that arise from dysregulated redox function and the design of 
new pharmacological strategies aimed at modulating DC function in the therapy of immune 
diseases. 
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1.1 Immunity 
Immunity is broadly defined as the organism’s ability to protect itself from invading 
pathogens. Immunity is mediated by the coordinated response of a large variety of 
immune cells and soluble mediators. Checks and balances also exist within the 
immune system that operate to prevent an attack against the body’s own 
constituents, a phenomenon termed tolerance. Immunity can be generally 
categorized into innate and adaptive (specific or acquired) immunity. 
Innate immunity represents the initial rapid defensive response against 
encountered microbes. This was previously believed to be a non-specific immune 
response, characterised by the engulfment and digestion of microorganisms and 
foreign substances via myeloid phagocytic cells. However, recent advances in 
immunology showed that innate immunity has considerable specificity in 
discriminating between pathogens versus host components and that it can be a 
prerequisite for the triggering of adaptive immunity. Innate immunity is present 
from birth and includes physical barriers (e.g. intact skin and mucous membranes), 
chemical barriers (e.g. gastric acid, digestive enzymes and bacteriostatic fatty acids 
of the skin), phagocytic cells, antigen presenting cells and the complement system 
(Beutler, 2004; Kimbrell and Beutler, 2001). 
The fundamental functional distinction between innate and adaptive immune cells 
is the acquisition of memory by adaptive immune cells (but not by innate cells) 
which is specific to a single antigen or to a group of closely related antigens (Lo et 
al., 1999). Adaptive immunity is characterised by specificity and memory with slow 
onset in comparison to the rapid innate arm and is mediated by T and B 
lymphocytes. 
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1.2 Innate immune cells  
Innate immune response is mostly dependent upon cells of myeloid origin that can 
engulf and destroy pathogens. While these cells have independent capabilities to 
deal with such infectious challenges, they have also evolved to be more effective in 
conjunction with cells and proteins of the adaptive immune system. For example, 
lymphoid cells of the adaptive immune system produce antibodies that opsonise 
bacteria which can then be destroyed by innate immune cells (Beutler, 2004). 
These myeloid cells include mononuclear and polymorphonuclear phagocytes. The 
mononuclear phagocytes are the macrophages and monocytes and under 
inflammatory conditions monocytes can also mature into a subtype of dendritic 
cells which are discussed in section 1.3. The mononuclear phagocytes are 
competent at presenting antigens to T cells of the adaptive immune system. 
Macrophages are widely distributed throughout the body mostly in the lining 
parenchyma of major organs (e.g. heart, brain, lung, and liver) where they come in 
contact with invasive pathogens. They are morphologically diverse with specialised 
tissue-resident cell types. Dendritic cells follow similar distribution and function and 
also exhibit a variety of morphologies (e.g. the Langerhans cell of the skin; the 
plasmacytoid dendritic cell of the spleen). Although they exist as a minority 
population among the mononuclear phagocytes, DCs are capable of initiating 
adaptive immune responses to most pathogens by presenting a wide range of 
antigens to CD4+ and CD8+ T cells (Banchereau and Steinman, 1998). 
The polymorphonuclear phagocytes include neutrophils, basophils, and eosinophils. 
They are of importance in the control of infection as they have a specialised ability 
to destroy microbes by a broad array of effector mechanisms including the 
production of pro-inflammatory mediators (Herant et al., 2003; Legrand et al., 
2008; Wedemeyer et al., 2000). 
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The innate immune system also contains cells that are of a lymphoid origin called 
natural killer cells (NK cells) that are morphologically similar to lymphocytes. 
Natural killer cells target and lyse abnormal/viral-infected cells which have 
low/absent expression of MHC class I cell surface molecules with no prior specific 
sensitization of the host (unlike T cells). They play important roles in anti-tumour 
and anti-viral immunity (Ljunggren and Karre, 1990). 
Dendritic cells are one of the crucial components of the immune system due to 
their essential role in the induction and control of T cell mediated immunity, as well 
as in the modulation of responses elicited by B cells and NK cells. 
 
1.3 Dendritic cells (DCs) 
Dendritic cells are professional antigen processing cells (APCs) with characteristic 
abilities in the acquisition, processing, and presentation of antigens to naive T cells 
in order to produce an adaptive immune response; therefore, they represent 
critical mediators of both immunity and tolerance (Banchereau and Steinman, 
1998). They possess long membrane extensions that resemble dendrites of nerve 
cells (hence the name), which allow them to intimately interact with antigens and 
other cells. Dendritic cells play an important role in linking the innate arm of the 
immune system to the adaptive immune system. They do this by their exclusive 
ability to induce the differentiation of naïve T cells into effector or memory cells 
each with its unique function and cytokine profile (Banchereau et al., 2000). The 
importance of DCs is not only focused on their ability to induce competent immune 
responses against harmful pathogen-derived antigens (e.g. peptides derived from 
virus and bacteria), but also to avoid autoimmunity or provide tolerance to self-
antigens (Guermonprez et al., 2002). 
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1.3.1 Origin and development of DCs 
Dendritic cells develop from myeloid or lymphoid precursors (Ardavin et al., 2001). 
Dendritic cells were considered previously to be solely of myeloid origin; however, 
increasing evidences have shown that DCs can also be generated from lymphoid 
progenitors (Karsunky et al., 2003). Differentiation and development of 
haematopoietic stem cells (HSCs), during the process of haematopoiesis, gives rise 
to common myeloid precursors (CMPs) and common lymphoid precursors (CLPs) as 
shown in Figure 1.1.  
 
Figure 1.1. Dendritic cells (DCs) differentiation from pluripotent haematopoietic 
stem cells (HSCs). In the bone marrow, the HSCs differentiate into common 
lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs). CMPs, 
within bone marrow, can be further differentiated into monocytes and pre-DCs. 
Monocytes and pre-DCs subsequently leave the bone marrow and enter the blood 
stream and migrate to lymphoid organs and peripheral tissues, where they 
differentiate into lymphoid DCs and tissue-resident DCs. In addition to CMPs, CLPs 
also have the potential to give rise to DCs, but their contribution is not well 
understood. Adapted from Kushwah and Hu 2011. 
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Macrophages, monocytes, granulocytes, megakaryocytes and erythrocytes 
originate from CMP, whilst NK cells, T cells and B cells originate from CLP (Akashi et 
al., 2000; Kondo et al., 1997). CMPs give rise to macrophage and dendritic cell 
precursors (MDPs) and these further differentiate into common DC-restricted 
progenitors (CDPs) (Cravens and Lipsky, 2002). Additional differentiation of CDPs 
yields either plasmacytoid DC (pDC) or pre-DC, which then migrate to various 
lymphoid tissues in order to differentiate into myeloid DC subsets. The 
differentiation into these subsets is programmed to be specific to particular tissue 
environments (Ardavin, 2003). Selective expression of cell surface proteins 
(markers) allows us to distinguish the multitude of DC subsets. For example, human 
pDCs express different cell markers such as CD123, BDCA-2, and BDCA-4, but do not 
express CD11c, while in mice pDCs are positive for CD11c, B220, PDCA-1 and Siglec-
H (Kvale et al., 2006). 
In order to study the function of DCs, many protocols have been developed to 
generate DCs in vitro from both human and murine cell sources. In vitro generation 
of DCs requires the culturing of progenitor cells present in the bone marrow and 
peripheral blood in the presence of cytokines like GM-CSF, IL-4, Flt3L, TNF- and 
TGF-β (Lutz et al., 1999; Merad and Manz, 2009). For example, mouse bone 
marrow-derived DCs can be obtained in vitro by culturing bone marrow precursors 
with GM-CSF for 7-12 days with frequent feedings at days 3, 6, 8 and 10. The 
resultant DC has a phenotype of CD11c+, CD8-, MHC class IIlow and CD86low (Lutz et 
al., 1999). Mouse DCs can also be isolated from spleen, a procedure which involves 
tissue digestion resulting in a DC population expressing MHC class IIhigh and CD8+ 
(Vremec et al., 1992). Human blood monocytes can be differentiated in vitro into 
cells expressing an identical phenotype and functional features of blood DCs under 
the effect of a triple combination of IL- 4, IFN- and GM-CSF (Xu et al., 1995) or 
from human cord blood CD34+ hematopoietic progenitors cultured with GM-CSF 
and TNF- (Caux et al., 1996). 
7 
 
DCs possess a significant functional flexibility for either inducing immunity or 
tolerance. The induction of tolerance versus immunity is dependent on distinct DC 
development and activation states (Lutz and Schuler, 2002). Such induction is 
predicated on the two-signal model of T cell stimulation, in which a productive T 
cell immune response requires specific recognition of major histocompatibility 
complex (MHC)/peptide complexes by the T cell receptor (TCR) (signal 1) along with 
signalling through co-stimulatory molecules (signal 2). Cytokines produced by 
activated DCs help to shape the resultant T cell immune response (signal 3). There is 
cumulative evidence to indicate that immature myeloid and plasmacytoid DCs (see 
section 1.3.2.1) induce T cell tolerance (Jonuleit et al., 2001; Mahnke et al., 2002), 
whereas mature DC types (see section 1.3.2.2) have been shown to induce 
immunity (Cella et al., 1997b; Cerundolo et al., 2004). 
 
1.3.2 Immature versus mature DCs 
Based on their phenotypic and functional state (depending on their shape, antigen 
acquisition capacity, cell surface markers expression and antigen specific T cell 
activation; see Figure 1.2), DCs exist in two distinct forms: immature DCs (iDCs) and 
mature DCs (mDCs) (Banchereau et al., 2000). 
1.3.2.1 Immature DCs 
Immature DCs reside in the body’s peripheral tissues (that are in contact with the 
external environment) such as the skin, the lining of nose, lungs, and the 
gastrointestinal tract (Banchereau et al., 2000). They detect pathogens, tissue 
damage and inflammation, and serve as sentinels and information carriers. 
Immature DCs exhibit a highly organized cytoskeleton, focal adhesion plaques, and 
slow motility with specialisation in capturing and processing antigens. These cells 
can efficiently capture pathogens, apoptotic cells, and antigens from the 
8 
 
environment through phagocytosis, macropinocytosis, or endocytosis. Immature 
DCs express low levels of MHC class II and co-stimulatory molecules (CD40, CD80, 
and CD86) on their surface (as shown in Figure 1.2), hence they are considered to 
be unable to present antigens efficiently to T cells and initiate an effective immune 
response (Banchereau et al., 2000). In steady-state conditions, DCs maintain 
themselves in the peripheral tissue in an immature state and they express low 
amounts of MHC and co-stimulatory molecules. Immature DCs that migrate to 
lymphoid tissues and present self-antigens to T cells induce T cell anergy instead of 
T cell activation which forms a basis for tolerance (Hawiger et al., 2001). 
Figure 1.2. Dendritic cells (DCs) have central role in the immune system by 
generating antigen-specific T cells from naïve T cells. DCs sense and take up 
antigens via various PRRs in peripheral tissues, process them intracellularly into 
proteolytic peptides, and load these peptides onto major histocompatibility 
complex (MHC) class I and II molecules and become mature DCs. Subsequently, 
mature DCs migrate to secondary lymphoid organs and become competent to 
present antigens to T lymphocytes to generate effector T cells. Adopted from Sato 
2007. 
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1.3.2.2 Mature DCs 
Maturation of DCs is a process initiated by the engagement of their surface 
receptors such as Toll-like receptors, Fc receptors, cytokine receptors or CD40 with 
their respective ligands (Ardavin, 2003). Mature DCs highly express MHC class II and 
co-stimulatory molecules (CD80, CD86, and CD40) on their surface and this is 
associated with high antigen presentation and T cell activating ability (Banchereau 
and Steinman, 1998). Dendritic cell maturation is also accompanied by 
morphological changes including rearrangement of cytoskeleton proteins, loss of 
adhesive structures and possession of high cellular motility. This is accompanied 
with down-regulation of chemokine receptors that bind inflammatory chemokines 
and an up-regulation of the chemokine receptor 7 (CCR7) that binds to the 
chemokines expressed on T cells in lymphoid tissue (Hawiger et al., 2001; Winzler et 
al., 1997). The mature DCs migrate from the peripheral tissues through the afferent 
lymphatics towards the T cell zones of draining lymphoid organs where they have 
the ability to activate antigen-speciﬁc cytotoxic or helper T cells and induce their 
differentiation (Cella et al., 1997b). DC maturation is accompanied by secretion of a 
wide array of cytokines which have a significant influence on the elicited immune 
response. The secreted cytokine profile depends on the antigens or microbe 
product originally encountered by the DC. The cytokine milieu is critically involved 
in selectively directing T cell responses, known collectively as T cell polarisation. 
These instructive cytokines are produced in the early phases of infection and are 
required for the generation of appropriate immune responses to bacteria, virus, 
fungi or parasite infections (Langenkamp et al., 2000). 
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1.4 Antigen acquisition by DCs  
Immature DCs are very efficient at capturing extracellular antigens and molecules 
through several mechanisms. This include: receptor-mediated endocytosis via C-
type lectin receptors (mannose receptor and DEC-205) (Figdor et al., 2002; Jiang et 
al., 1995; Sallusto et al., 1995a), macropinocytosis (uptake of large vesicles of 0.5-3 
µm) mediated by membrane ruffling driven by the actin cytoskeleton or 
macropinocytosis by uptake of small vesicles via clathrin-coated pits (Sallusto et al., 
1995a), phagocytosis of bacteria, apoptotic and necrotic cell fragments and 
particulate matter via Fc receptor types I (CD64) and II (CD32) and scavenger 
receptor (CD36) (Albert et al., 1998; Fanger et al., 1996; Greenberg et al., 2006; 
Rescigno et al., 1999). Endocytosis is measured experimentally through DC uptake 
of fluorescently labelled particles such as dextran beads (Sallusto et al., 1995a). 
Phagocytosis of foreign antigens is enabled through engagement of DC receptors 
such as Fc, scavenger receptors, pathogen-specific receptors (e.g. Toll-like 
receptors), lectins or complement receptors. This is accompanied by actin-
dependent internalization processes and rearrangement of the plasma membrane 
resulting in the formation the phagosome (Jutras and Desjardins, 2005; Niedergang 
and Chavrier, 2004). The remodelling of the cytoskeleton involves key players that 
include small Rho GTPases such as Rac, Cdc42 and RhoA (Hall, 1998a). The rate of 
DC phagocytosis can also be influenced by receptor systems such as TLR or CCR7 
engagement both of which enhance phagocytosis (Doyle et al., 2004; Kikuchi et al., 
2005; West et al., 2004b). While phagocytosis of pathogens by DCs delivers 
antigens to T cells, phagocytosis of apoptotic cells by iDCs suppress immune 
responses and induce self-tolerance by preventing the leaking of inflammatory 
intracellular components as well as through presentation of self-peptides to T cells 
(Banchereau et al., 2000). 
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1.5 Dendritic cell antigen presentation – role of MHC Class I and II 
Dendritic cells (DCs) initiate immune responses through activation of naive T 
lymphocytes. This process requires DCs to take up antigens and cleave them into 
peptides, which are loaded onto highly polymorphic MHC molecules and presented 
to antigen-specific T lymphocytes. On mDCs, antigenic peptides bound to MHC class 
II initiates immunogenic responses by CD4+ T lymphocytes (Banchereau and 
Steinman, 1998), while antigenic peptides bound to MHC class I enable mDCs to 
activate CD8+ T lymphocytes and generate effector cytotoxic T lymphocytes (CTLs) 
that possess anti-viral and anti-tumour activity (Chai et al., 1999; Kemball et al., 
2006). 
1.5.1 MHC class I 
MHC class I molecules are expressed on the surface of virtually all nucleated cells 
including DCs where they serve as the target antigens for CD8+ T cells. Their main 
structure consists of a membrane-integrated glycoprotein ( chain), a small soluble 
protein, β2 microglobulin (2m) with a binding groove that accommodates a short 
peptide usually of 8–10 amino acids (antigenic or self peptides) (Pamer and 
Cresswell, 1998). Endogenous or captured antigens are degraded by the ubiquitin-
proteasome pathway, to generate peptides with appropriate length (8- to 10-amino 
acids) for the transporters associated with antigen processing (TAP) that matches 
distinct peptide preferences of different MHC class I molecules (Rock and Goldberg, 
1999). This process is followed by the loading of peptides onto newly synthesized 
MHC class I molecules within the endoplasmic reticulum. DCs can load antigenic 
peptides on their MHC class I molecules through both an endogenous (generated in 
the cytosol by degradation of cytosolic proteins) and an exogenous pathway 
(through cross-presentation) and present them on the cell surface to CD8+ cytotoxic 
T cells (Rock and Goldberg, 1999). 
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1.5.2 MHC class II 
MHC class II proteins are polymorphic cell surface proteins which present foreign 
antigens to the T cell receptor of T helper cells. They are heterodimers of two 
polypeptide chains (α and β peptide chains) both of which span the membrane. 
These peptide chains are synthesized in the endoplasmic reticulum (ER), where they 
associate with the invariant chain (Ii) which protects the peptide-binding groove of 
the MHC class II heterodimer from being prematurely ﬁlled with self-proteins. MHC 
class II molecules are transported from ER to Golgi complex and accumulate within 
lysosome-related internal membrane vesicles or membrane sheets as intracellular 
compartments known as MHC class II–rich compartments (MIICs). Extracellular 
soluble and particulate antigens engulfed by iDCs are subjected to partial 
proteolysis and targeted to MIISCs (Inaba et al., 1997) where they are loaded on to 
MHC class II molecules and trafficked to the cell surface (Kleijmeer et al., 1995; 
Nijman et al., 1995). The MHC-II transactivator CIITA has been found to act as a 
master-regulator of MHC-II gene expression (Muhlethaler-Mottet et al., 1997). In 
iDCs, class II molecules have a short half-life (about 10 hours) and are rapidly 
degraded and internalized. Conversely, maturation induced stimuli will cause a 
burst of class II synthesis and translocation of the MHC class II-peptide complexes 
to the cell surface with several fold increase in their surface expression of MHC 
class II molecules where they remain stable for days (half- life increases to over 100 
hours) and are available for recognition by CD4+ T cells (Cella et al., 1997a). The 
major contributor for the build-up of MHC class II molecules at the mDCs cell 
surface is the down-regulation of MHC class II degradation and internalization. This 
down-regulation guarantees that the complexes created during maturation process 
will remain on the cell surface for prolonged periods, allowing mature DCs to 
display antigens for a sufficient time. Although there is increase in the cell surface 
MHC class II expression, MHC class II mRNA de novo biosynthesis is turned off 
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during DC maturation and this is due to a remarkably rapid reduction in the 
synthesis of class II transactivator (CIITA) mRNA (Landmann et al., 2001). 
1.6 Activation of T cells by antigen bearing mature DCs  
When a naïve T cell has recognised, via its T cell receptor (TCR), a specific antigen 
presented by the DC, a specialized area of contact between T cell and DC called the 
immunological synapse is formed. This synapse consists of clusters of TCRs with 
MHC-peptides surrounded by a ring of adhesion molecules (Grakoui et al., 1999). 
Signals through the TCR render the T cell fully activated. It will undergo several 
rounds of proliferation resulting in its distinct clonal expansion and functional 
differentiation into effector T cells of either CD4+ T helper cells or CD8+ cytotoxic T 
cells (CTLs) depending on the type of MHC molecules presented on DCs being either 
MHC class II or MHC class I molecules respectively (first signal). Additionally, T cells 
require a second signal for full activation. This second signal comes from co-
stimulatory receptors expressed by DCs (Dhodapkar et al., 2000; Mellman and 
Steinman, 2001). The experimental study of DC induced T cell activation requires 
the use of transgenic systems and these are briefly described in Box 1. 
1.6.1 Role for DC co-stimulatory receptors in T cell activation 
Dendritic cell maturation is characterized by up-regulation in the expression of co-
stimulatory molecules such as CD40, CD80, and CD86 (Hart, 1997). These molecules 
do not initiate antigen-specific T cell responses but rather help in their generation 
and amplification by providing the second signal that is needed for the complete 
activation of T cells. Furthermore, without co-stimulatory molecules, antigen-
specific T cell stimulation will lead to T cell anergy or cell death (Guinan et al., 
1994). Immature DCs present self-antigens to T cells and in the absence of co-
stimulatory molecules results in their deletion or inactivation thus preventing an 
autoimmune response (Bachmann et al., 1999a; Bour-Jordan and Bluestone, 2009). 
Conversely, if self-antigens are presented on DCs expressing high co-stimulatory 
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signals, this may lead to the inappropriate activation of auto-reactive T cells 
resulting in an autoimmune response (Fife and Bluestone, 2008). 
Co-stimulatory molecules expressed on DCs engage with their counterpart 
molecules on T cells and one of the dominant co-stimulatory pathways is the 
CD80/CD86 on DCs with its ligand CD28 on T cells (Fife and Bluestone, 2008; June et 
al., 1994). Binding of CD80/CD86 to CD28 will transmit co-stimulatory signals into T 
cells that lead to amplification of the signalling processes within T cells (Viola et al., 
1999), signiﬁcantly lowering the TCR activation threshold and allowing naive T cells 
to be readily activated (Lenschow et al., 1996). 
1.6.2 Role for DC cytokines in T cell activation and differentiation 
Functional differentiation of naïve T cells into effector T cells is highly influenced by 
the cytokines secreted by the DCs themselves (third signal) (Banchereau et al., 
2000). Additionally, the cytokine environment has an impact on DC functions that 
can be altered by anti-inﬂammatory cytokines such as IL-10 (Buelens et al., 1995; 
De Smedt et al., 1997) and TGF- (Takeuchi et al., 1997) or with steroids (Piemonti 
et al., 1999) or prostaglandin E2 (Kalinski et al., 1998). Cytokines are secreted small 
proteins that are considered to be mediators of immune and inflammatory 
reactions. They may act in an autocrine mode influencing the biology of the cell that 
releases them, or in a paracrine fashion, affecting the biology of adjacent cells. 
Some cytokines are stable enough to act in an endocrine mode, modulating the 
biology of very distant cells from the site of cytokine release (Wang et al., 2004). 
Dendritic cell derived cytokines can govern the type of T cell response that develops 
depending on the type of cytokine they produce. For example IFN- generates TH1 
cells, IL-4 generates TH2 cells or IL-10 generates regulatory T cells (Furio et al., 
2009; Iwasaki and Kelsall, 1999). The cytokines secreted by DCs in response to 
stimulation through different pattern recognition receptors (PRR) include: IL-1β, IL-
6, IL-8, IL-10, IL-12, and TNF- (Dodge et al., 2003; Reis e Sousa et al., 1999; Scanga 
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et al., 2002; Schakel et al., 2002; Sporri and Reis e Sousa, 2005; Trinchieri, 1995). 
The wide range of pathogen recognition by DCs, due to their various PRRs 
expression, result in the variation of cytokines produced thus linking the type of 
pathogen encountered to the type of T cell response elicited.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7 Key signalling pathways involved in DC maturation 
Intracellular signalling cascades are essential for the transduction of DC receptor 
(e.g. PRRs, CD40 and cytokine receptors) engagement to DC maturation. The key 
signalling pathways involved in DC maturation are the nuclear factor kappa B (NF-
B) and the mitogen activated protein kinases (MAPKs). A major trigger for these 
signalling pathways is through the TLRs which are prototype PRRs expressed in 
Box 1: Measurement of antigen-specific T cell responses 
The identification and isolation of monoclonal CD8
+
 T cells of known antigen-specificity 
directly from humans or animals is difficult due to the low copies of T cells expressing the 
same TCR. In order to isolate a specific T cell clone, T cells from an immunised individual are 
subjected to repeated rounds of re-stimulation with the same antigen. Cloning of single 
antigen-specific T cells can be accomplished by the re-culturing of proliferating cells in serial 
dilutions of cultures. To enable the comprehensive study of immune responses of T cells 
bearing known TCRs that recognise specific antigens, a number of transgenic mice have been 
generated (Hogquist et al., 1994; Kurts et al., 1997b; Teague et al., 2004). These TCR 
transgenic mice have T cells that carry a single type of TCR with known antigen-specificity 
(Hogquist et al., 1994). For example, the generation of DO.11.10 , OT-II and OT-I transgenic 
mice allows us to study the activation and proliferation of naive T cell responses to antigens 
derived from ovalbumin in the context of MHC class II (DO.11.10 and OT-II) and MHC class I 
(OT-I). However, the transgenic T cell receptors can mix up peptides with native receptors to 
produce hybrid molecules with specificity against self-antigens. The F5 TCR transgenic mouse 
is another TCR transgenic mouse model that has been extremely useful in studying antigen-
specific CD8
+
 T cell responses (Mamalaki et al., 1993). The generation of a transgenic mouse 
expressing on most T cells a transgenic T cell receptor (termed F5) specific for a peptide 
(termed NP68, aa 366-374) derived from the nucleoprotein (NP) of influenza A virus 
(Mamalaki et al., 1993) allows for robust quantification of T cell responses in the context of 
defined doses of the viral antigenic peptide, NP68. CD8
+
 T cells have been shown to be 
important in viral infection (Butz and Bevan, 1998). Cytotoxic CD8
+ 
T cells are able to directly 
kill virus infected cells by delivering granzymes to the target cells via pores formed by the 
insertion of perforin through the cytoplasmic membrane of target cells. Furthermore, CD8
+ 
T 
cells can mediate target cell apoptosis by engaging Fas (CD95) molecules on the target cells 
with FasL (CD178) expressed on the CD8 T cell surface (Parkin and Cohen, 2001). 
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sentinel cells such as macrophages and dendritic cells. To-date, 13 different types of 
PRRs has been recognised. They can recognize pathogen-associated molecular 
patterns (PAMPs) from microorganisms or danger-associated molecular patterns 
(DAMPs) from damaged tissue (Akira et al., 2001). The different TLRs and their 
respective ligands are shown in Table 1.1.  
Table 1.1 Summary of Toll like receptor classes and ligands. Adapted from  Akira & 
Takeda 2004.  
DC maturation is initiated when a TLR is engaged by its ligand, for example binding 
of TLR4 by the bacterial cell wall component, lipopolysaccharide (LPS). TLR4 is a 
type I transmembrane protein with an extracellular domain consisting of a leucine-
rich repeat (LRR) domain responsible for the recognition of pathogens, and a 
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cytoplasmic domain, required for initiating intracellular signalling, homologous to 
the cytoplasmic domain of the interleukin (IL)-1 receptor (TIR) (Medzhitov et al., 
1997). 
Ligation of a TLR4 promotes its dimerisation and results in the recruitment of the 
cytosolic adaptor molecule (MyD88) which contains two domains: a C-terminal Toll 
homology domain that interacts with the Toll homology domain of the receptor, 
and an N-terminal death domain (DD), however, the efficient triggering of TLR4 
response requires the expression of the secreted protein MD-2 (Re and Strominger, 
2002). MyD88 also has an intermediate domain (ID) that is crucial in TLR signalling 
as it interacts with IL-1R associated kinase (IRAKs) (Arancibia et al., 2007). Upon 
ligand binding to TLR, IRAK is activated by phosphorylation and this subsequently 
causes its dissociation from the receptor complex and association with tumor 
necrosis factor (TNF) receptor-activated factor 6 (TRAF6). This event results in 
activation of the Rel family transcription factor NF-B and MAPK family (Akira et al., 
2001). 
Beside the TLR family, DC maturation can be induced by engagement of certain cell 
receptors with their ligands like co-stimulatory receptor CD40 with CD40 ligand (van 
Kooten and Banchereau, 2000) and cytokine receptors with interferon gamma (IFN-
) and tumor necrosis factor alpha (TNF-) (Bernhard et al., 2000). Signal 
transduction downstream of these receptors shows a complex picture involving 
different mediators and pathways. These pathways include MAPKs, NF-B and 
protein tyrosine kinases (Grammer et al., 1998; Purkerson and Parker, 1998; Rothe 
et al., 1995). 
1.7.1 The NF-B pathway  
NF-B is a major regulator of the innate and adaptive immune response, cell 
proliferation, and survival. It is an inducible transcription factor responding to 
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inflammation, infection and stress stimuli and rapidly reprograms gene expression 
through activation of an exceptionally large number of genes (Rothwarf and Karin, 
1999). Mature DCs express high levels of the NF-B family of transcription factors 
(Ouaaz et al., 2002). The NF-B family members are formed by combinations of five 
distinct DNA binding subunits, p65/RelA, RelB, c-Rel, p50, and p52 and exist as 
homo- or heterodimeric complexes. RelA, RelB and c-Rel are synthesized in their 
mature forms and contain a transactivation domain that interacts with the 
transcriptional apparatus. Both p50 and p52 lack a transactivation domain although 
they contain a DNA binding domain; they are synthesized in precursor forms that 
are proteolysed by the proteasome resulting in the production of mature proteins 
(Ghosh et al., 1998). In unstimulated cells, NF-B is found in an inactive form 
sequestered in the cytoplasm and bound to inhibitory IB proteins. When cells are 
stimulated, this leads to rapid phosphorylation, ubiquitination, and eventually 
proteolytic degradation of IB thereby freeing NF-B. NF-B then translocates to 
the nucleus and drives gene expression, including that of IB, which facilitates the 
termination of the transcriptional response by binding and retaining the NF-B 
dimers in the cytoplasm genes (Rothwarf and Karin, 1999) as shown in Figure 1.3. 
Phosphorylation of IB is induced by the multi-subunit IB kinase (IKK) which has 
two catalytic subunits, IKKα and IKKβ and a regulatory subunit IKK (NEMO) which is 
proposed to serve as a recognition site for upstream activators (Rothwarf et al., 
1998). Binding of TLR with its ligand will induce IKK activity and thereby activate NF-
B mediated gene transcription. NF-B targets include the stress-response genes 
cyclooxygenase 2 (COX 2) and inducible nitric oxide synthase (iNOS), the 
detoxification enzyme superoxide dismutase (SOD), the apoptotic regulators p53, 
Bcl-xL and FasL, and proteins involved in antigen presentation and receptors like 
MHC class II and CD86 (Pahl, 1999). It has been shown that inhibiting NF-B 
translocation to the nucleus decreases the up-regulation, by LPS, of MHC class II, 
CD80 and CD86 (Rescigno et al., 1998). NF-B has also been implicated in DC 
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development, maturation, and survival through transcription of a number of 
different genes, including those coding for chemokines (IL-8), cytokines (IL-1, IL-2, 
IL-12, and TNF-), and adhesion molecules (endothelial leukocyte adhesion 
molecule, vascular cell adhesion molecule, and intercellular adhesion molecule) 
(Caamano and Hunter, 2002). 
 
 
 
 
 
 
 
 
Figure 1.3 Signalling cascades leads to NF-B activation. 
1.7.2 The MAPK pathways  
The MAPKs represent vital intracellular signalling pathways that can be activated by 
an enormous array of stimuli leading to regulation of a variety of cellular processes 
including cell differentiation, proliferation, and apoptosis (Chang and Karin, 2001). 
Classical MAPKs pathways consist of at least three-modular cascades that involve 
activation by phosphorylation of downstream kinases by upstream kinases. 
Engagement of cell receptors with their ligands causes recruitment of cytoplasmic 
domain receptors, through multi-protein complexes, with the MAPK kinase kinases 
(MAPKKKs or MAP3Ks) leading to their activation and phosphorylation, these 
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phosphorylated MAPKKKs subsequently phosphorylate MAPK kinases (MAPKKs or 
MAP2Ks or MEKs), which in turn will phosphorylate MAPKs. Different MAPKKKs 
exist and have large regulatory domains that interact with upstream regulators. 
MAPKKs typically have smaller regulatory domains and are activated by dual 
phosphorylation of serine and threonine residues within the activation loop of the 
catalytic domain. They show great specificity for their cognate MAPK but are 
regulated by multiple MAPKKKs (Qi and Elion, 2005). The sequential activation of 
the individual components of the MAPK cascade enables the final MAPK to be 
phosphorylated and thus modify the activity of its downstream effector molecules 
to generate a specific intracellular response (Lewis et al., 1998). In DCs, MAPKs 
pathways regulate their maturation and modulate the type of immune response in 
concert with NF-B and other pathways (Breckpot and Escors, 2009). Three groups 
of classical MAPKs have been identified: the extracellular signal-regulated protein 
kinases (ERK) (Boulton et al., 1991), the c-Jun N-terminal kinases (JNK) (Kyriakis et 
al., 1994) and the p38 stress-activated protein kinases (p38MAPK) (Lee et al., 1994). 
They are structurally related and their catalytic domain is blocked by a conserved 
activation loop. When they are activated by phosphorylation, the loop unblocks the 
catalytic site leading to phosphorylation of specific targets. All the MAPKs contain a 
Thr-X-Tyr (TXY) motif within their activation loop. The phosphorylation of both 
threonine and tyrosine within the activation loop is essential and sufficient for their 
activation (Zhang and Dong, 2007). They are activated by specific MAPKKs: MEK1/2 
for ERK1/2, MEK3/6 for the p38MAPK and MEK4/7 for the JNKs (JNKK1/2) (Chang 
and Karin, 2001). 
MAPKs activation, under physiological conditions, is often transient. The actual 
levels of MAPKs do not change throughout the course of stimulation; therefore, 
dephosphorylation by phosphatases would seem to play a major role in the down-
regulation of MAPK activity. Mitogen-activated protein kinase phosphatases (MKPs) 
are dual protein phosphatases that can dephosphorylate both the phosphotyrosine 
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and phosphothreonine residues on activated MAPKs (Liu et al., 2007). Structurally, 
all MKPs have a highly conserved C-terminal catalytic domain and a less conserved 
N-terminal region that engages the cognate MAPKs (Liu et al., 2007). MAPK 
phosphatase-1 (MKP-1) is the typical member of the MKP family and has activity, 
along with MKP5, for p38MAPK (Franklin and Kraft, 1997; Sun et al., 1993; Tanoue 
et al., 1999). For ERK1/2 the key MKPs are MKP2, MKP3 and MKP4 (Guan and 
Butch, 1995; Muda et al., 1996; Muda et al., 1997), whereas for JNK it is MKP7 
(Matsuguchi et al., 2001). However, it is pertinent to note that a single MKP can 
simultaneously dephosphorylate multiple MAPKs. 
1.7.2.1 Extracellular signal-regulated protein kinases 1/2 (ERK1/2) 
The extracellular signal-related kinase (ERK) family consists of: A. Classical MAPK-
ERK which include p44mapk/erk1 (ERK1) and p42mapk/erk2 (ERK2) and are closely 
related to each other (90% identity) and activated in response to growth factors 
through serine/threonine phosphorylation (Boulton et al., 1991), and B. the large 
MAPKs such as ERK3, ERK5, ERK7, and ERK8 that consist of both a kinase domain 
and a C-terminal domain and range in size from 60 to greater than 100 kDa (Abe et 
al., 1996; Kuo et al., 2004; Lechner et al., 1996). Both ERK1 and ERK2 are activated 
by upstream MAPKKs (MEK1/2). Stimulation can be induced by engagement of a 
variety of pathogenic or mitogenic stimuli including LPS, growth factors, cytokines, 
and phorbol esters, with TLRs and G protein coupled receptors (An et al., 2002; Qi 
and Elion, 2005; Rescigno et al., 1998). Activated MEK1/2 phosphorylates threonine 
and tyrosine residues in the Thr–Glu–Tyr (TEY) sequence of ERK1/2, resulting in the 
activation of ERK1/2. Activated ERK1/2 phosphorylates many substrates including 
transcription factors, such as ETS domain-containing protein ELK-1 and cAMP 
response element-binding protein (CREB) and protein kinases, such as ribosomal S6 
kinase (RSK). These induce transcription of immediate early genes, such as c-Fos 
(Agrawal et al., 2003; Yang et al., 1998a) as shown in Figure 1.4. 
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In DCs, the ERK signalling pathway negatively regulates maturation and IL-12 
production upon LPS stimulation but positively regulates inﬂammatory cytokine 
production like TNF-, IL-1, IL-6, or IL-8 (Nakahara et al., 2006; Yanagawa et al., 
2002). Additionally, the ERK signal-transduction pathway negatively regulates NF-
B DNA- binding and IB levels on TNF- –induced maturation with enhancement 
of allogenic T cell response elicited by TNF- matured dendritic cells (Puig-Kroger et 
al., 2001)  
 
 
 
 
 
 
 
 
Figure 1.4 Signalling cascades leads to ERK1/2 activation. 
 
1.7.2.2 c-Jun N-terminal kinases (JNKs) 
c-Jun N-terminal kinases are serine threonine stress-activated protein kinases that 
can be induced in response to a variety of extracellular stresses such as bacterial 
endotoxin, inﬂammatory cytokines, UV radiation, osmotic shock, and hypoxia 
(Kyriakis et al., 1994). Three JNK genes (Jnk1, Jnk2 and Jnk3) are found in mammals; 
the Jnk1 and Jnk2 genes are expressed ubiquitously, while the jnk3 gene has a more 
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limited pattern of expression and is largely restricted to the brain, heart, and testis. 
They are activated by the MAPK kinases MEK4 and MEK7, via dual phosphorylation, 
on a speciﬁc Tyr residue by MEK4 and a speciﬁc Thr residue by MEK7 in a typical 
Thr–Pro–Tyr (TPY) motif within their “activation/phosphorylation loop” sequences 
(Davis, 2000). They have the ability to bind and phosphorylate the N-terminal 
transactivation domain of the transcription factor c-Jun and increase its 
transcriptional activity (Kyriakis et al., 1994). c-Jun is a component of the signal-
responsive transcription complex activated protein-1 (AP-1), which is involved in 
regulation of gene expression (Leppa and Bohmann, 1999). Additionally, JNKs can 
also phosphorylate a variety of transcription factors such as ATF2, NFAT, Elk-1 and 
p53 (Buschmann et al., 2001; Chow et al., 1997; Gupta et al., 1995; Yang et al., 
1998b) (Figure 1.5).  
 
 
 
 
 
 
 
 
Figure 1.5 Signalling cascades leads JNK activation. 
JNKs can activate apoptotic signalling by directly modulating the activities of 
mitochondrial pro- and anti-apoptotic proteins like Bcl-2 or Bcl-X through 
phosphorylation or through up-regulation of pro-apoptotic genes by enabling 
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transactivation of a wide range of transcription factors such as JunD, activating 
transcription factor 2 and 3 (ATF2, ATF3), Elk-1, Elk-3, p53, Retinoid X receptor 
alpha and beta (RXR, RAR, androgen receptor (AR), Nuclear factor of activated T 
cells 4 (NFAT4), Heat shock factor protein 1 (HSF-1) and c-Myc (Dhanasekaran and 
Reddy, 2008; Johnson and Nakamura, 2007). In DCs, LPS is found to induce JNK 
activation by phosphorylation mainly by MEK7 (Yoshizawa et al., 2008) and a 
speciﬁc inhibitor of JNK, SP600125, inhibited the LPS-induced up-regulation of co-
stimulatory molecules CD80 and CD86, but augmented the up-regulation of MHC 
class II (Handley et al., 2007; Nakahara et al., 2004).  
1.7.2.3 The p38MAPK pathway 
The p38MAPK participates in many aspects of immune cell functional responses, 
including respiratory burst activity, chemotaxis, cell differentiation, granular 
exocytosis, adherence, and apoptosis (Ono and Han, 2000; Roux and Blenis, 2004). 
Activation of p38MAPK is critical for DC maturation and secretion of pro-
inflammatory cytokines; and it is constitutively activated at a low level in mature 
DCs (Fukao et al., 2000). 
Four splice variants of the p38MAPK family have been identified: α (XMpk2/CSBP), 
β (Beta22),  (SAPK3/ERK6), and δ (SAPK4). While p38 and p38δ are differentially 
expressed depending on tissue type, p38α and p38β are ubiquitously expressed. 
The p38α enzyme is the best characterized and is expressed in most cell types 
including DCs (Zarubin and Han, 2005). In general p38MAPK can be activated by 
various stimuli, such as LPS, proinﬂammatory cytokines (e.g. IL-1β and TNF-), and 
various environmental stresses (osmotic stress, heat, and UV irradiation) (Arrighi et 
al., 2001; Raingeaud et al., 1995). Activation of p38MAPK pathway can enhance 
protein expression by its direct effect on gene transcription, by the activation of 
speciﬁc transcription factors, or through post-transcriptional regulation (mRNA 
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stability, mRNA processing, protein stability, nuclear export, and translation) 
(Raingeaud et al., 1996). 
All p38MAPKs can be phosphorylated specifically on a Thr–Gly–Tyr (TGY) dual 
phosphorylation motif by upstream MEK3 and MEK6 kinases (Moriguchi et al., 
1996). However, upstream phosphorylation of the MEKs/p38MAPK signalling 
pathways is less specific, which may explain why diverse stimuli can activate the 
p38MAPK pathway. Several MK kinases (MAP2Ks) have been reported to lead to 
p38MAPK activation such as: MTK1, MLK2/MST (Cuenda and Dorow, 1998; Hirai et 
al., 1997; Takekawa et al., 1997), MLK3/PTK/SPRK (Tibbles et al., 1996), 
ASK1/MAPKKK5 (Ichijo et al., 1997), DLK/MUK/ZPK (Fan et al., 1996), and TAK1 
(Moriguchi et al., 1996). Increased activity of these MAP2Ks leads to activation of 
both the p38MAPK and JNK pathways, explaining why p38MAPK and JNK are often 
co-activated. However, specific activation of either p38MAPK or JNK has also been 
observed, indicating selectivity in this pathway at this level (Ogura and Kitamura, 
1998). In addition to the downstream differential effects of the MAP2Ks, different 
upstream signals can be mediated by different MAK3Ks. For example, MTK1 may 
only mediate stress signals but not those from cytokines. This is evident by the 
observation that the dominant negative MTK1 mutant can only inhibit the 
activation of the p38MAPK pathway by environmental stress (osmotic shock, UV, 
and anisomycin), but not by the cytokine TNF- (Takekawa et al., 1997). The 
downstream targets of p38MAPKs vary from kinases such as MK2 and MK3 
(MAPKAP kinases) to transcription factors such as CREB, ATF1, ATF2, p53, c/EBPβ 
and NFAT (Zarubin and Han, 2005) (Figure 1.6). 
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     Figure 1.6 Signalling cascades leads to p38MAPK activation. 
1.7.2.4 The transcription factors CREB/ATF1 are targets of MAPKs 
The regulation of gene transcription is important for both tissue specific-gene 
expression and regulation of gene activity in response to specific stimuli (Latchman, 
1997). Transcription factors (TFs) have crucial roles in mediating gene expression 
and hence in almost controlling all biological processes. TFs contain a basic domain 
that binds specific DNA sequence (DBDs) which influence the rate of transcription 
(Jakoby et al., 2002). CREB and the closely related protein ATF1 constitute a 
subfamily of bZIP transcription factors that binds to its DNA target sequence as a 
dimer and play critical roles in the regulation of gene expression as well as cell 
cycle, metabolism, growth, and survival (Mayr and Montminy, 2001). CREB and 
ATF1 represent the major transcriptional effectors of MAPKs (particularly p38MAPK 
but also ERK1/2). These transcription factors bind to DNA sequences termed cAMP 
responsive elements (CRE) and drive gene expression. 
CREB activation occurs through phosphorylation of its Ser133 and Ser142 residues 
within the 60-amino-acid kinase-inducible domain (KID). ATF1 is structurally and 
functionally related to CREB and is activated by phosphorylation at Ser63 and 
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Ser133 (Shaywitz and Greenberg, 1999). ATF1 mediates its responses as 
homodimers or as heterodimers with CREB. ATF1/CREB heterodimers have a longer 
half-life compared with ATF1/ATF1 homodimers, when bound to the cAMP 
response elements (CRE) (both approximately several minutes), while CREB/CREB 
homodimers have the longest half-life (10–20 min). Therefore, CREB appears to be 
responsible for the bulk of essential functions carried out by CREB/ATF1 family 
members. The duration of CREB phosphorylation is of significance in determining 
whether transcription occurs or not (Wu et al., 2001). 
Gene transcription ability of CREB/ATF1 depends on its phosphorylation state, 
which, in turn, regulates its recruitment to the versatile co-activators like CREB-
binding protein (CBP) or p300, both responsible for trans-activation of the cell 
transcriptional machinery. CREB/ATF1 may compete with other transcription 
factors such as NF-B for recruitment and binding of CBP (Gerritsen et al., 1997; 
Katoh et al., 2001; Vo and Goodman, 2001). Genes that are CREB-responsive 
include the proinﬂammatory cytokine TNF- (Roach et al., 2005) and 
cyclooxygenase 2 (COX2) (Eliopoulos et al., 2002), anti-inﬂammatory cytokines such 
as IL-10 (Platzer et al., 1999) and the pro-survival gene, bcl-2 (Chao and Korsmeyer, 
1998). 
In DCs, phosphorylation of CREB is known to be associated with up-regulation of co-
stimulatory molecules (CD80 and CD86) (Ardeshna et al., 2000) and increased 
secretion of IL-10 (Alvarez et al., 2009). 
CREB is inactivated by phosphatases like protein phosphatase 1 (PP1) and protein 
phosphatase A2 (PPA2) through dephosphorylation at Ser-133 (Hagiwara et al., 
1992; Vo and Goodman, 2001; Xing et al., 1998).  
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1.8 Redox homeostasis and immune cell function 
Redox homeostasis can be generally defined as a relatively stable state of 
equilibrium or a tendency towards such a state between the diverse but mutually 
dependent oxidative and antioxidant elements or groups of elements of an 
organism (Buettner, 1993). Redox homeostasis is important for a variety of cellular 
functions such as proliferation, apoptosis, and intracellular signalling pathways 
including MAPK signalling (Go et al., 2004). 
Disturbance in redox homeostasis leads to a condition known as oxidative stress 
which can be defined as a disorder in the pro-oxidant–/antioxidant balance in 
favour of the former, leading to potential injury. Disturbances in this normal redox 
state can cause toxic effects resulting in damage to components of the cell, 
including DNA, proteins, and lipids (Trachootham et al., 2008). 
Oxidative damage is characterised as the biomolecular impairment caused by the 
attack of reactive species upon the constituents of living organisms.  
Oxidative stress can have deleterious effects on cell function including immune cell 
function. It has been widely recognized that oxidative stress is involved in the 
aggravation of immune disorders such as pulmonary injury, inflammation and 
emphysema (associated with chronic obstructive pulmonary disorders, COPD) 
(Matthay and Zimmerman, 2005). 
Oxidative stress leads to a very wide spectrum of metabolic, genetic, and cellular 
responses. Most oxidative stress conditions that cells might come across may 
stimulate cell growth, modulate gene expression, or may cause a transient adaptive 
response and protective temporary growth-arrest. In the most extreme outcome, 
which involves direct cell destruction, necrosis occurs (Davies, 2000). 
A large number of pro-oxidants are generated within the cell and the organism as 
well as from exogenous sources as shown in Box 2 (Nathan, 2003). These pro-
oxidants include reactive oxygen species (ROS) which comprises superoxide, 
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hydrogen peroxide, singlet oxygen, ozone, hypohalous acids, and organic peroxides, 
and reactive nitrogen species (RNS) which comprises nitric oxide (NO•) and NO2
•; 
hydrogen sulphide (H2S) and its anion HS
−. 
Reactive oxygen species are free radicals that are extremely reactive owing to the 
presence of unpaired electron/s in their highest atomic or molecular orbitals. 
Reactive oxygen species are generated as by-products of aerobic metabolism or 
exposure to various natural and synthetic toxicants (Davies, 2000). Furthermore, 
ROS can be induced by the accumulation of hemin, lipid aldehydes, and arsenic 
(Hsieh et al., 2006; MacKenzie et al., 2008; Reichard et al., 2007; Tjalkens et al., 
1998). 
Transient, low level, and controlled production of ROS is part of normal cell 
physiology and plays an essential role in signal transduction cascades, protein 
ubiquitination and degradation, as well as cytoskeleton arrangement (Yan et al., 
2008). However, excessive or prolonged ROS could cause lipid peroxidation, protein 
amino acid side-chain oxidation, and DNA single- and double-strand breaks 
(D'Autreaux and Toledano, 2007). These different effects of ROS influence cell cycle 
progression which is dependent upon the amount and duration of ROS exposure 
(Boonstra and Post, 2004). ROS are found to be related to a wide variety of human 
disorders, such as chronic inflammation, age-related diseases, and cancers. 
ROS can modulate immune responses through affecting many physiological 
processes in different types of cells. For example in macrophages, ROS contributes 
to the expression of inflammatory mediators by acting as second messengers and 
are necessary for the induction of the respiratory burst which is essential for 
macrophage and neutrophil pathogen destruction  (Forman and Torres, 2002; 
Gwinn and Vallyathan, 2006; Schaur et al., 1994). Additionally, ROS levels were 
increased after LPS challenge in peritoneal macrophages and lymphocytes in 
different models of septic shock causing increase in adherence and phagocytosis 
and a decrease in chemotaxis (Victor et al., 2004). 
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Evidence has shown that the intracellular redox status and ROS can serve as 
signalling mediators to initiate multiple signalling pathways in DCs. This can result in 
co-stimulatory molecule expression (MHC class II and CD86) up-regulation which 
have significant effects on DC functions with subsequent impact on the type of T 
cell immune response elicited (Kantengwa et al., 2003; Kim et al., 2007; Williams et 
al., 2008). Furthermore, ROS may induce DC chemokines and cytokines production 
through NF-B and MAPKs pathways so that they can act as a “danger” signal from 
the inﬂammatory micro-environment leading to DC activation, and hence an 
antigen-speciﬁc immune response (Rutault et al., 1999; Yan et al., 2008). Previous 
studies have shown that modulating redox balance in DCs leads to reduction in IL-
Box 2: Sources of ROS and mediators of their catabolism  
(Adopted from Nathan 2003) 
 
Exogenous sources of ROS 
•Smoke 
•Air pollutants 
•Ultraviolet radiation 
•γ-irradiation 
•Several drugs 
 
 
 
 
Endogenous sources of ROS 
•NADPH oxidases 
•Mitochondria 
•ER flavoenzyme ERO1 
•Xanthine oxidase 
•Lipoxygenases 
•Cyclooxygenases 
•Cytochrome P450 enzymes 
•Flavin-dependent demethylase 
•Polyamine and amino acid oxidases 
•Nitric oxide synthases 
•Free iron or copper ions 
•Haem groups 
•Metal storage proteins 
 
Catabolism by antioxidant systems 
•Superoxide dismutases 
•Catalases 
•Glutathione peroxidases 
•Glutathione reductase 
•Thioredoxins 
•Thioredoxin reductases 
•Methionine sulphoxide reductases 
•Peroxiredoxins or peroxynitrite reductases 
Catabolism by small molecules 
that  react with ROS non-
enzymatically 
•Ascorbate 
•Pyruvate 
•α-ketoglutarate 
•Oxaloacetate 
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12 and TNF- cytokine production (Yamada et al., 2006) and decrease in antigen-
speciﬁc T cell proliferation and IFN- synthesis (Tse et al., 2007). 
 
1.9 Influence of redox on signalling pathways 
Several reports have shown, in many cell types, that an altered redox status results 
in the activation of several intracellular signalling pathways like MAPKs and NF-B, 
suggesting a role for ROS as second messengers (Gaitanaki et al., 2003; Schaeffer et 
al., 2003; Wang et al., 1998). ROS may have direct protein target interactions with 
these signalling pathways wherein exposure of these molecules to an altered redox 
state alters the function of the target protein. Some recent evidence supports this 
notion and suggests that both certain protein-protein interactions and enzymatic 
functions might be regulated by cellular ROS levels (Finkel, 2000). ROS was found to 
induce the phosphorylation of p38MAPK, ERK, and JNK members of MAPK family 
and inhibition protein phosphatases (Lee and Esselman, 2002). 
1.10 Cellular defence against reactive oxygen species 
At the cellular level, an extensive defence system against ROS has evolved, this 
system includes: small thiol-rich molecules such as glutathione and 
metallothioneins that can directly inactivate ROS; and enzymes such as heme-
oxygenases, SOD, NAD(P)H:quinone oxidoreductases (NQO), glutathione S-
transferases (GST), catalase (CAT) and peroxidases which metabolise ROS into non-
reactive metabolites (Chelikani et al., 2004; Halliwell and Gutteridge, 1990; Miao 
and St Clair, 2009; Ross, 2004). A second line of defence against oxidative stress 
involves small molecules that react with ROS non-enzymatically and can be recycled 
or replenished, giving them a ROS-buffering capacity. These include ascorbate, α-
tocopherol, and the α-ketoacids of central carbon metabolism, such as pyruvate, α-
ketoglutarate and oxaloacetate (O'Donnell-Tormey et al., 1987). 
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1.10.1 Thiol-containing cellular antioxidants 
Glutathione is an important tripeptide (glutamate, cysteine, and glycine) thiol 
molecule that protects cells against oxidative damage from ROS generated during 
normal metabolism and xenobiotic exposure, and it also functions as an important 
substrate in enzyme catalysed detoxification reactions (DeLeve and Kaplowitz, 
1991). Glutathione exists in thiol-reduced (GSH) and disulfide-oxidized (GSSG) 
forms. Under physiological conditions glutathione reductase will rapidly reduce any 
GSSG to the reduced, thiol form, GSH. More than 98% of intracellular glutathione is 
GSH. The rest is present within the cell as the oxidized disulfide form (GSSG), as 
mixed disulfides (mainly GSS-protein) and as thioethers (Kaplowitz et al., 1985). -
Glutamylcysteine synthetase ( -GCS) is a rate-limiting enzyme involved in the de 
novo synthesis of GSH, and is structurally made up of glutamate cysteine ligase, 
catalytic subunit (GCLc) and glutamate cysteine ligase, regulatory subunit (GCLm) 
(Jeyapaul and Jaiswal, 2000). The antioxidant capacity of GSH does not only come 
from its direct ability to react with ROS alone, but also from its function as a 
substrate for GSH peroxidases (GPX), which catalyse the reduction of hydrogen 
peroxide (H2O2) and lipid hydroperoxides (DeLeve and Kaplowitz, 1991). 
Additionally antioxidant capacity of GSH can be attributed to GSTs, which constitute 
a family of enzymes that detoxify xenobiotics by conjugating GSH to a range of 
electrophilic substrates (Thimmulappa et al., 2002). These enzymatic activities yield 
GSH disulphide (GSSG), which is reduced back to GSH via a nicotinamide adenine 
dinucleotide phosphate (NADPH) dependent, GSH reductase-mediated reaction, a 
cycle that serves to maintain essential redox balance (DeLeve and Kaplowitz, 1991). 
Another important thiol-containing molecule is thioredoxin (TRX), a small protein 
that contains two critical cysteine residues (32 and 35) (Haendeler, 2006). The 
preservation of cysteine redox state is particularly important for the function of 
certain enzymes whose catalytic activity is dependent upon the integrity of a 
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sulphydryl or disulphide moiety. The cysteine thiolate residue (Cys-S) is more 
readily oxidized by peroxides than is the Cys-sulfhydryl residue (Cys-SH) which serve 
as the immediate electron donor for the peroxidase function (Rhee et al., 2005). 
This leaves a reduced or dithiol target protein and a disulﬁde in the active site of 
TRX. This disulﬁde is reduced by TRX reductase (TRXR) using electrons from NADPH 
(Berndt et al., 2007). The peroxiredoxins (PRX) are a protein family which contain a 
conserved Cys residue that undergoes a cycle of peroxide-dependent oxidation and 
thiol-dependent reduction during the catalysis process which is capable of directly 
reducing peroxides, e.g. hydrogen peroxide and different alkyl hydroperoxides 
(Rhee et al., 2005). 
1.10.2 Enzymes as effectors of redox homeostasis 
Among the enzymes that are involved in countering ROS are members of the SOD 
family that utilise the transition metals copper and zinc (Cu, Zn-SOD present in 
cytosol Mn-SOD present in mitochondria) at their active sites, and catalyse the 
dismutation of two superoxide anion radicals (O2·-) to H2O2 and O2. The H2O2 
cytotoxic product of this reaction is subsequently detoxified by GPX, and/or PRX 
producing H2O and O2 (Nordberg and Arner, 2001). Catalases also accelerate the 
degradation of two molecules of H2O2  into water and oxygen (Chelikani et al., 
2004). NADP(H)-quinone oxidoreductases (NQO) are flavoenzymes that catalyse the 
two-electron reduction of quinones to hydroquinones (Vasiliou et al., 2006). Two 
isoforms of the enzyme exist, NQO1 (molecular mass of 31 kDa) utilizes NAD(P)H, 
whereas NQO2 (molecular mass of 25 kDa) employs dihydronicotinamide riboside 
(NRH) as the electron donors. NQO1 also has other cytoprotective properties such 
as maintenance of the endogenous lipid-soluble antioxidants α-tocopherol and 
direct scavenging of O2
- radicals via NAD(P)H- dependent redox reactions (Ross, 
2004; Siegel et al., 2004). These enzymes are widely distributed through 
mammalian tissues with the highest levels being in liver and cardiovascular tissues 
(Vasiliou et al., 2006). 
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1.10.3 Small non-protein antioxidant molecules 
α-Tocopherol (vitamin E) is a potent lipid-soluble antioxidant that has a primary role 
in breaking chain reactions involving O2 and lipid peroxyl free radicals (Yu, 1994). 
Additionally it can stabilize and activate the redox sensitive transcription factor 
nuclear factor E2 p45-related factor 2 (Nrf2) (Rahman et al., 2006). Vitamin E plays 
a central role in disease prevention by scavenging both ROS and RNS (Zingg, 2007). 
Ascorbic acid (vitamin C) is a hydrophilic antioxidant that has free radical 
scavenging capacity and is widely distributed in mammalian tissues. In addition to 
this direct role, vitamin C can restore the antioxidant properties of oxidised vitamin 
E (Yu, 1994). 
Vitamins C and E have been shown to reduce ROS levels in different cell types 
including neutrophils (Kanno et al., 1995), monocytes (Cachia et al., 1998; Devaraj 
et al., 1996), and macrophages (Sakamoto et al., 1990). Addition of vitamins C and E 
to DCs before challenge with stimuli that are known to induce ROS production, 
resulted in a reduction in ROS levels comparing to untreated DCs (Tan et al., 2005). 
This effect is more prominent when DCs are incubated with vitamins for longer 
durations before stimulation. DCs treated with these antioxidant vitamins are found 
to be resistant to phenotypic and functional changes subsequent to 
proinﬂammatory cytokines stimulation (Tan et al., 2005). 
Other ROS scavenging molecules include: uric acid (the end product of purine 
metabolism), ceruloplasmin (a major copper-carrying protein), β-carotene (a 
metabolic precursor of retinol) and bilirubin (a breakdown product of heme 
catabolism) (Davies, 2000; Yu, 1994). 
In general, the above-mentioned antioxidants demonstrate their scavenging actions 
by donating an electron to a radical, and thus generating a non-radical species. 
Their role is considered to be unavoidably suicidal by becoming alternative targets 
for reactive species in the place of critical macromolecules (Davies, 2000). 
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Glutathione and detoxifying enzymes expression (both basally and inducibly) are 
mainly regulated by Nrf2, a redox-responsive transcription factor which has a 
central role in cellular adaptive and defence systems against oxidative and 
electorphilic stress (Itoh et al., 1997b; Jaiswal, 2004; McMahon et al., 2001). 
 
1.11 Nrf2 
The transcription factor Nrf2 is a member of the cap‘n’collar (CNC) basic leucine 
zipper transcription factors and is essential for the coordinated induction of genes 
that encodes cytoprotective enzymes or stress-responsive proteins, such as HO-1, 
NQO1, SODs, GPx, GSTs, GCL, CAT and TRX (Reddy et al., 2007b). 
Other members of the CNC family of transcription factors include the Nrf1, Nrf3 and 
the repressive factors bric-a-brac/tram-track/broad complex (BTB) and CNC 
homolog 1: Bach1 and Bach2 (Chan et al., 1998; Kobayashi et al., 1999), and are 
named as such due to structural similarities with the Drosophila protein cap ‘n’ 
collar (CNC). Nrf2 contains a C-terminal basic leucine zipper (bZip) structure that 
facilitates dimerisation and DNA binding (Moi et al., 1994). Nrf1 is less potent than 
Nrf2 at transactivating gene expression (Zhang et al., 2006), while Nrf3 has been 
proposed as a negative regulator of Nrf2 by interfering with ARE-mediated 
transcription (Sankaranarayanan and Jaiswal, 2004). 
Nrf2 was first cloned during a screen for nuclear factor erythroid 2 (NF-E2) -
regulating proteins in hemin-induced erythroleukemia cells (Moi et al., 1994). It is 
homologous to another CNC transcription factor nuclear factor erythroid 2 (NF-E2). 
While NF-E2 regulates globin gene expression in developing erythroid cells (Igarashi 
et al., 1994), Nrf2 is also highly expressed in non-haemopoietic tissues including 
heart, muscles, pancreas (Moi et al., 1994), in organs particularly associated with 
detoxification (liver and kidney), and those that are exposed to the external 
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environment (skin, lung and digestive tract) (Motohashi et al., 2002). The Nrf2 
structure consists of six highly conserved regions named as homology domains 
(Nrf2-ECH homology) Neh1 to Neh6 as shown in Figure 1.7 (Itoh et al., 1999). 
Figure 1.7. Schematic representation for the basic structure of transcription factor 
Nrf2. Neh1 is the first conserved domain and contains the basic-leucine zipper 
domain and CNC homology region. The amino and carboxyl termini of the proteins 
are also highly conserved, and are referred to as Neh2 and Neh3, respectively. 
Additionally, there are two conserved acidic domains (Neh4 and Neh5) as well as a 
serine-rich conserved region (Neh6). Adopted from Itoh et al. 1999.  
 
Nrf2 binds to the antioxidant response element (ARE), a DNA motif found within 
the promoter regions of numerous cytoprotective genes, with high affinity only as a 
heterodimer with its obligatory partner a small Maf protein (Itoh et al., 1997b). 
Small Maf proteins lack transactivation domains, and thus the ability of the Nrf2-
Maf heterodimer to promote transcription is solely dependent on the 
transactivation ability of Nrf2 (Motohashi et al., 2002). Amongst members of the 
CNC family, Nrf2 is the most potent transcriptional activator from the ARE 
(Kobayashi et al., 1999; Papaiahgari et al., 2006). 
Nrf2 requires the recruitment of co-activators that include CBP/p300, co-activator-
associated arginine methyltransferase 1 (CARM1), protein arginine N-
methyltransferase 1 (PRMT1) and p300/CBP-associated factor (p/CAF) for initiation 
of Nrf2 related gene transcription (Lin et al., 2006). The cAMP responsive element 
binding protein (CREB)-binding protein (CBP) has been shown to bind to the 
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transactivation domains of Nrf2, Neh4 and Neh5, which act synergistically to attain 
maximum activation of reporter gene expression. Indeed, specific inhibition of CBP 
significantly reduced Nrf2 activity (Katoh et al., 2001). CBP helps transcription 
through a) its intrinsic histone acetyltransferase (HAT) activity, b) interaction with 
other proteins possessing HAT activity, and c) bridging to components of the 
general transcriptional machinery (Bannister and Kouzarides, 1996; Kalkhoven, 
2004). Histone acetylation (as well as DNA methylation) control the access of 
transcription factors to the promoter regions and thereby affect the pattern of gene 
transcription. Nucleosomes contain histones in their core, around which DNA is 
wound into a condensed structure that represses transcription, but that can be 
selectively unfolded to increase accessibility to general transcription factors and 
RNA polymerase II, and thus promote gene transcription (Grunstein, 1990; Kuo and 
Allis, 1998). 
Transcriptional repressors Bach1 and Bach2 are basic leucine zipper (bZip) protein 
and forms heterodimers with one of the small Maf proteins (i.e. MafK, MafF, and 
MafG) that bind to the Maf recognition element (MARE) and effectively function as 
repressors of gene transcription over NFE2-related transcription, including 
suppression of a key gene in heme metabolism, heme oxygenase-1 (HO-1) 
(Kitamuro et al., 2003; Yoshida et al., 2007). 
1.11.1 Kelch-like ECH-associated protein-1 (Keap-1) 
Analyses of Nrf2 activity has led to the identification of Nrf2 transcriptional activity 
suppressor, Kelch-like ECH-Associated Protein 1 (Keap1), which specifically binds to 
Nrf2 via its evolutionarily conserved amino terminal regulatory domain. In the 
absence of cellular stress, Nrf2 is tethered within the cytosol by keap1, which binds 
to Nrf2 via the Neh2 domain (to the seven lysine residues located between the 
conserved 29DLG31 and 79ETGE82 motifs) of the transcription factor (Itoh et al., 
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1999). This interaction represses cellular Nrf2-dependent transcription activity 
(Zipper and Mulcahy, 2002). 
The Neh2 moiety of Nrf2 is required for the repression activity by Keap1 (Itoh et al., 
1999; Xue and Cooley, 1993). Keap1 resides within the cytosol where it interacts 
with the actin cytoskeleton and, in the absence of chemical/oxidative stress, 
associates with Nrf2 leading to Nrf2 proteasomal degradation. Structurally, Keap1 
contains three major domains; N-terminal BTB domain, an intervening region (IVR) 
bridge that is rich in cysteine residues and regulates activity of Keap1 and links BTB 
to double glycine (DGR) domain situated on the C-terminal containing six conserved 
repeats also known as kelch (Figure 1.8) (Itoh et al., 1999; Kang et al., 2004). The 
BTB domain mediates protein dimerisation which is required for effective Nrf2 
sequestration in the cytosol, whereas Kelch repeats have been implicated in binding 
to the actin cytoskeleton and the formation of multi-protein complexes (Albagli et 
al., 1995; Robinson and Cooley, 1997). Cullin3 (Cul3), a subunit of the E3 ligase 
complex, serves as a molecular bridge bringing together substrate adaptor protein 
(Keap1) and substrate (Nrf2) through Keap1 BTB and intervening-region (IVR) 
domains. Therefore, Keap1 would participate directly in the regulation of Nrf2 
polyubiquitination and subsequent 26S proteasome-mediated degradation 
(Cullinan et al., 2004; Kobayashi et al., 2004). 
 
Figure 1.8. Schematic presentation of Keap1. Five domains within Keap1 are 
demonstrated: NTR, BTB, IVR, DGR, and CTR. Adopted from Kang et al 2004.  
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1.11.2 Regulation of Nrf2 by Kelch-like ECH-associated protein-1 (Keap-1) 
In the absence of chemical and oxidative stress, Nrf2 is sequestered in the cytosol 
by the repressor protein Keap-1 which directs the transcription factor for 
ubiquitination and degradation by the 26S proteasome (Zipper and Mulcahy, 2002). 
Therefore, Nrf2 proteasomal degradation is achieved via its cytosolic interactions 
with Keap-1 (Kobayashi et al., 2004). Treatment with the organic compound diethyl 
maleate (DEM) was shown to liberate Nrf2 from Keap-1-mediated sequestration in 
the cytosol, thus enabling its translocation into the nucleus and binding to the ARE 
(Itoh et al., 1999). This highlights the pivotal role of keap-1 in the inhibition of Nrf2 
activation and nuclear translocation. Under basal conditions, a minimal cytoplasmic 
pool of Nrf2 is maintained as a result of its rapid degradation by the proteasome 
pathway, giving Nrf2 a relatively short half-life of approximately < 20 minutes 
(Katoh et al., 2005; Kobayashi et al., 2004). Studies using proteasome inhibitors that 
caused the nuclear accumulation of Nrf2 and initiation of Nrf2 target gene 
upregulation, further emphasised the role of the proteasomal machinery in the 
regulation of Nrf2 activity (Kobayashi et al., 2004; McMahon et al., 2003). Under 
resting conditions, Keap-1 presents Nrf2 to the ubiquitin ligase enzyme resulting in 
its polyubiquitination and rapid degradation via the 26S-proteosome (Ma and He, 
2012). However, upon oxidative insult, Keap-1 mediated Nrf2 ubiquitination is 
inhibited. As a result, Nrf2 accumulates in the cytoplasm allowing it to freely 
translocate into the nucleus (Kobayashi et al., 2004; Zhang et al., 2004a). Nrf2 
regulation by Keap-1 proceeds via a two site recognition mechanism known as the 
‘Hinge and Latch’ model, where hinge refers for ETGE motif and latch for DLG motif 
(Tong et al., 2006b). When cellular GSH is depleted under oxidative stress 
conditions, critical cysteine within the BTB and IVR regions of the Keap-1 are 
modified, resulting in the displacement of Nrf2 from the low affinity DLG binding 
site; whilst remaining associated to Keap-1 via its high affinity ETGE site (Tong et al., 
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2006a). This conformational change in Keap-1 disables it from directing Nrf2 for 
degradation via the proteasome (Kobayashi et al., 2004). Other Nrf2 molecules then 
saturate the Keap-1 via binding to the newly available BTB site within the 
homodimer, subsequently Nrf2-binding capacity of Keap1 is saturated and even 
diminished due to Keap1 self-ubiquitination allowing any newly synthesised Nrf2 to 
translocate into the nucleus (Li and Kong, 2009). Nrf2 then associates with small 
maf protein forming a heterodimer which facilitates its capacity to bind to the ARE 
regions found in the regulatory domains of its nrf2-regulated genes (Itoh et al., 
1997b). The co-activator CBP is then recruited to the Nrf2 heterodimer resulting in 
its transactivation (Katoh et al., 2001; Lin et al., 2006) and subsequent transcription 
of enzymes involved in xenobiotic detoxification ultimately resulting cellular 
protection and maintenance of redox homeostasis (Figure 1.9).  
Figure 1.9. Schematic presentation of Nrf2 activation. In resting state, Nrf2 is 
sequestered in the cytosol via the Keap-1. Under oxidative stress intracellular GSH 
is depleted, resulting in conformational changes in Keap-1. This disables Keap1 from 
directing Nrf2 for degradation via the proteasome and enabling any newly 
synthesised Nrf2 to translocate into the nucleus. Nrf2 then associates with small 
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Maf protein forming a heterodimer which facilitates its capacity to bind to the ARE 
regions found in the regulatory domains of its Nrf2-regulated genes. Adopted from 
Copple et al 2008.  
Prevention of cysteine modification within the BTB and IVR regions of the Keap-1 
was found to facilitate Nrf2 ubiquitination (Zhang et al., 2004b), indicating that the 
targeting of these residues within the Neh2 domain is critical for Keap1-mediated 
repression of Nrf2. There is evidence that Keap1 acts as a “sensor” of chemical or 
oxidative stress, through its many cysteine residues.  Furthermore, several recent 
reports have described the phosphorylation of Nrf2 as an event that is required for 
the nuclear export of the transcription factor (Jain and Jaiswal, 2006; Kaspar et al., 
2009). Protein kinase C has been shown to phosphorylate Nrf2 in its Neh2 domain 
at Ser-40, disrupting the association between Nrf2 and Keap1 thus promoting the 
translocation of Nrf2 into the nucleus (Huang et al., 2002).  
1.11.3 Nrf2 activators differentially modify Keap1 
In response to electrophilic or oxidative insult, Nrf2 drives the induction of a battery 
of cytoprotective and anti-oxidant defence systems resulting in the maintenance of 
cellular redox homeostasis and prevention of cellular damage (Copple et al., 2010). 
It is possible that modification of any single cysteine residue in Keap1 may be 
sufficient to trigger the activation of Nrf2. Such a nonspecific triggering mechanism 
may underlie the chemical versatility of the Keap1-Nrf2 pathway, in terms of its 
capacity to “sense” and respond to a variety of structurally distinct molecules 
(Yamamoto et al., 2008). More specifically, it is possible that the modification of a 
single cysteine residue/group of residues within a critical domain of Keap1 provides 
the molecular trigger for Nrf2 activation (Zhang and Hannink, 2003). Administration 
of sulfhydryl reactive compounds, such as diethylmaleate, abolishes Keap1 
repression of Nrf2 activity in cells and facilitates the nuclear accumulation of Nrf2 
(Kwak et al., 2003). Additionally, the synthetic triterpenoids, CDDO-Methyl ester 
(CDDO-Me) and CDDO-Imidazolide (CDDO-Im), are found to be potent inducers of 
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heme oxygenase-1 and Nrf2/ARE signalling as well as up-regulating Nrf2 nuclear 
translocation (Yates et al., 2006). These triterpenoid derivatives provide an effective 
tool for investigating the role of Nrf2 in the maintenance of oxidative stress. Pre-
treatment with CDDO-Me or CDDO-Im attenuates LPS-induced pro-inflammatory 
cytokine production and ROS generation in human PBMCs and neutrophils, 
respectively (Thimmulappa et al., 2007).  
Because Nrf2–regulated cytoprotective genes protect from oxidative damage as 
well as suppress inflammation by modulating immune cell function, it is possible 
that the molecules which are able in activation of the Nrf2 pathway might prove to 
be suitable therapeutic strategy for intervention in sepsis as well as in systemic 
inflammatory response and other inflammatory disorders. (Thimmulappa et al., 
2002). 
 
1. 12 Role of Nrf2 in redox homeostasis and immune cell function 
Nrf2 plays a vital role in maintaining cellular redox homeostasis through its ability to 
regulate the basal and inducible expression of a multitude of antioxidant proteins 
and detoxiﬁcation enzymes (Nguyen et al., 2005). Nrf2 contributes to wide range of 
cellular functions including differentiation, proliferation, lipid synthesis and 
inﬂammation and there is an increasing evidence of association of aberrant 
expression and/or function of Nrf2 with different pathologies including cancer, 
neurodegeneration and cardiovascular disease (Osburn and Kensler, 2008). The 
development of Nrf2 knockout mice has provided principal understanding of the 
toxicological importance of this pathway, as these mice are found to be more 
vulnerable to the hepatic, renal, pulmonary, and neurotoxic consequences of acute 
or chronic exposures to environmental agents, drugs, inﬂammatory stresses, 
cigarette smoke and carcinogens (Kensler et al., 2007). 
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Nrf2 deficiency in mice have been shown to result in enhanced expression of 
several innate immune response proteins including specific cytokines, chemokines, 
and cell surface adhesion molecules and receptors. The lungs of Nrf2-deﬁcient mice 
exhibited persistent cellular injury, pro-inflammatory IL-6 and TNF- production, 
impaired endothelial and alveolar cell regeneration, and continual cellular 
inﬁltration by macrophages and lymphocytes which might impair lung innate 
immunity and promotes susceptibility to bacterial infection (Reddy et al., 2009). 
Disruption of Nrf2 causes regenerative immune-mediated hemolytic anemia (Lee et 
al., 2004). Furthermore, it was demonstrated that Nrf2-deﬁcient mice exhibit 
prolonged inﬂammation during cutaneous wound healing (Braun et al., 2002). 
Through its influence on macrophages and neutrophil function, Nrf2 is implicated in 
the inﬂammatory response to bacterial infection, and protection against sepsis. 
Hence, Nrf2 has been described as a gene modifier for mounting appropriate innate 
immune responses (Thimmulappa et al., 2006). 
Nrf2 has been revealed to influence DC redox homeostasis and on aspects of DC 
biology; however, the role of Nrf2 in DC immune function has not been fully 
elucidated. Evidence has shown that the intracellular redox status of the DC has a 
profound impact on its functions such as cell survival (Guyton et al., 1996; 
Nakamura et al., 1997b), DC activation and maturation (Kim et al., 2007; Matsue et 
al., 2003a; Verhasselt et al., 1999a) and DC cytokine production (Murata et al., 
2002; Peterson et al., 1998; Sozzani et al., 2005). Additionally, ROS signalling and 
interactions with GSH have been implicated in the immunosenescence of DCs 
whereby a multitude of functions are impaired (Peters et al., 2009). Studies on DCs 
derived from Nrf2 deficient mice have identified the potential role of Nrf2 in the 
modulation of DC co-stimulatory receptor expression (Williams et al., 2008). 
Furthermore, Nrf2 deficient mice developed complex disease manifestations, 
exhibiting a lupus-like autoimmune syndrome with marked female dominance. This 
includes the presence of nuclear autoantigens, anti-double-stranded DNA 
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antibodies, multi-organ inflammation, immune complex deposition in blood vessels 
and glomerular nephritis (Ma et al., 2006). 
However, the molecular and mechanistic basis for these altered co-stimulatory 
receptor expression of Nrf2-/- DCs are unknown and require investigation. 
1.13 Heme oxygenases (HOs) in redox homeostasis 
Heme is the product of catabolism of heme containing metalloproteins that has the 
potential to induce the generation of ROS (Figueiredo et al., 2007; Jeney et al., 
2002). Heme chemically consists of an iron ion contained in the centre of a large 
heterocyclic organic ring called a porphyrin, made up of four pyrrolic groups joined 
together by methine bridges (protoporphyrin IX). Most of porphyrin-containing 
metalloproteins have heme as their prosthetic group which are known as 
hemoproteins, nevertheless not all porphyrins contain iron. Hemes are most 
commonly recognized as components of haemoglobin but they are also 
components of a number of other hemoproteins such as myoglobin, cytochrome, 
endothelial nitric oxide synthase and catalase (Maines, 1988). Excessive 
accumulation of heme within cells or in the extracellular environment can underlie 
pathological states such as neurodegenerative diseases (Alzheimer's disease, 
Parkinson's disease, and Huntington's disease), malaria (Prentice et al., 2007), and 
hemoglobinopathies (thalassemia and sickle Cell diseases) (Mariani et al., 2009). 
Three HO isoforms: HO-1 (32 kDa), HO-2 (36 kDa), and HO-3 (33 kDa) have been 
described. HO-1 is normally expressed at low levels in most tissues but can be 
dramatically induced by a variety of stimuli, while HO-2 is constitutively expressed 
and is essentially un-inducible, and HO-3 is constitutive with limited tissue 
expression (Siow et al., 1999). The crystal structure of HO-1 consists of two helical 
folds with heme sandwiched between them (Figure 1.10). The proximal helix 
provides a heme iron ligand while the distal helix contains conserved glycines near 
the oxygen binding site that allows close contact between the helix backbone and 
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heme in addition to providing flexibility for substrate binding and product release 
(Schuller et al., 1999). 
 
 
 
 
 
 
       
 
Figure 1.10. Schematic diagram of heme oxygenase-1. The N-terminus is blue and 
the C-terminus is red, with green in the middle. Adopted from Schuller et al. 1999.  
 
Heme oxygenase-1 is a rate limiting microsomal membrane protein that catalyses 
the oxidative cleavage of heme molecules to yield equimolar quantities of 
biliverdin, carbon monoxide (CO), and iron. Biliverdin is subsequently reduced to 
bilirubin by the cytosolic enzyme biliverdin reductase (Figure 1.11), HO-1 is not a 
heme protein by nature, but it binds heme to form a 1:1 complex (Ryter et al., 
2006). 
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Figure 1.11. Schematic representation of heme degradation by heme oxygenase-
1. Heme oxygenase-1 degrades heme to generate iron, carbon monoxide, and 
biliverdin-IX. Biliverdin-lX is subsequently reduced to bilirubin-IX by biliverdin 
reductase. Iron is sequestered by ferritin. Carbon monoxide can bind to the heme 
moiety of guanylyl cyclase to increase cellular levels of cGMP. 
 
HO-1 is transcriptionally up-regulated as a sensitive cytoprotective protein by 
various types of oxidative stressors including its substrate heme and various 
environmental factors (Kitamuro et al., 2003). Nrf2 transcriptional activity was 
found to increase transcription of HO-1 expression (Sun et al., 2002). In the 
presence of low levels of heme, Bach1 (Figure 1.12) represses target genes with the 
Maf recognition elements (MAREs) in their regulatory regions by preventing 
activators such as Nrf2 from binding to MAREs.  
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Figure 1.12. Schematic representation of Bach1 structure. Bach1 responds to 
heme and cadmium, two potent inducers of HO-1. Numbered circles represent 
cysteine-proline (CP) motifs. Subcellular localization of Bach1 is regulated by its 
interaction with the cytoplasmic, microtubule-associated, intracellular hyaluronic 
acid binding protein IHABP. Adopted from Igarashi et al 2006.  
 
When heme levels build-up, this causes inhibition of the DNA-binding activity of 
Bach1, resulting in dissociation of Bach1 from the enhancers and de-repression of 
the target Nrf2 genes which means HO-1 induction by Nrf2 requires inactivation of 
the transcriptional repressor Bach1 (Figure 1.13) (Igarashi and Sun, 2006; Ogawa et 
al., 2001; Reichard et al., 2007). While Nrf2 is responsible for the production of HO-
1 during oxidative insult, Bach1 plays the antagonistic role that is responsible for 
both positive and negative control over this critical gene (Sun et al., 2004). Indeed, 
HO-1 may be among the most critical cytoprotective mechanisms that are activated 
by heme as well as through non-heme cellular stress such as inﬂammation, 
ischemia, hypoxia, hyperoxia, hyperthermia, or radiation (Choi and Alam, 1996). 
Heme oxygenase-1 plays a critical role in counterbalancing oxidative stress and is an 
important modulator of physiological function with cytoprotective properties 
through inhibiting immune responses and inflammation in vivo. Indeed induction of 
HO-1 expression by pharmacologic activators or gene transfer has had therapeutic 
effects in a variety of conditions or disorders involving the immune system, 
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including transplantation and inﬂammatory disorders (Abraham, 2003; Soares et al., 
2009). 
 
Figure 1.13. Transcriptional control of HO-1 expression. In the presence of lower 
concentrations of heme within a cell, Bach1 represses genes with MAREs together 
with small Maf proteins. In the presence of higher concentrations of heme, Bach1 is 
inactivated by binding to heme, leaving MAREs available for the activator class of 
factors such as Nrf2 or other MARE-binding proteins. In this way, heme directly 
regulates the balance of repression and activation of gene expression. Adopted 
from Ogawa et al, 2001.  
 
Essential cytoprotective functions of HO-1 against oxidative stress could also be 
attributed to its enzymatic by-product CO and biliverdin (BV)/bilirubin (Chora et al., 
2007; Ollinger et al., 2005). CO exerts anti-inﬂammatory, anti-apoptotic, and anti-
proliferative effects (Kim et al., 2006). Additionally, exogenously administered CO 
has been shown to exert potent cytoprotective effects in various experimental 
models of oxidant stress including hemorrhagic shock (Zuckerbraun et al., 2005), 
hyperoxic lung injury (Otterbein et al., 1999), and endotoxemia (Kyokane et al., 
2001). It has recently been suggested that bilirubin can be reconverted to BV when 
bilirubin is oxidized by peroxyl radicals and is then recycled by BV reductase to 
bilirubin (Baranano et al., 2002). This redox cycle might explain the antioxidant 
cytoprotective effects assigned to bilirubin and BV. The antioxidant activity of BV is 
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predominantly due to its ability to scavenge free radicals (Farrera et al., 1994; 
Stocker et al., 1987). Administration of BV provides effective protection in 
endotoxic shock (Sarady-Andrews et al., 2005) and decreases the production of 
inflammatory mediators such as cytokines and nitric oxide (NO) (Sawle et al., 2005). 
Experimentally, metalloporphyrins have been found to either induce HO-1 gene 
expression, through up-regulation of transcription factor Nrf2 (for example, by 
cobalt protoporphyrin (CoPP)) (Shan et al., 2000), or inhibit HO-1 enzymatic activity 
(for example by zinc protoporphyrin (ZnPP) and tin protoporphyrin (SnPP)) 
(Chauveau et al., 2005; Kappas and Drummond, 1986; Maines, 1981). 
In the context of DCs, HO-1 induction resulted in reduction of the LPS-induced 
expression of MHC class II and CD80 and CD86 along with decreased T cell 
proliferation and production of IFN- and IL-12 (Chauveau et al., 2005). Additionally, 
HO-1 expression was found to be down regulated upon DC maturation (Chauveau 
et al., 2005). However, the key signalling pathways through which HO-1 exerts its 
influence on DC function are unknown. 
1.14 Aims of the study  
The main focus of this study is to define the key signalling pathways involved in DC 
maturation and function that are subject to modulation by Nrf2 and HO-1.  
Specifically, the thesis aims are to 
1. Characterise the effect of Nrf2 activity on DC phenotype and function. 
2. Define the effects of Nrf2 on NFB, ERK, JNK and p38MAPK-CREB/ATF1 
pathways in DCs 
3. Test the requirement of ROS dysregulation in Nrf2-mediated effects on DC 
phenotype, function and signalling 
4. Characterise the effect of HO-1 activity on DC phenotype, function and 
signalling 
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5. Examine the relevance of ROS disequilibrium in HO-1-mediated effects on 
DC phenotype and function 
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CHAPTER TWO 
 
 
MATERIALS AND METHODS 
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2.1 Cell culture materials and reagents  
Cell culture 10 cm microbiological petri dishes, Nunclon cell culture flasks, flat and 
round-bottom 96-well microtitre plates, 24 and 48 multi-well plates were 
purchased from Nunc [Thermo Fisher Scientific; MA, USA]. FACS tubes and sheath 
fluid were purchased from BD Bioscience [Oxford, UK]. Foetal bovine serum (FBS) 
and acrylamide gel cassettes were both purchased from Invitrogen [Paisley, UK]. 
Tris glycine, 4x Proto Gel Resolving Buffer, Proto Gel Stacking Buffer and 30% 
acrylamide: 0.8% (w/v) Bis-acrylamide stock solution were purchased from Gene 
Flow [Lichfield, UK]. Recombinant Granulocyte-macrophage colony-stimulating 
factor (GM-CSF) was purchased from Peprotech [London, UK]. Precision Plus 
protein Kaleidoscope standards, protein assay dye reagent and non-fat dry milk 
were all purchased from Bio-Rad [Hemel Hempstead, UK]. SB203580 (a specific 
inhibitor of p38MAPK which suppresses downstream activation of MAPKAP kinase-
2) and PD98059 (a potent and selective inhibitor of MEK kinase) were both 
purchased from Cell Signalling Technology [Danvers, MA, USA]. BAY 11-7082 ((E)3-
[(4-Methylphenyl) sulfonyl]-2-propenenitrile, a selective and irreversibly inhibitor of 
NF-B activation) and cAMPS-Rp ((R)-Adenosine, cyclic 3',5'-
(hydrogenphosphorothioate) triethylammonium, a competitive antagonist of 
cAMP-induced activation of PKA)  was obtained from Merck Chemicals Ltd 
[Nottingham, UK] and Tocris Bioscience [Bristol, UK], respectively.  Tin 
protoporphyrin IX dichloride (SnPP IX) and cobalt protoporphyrin IX chloride (CoPP) 
were both purchased from Frontier Scientific [Newark, USA]. All chemicals and 
reagents were of analytical grade and purchased from Sigma-Aldrich [Dorset, U.K.], 
unless otherwise stated.  
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2.2 Antibodies 
Fluorochrome conjugated antibodies: the intracellular fluorescent dye, 
carboxyfluorescein succinimidyl ester (CFSE) and fluorescein (FITC)-dextran [40,000 
MW], PE-Cy®5.5 conjugated anti-mouse CD11c (N418), were purchased from 
Invitrogen [Paisley, UK]. FITC-conjugated anti-mouse CD40 (Clone 3/23), FITC-
conjugated anti-mouse CD86 (GL1), PE-conjugated anti-mouse I-A/I-E 
(M5/114.15.2), FITC-conjugated Annexin V and PE-Cy®5.5 conjugated Propidium 
iodide (PI) detection kit were purchased from BD Bioscience [Oxford, UK]. 
Dihydroethidium (DHE), the fluorescent ROS indicator, was purchased from Sigma-
Aldrich [Dorset, UK]. 
Primary antibodies for Western immunoblotting (IκBα; p-p65; p-ERK1/2; ERK1/2; p-
p38; p38; p-JNK; JNK; p-CREB/ATF1; CREB and Bcl-2) were purchased from Cell 
Signaling Technology [MA, USA]. p65 and tubulin were purchased from Santa Cruz 
Biotechnologies [CA, USA]. Actin and HO-1 were both purchased from Abcam 
[Cambridge, UK]. The secondary horseradish peroxidase (HRP) conjugated anti-
mouse IgG and anti-rabbit IgG antibodies were purchased from Cell Signaling 
Technology [MA, USA]. 
 
2.3 Cell lines 
The human leukaemic Jurkat T cell line, E6.1 was purchased from American Type 
Culture Collection (ATCC) [Middlesex, UK]. These cells were utilised for the dendritic 
cell phagocytosis assay. Cells were cultured in CM at a density of 0.5 x106 cells / ml 
in nunclon cell culture flasks and media was changed every two days until required 
for functional assays. 
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2.4 Mice 
Black C57BL6/SV129 wild type and Nrf2 knockout mice (Nrf2-/-) were purchased 
from Riken BRC [Ibaraki, Japan] (Itoh et al., 1997a). Nrf2 colonies were maintained 
as heterozygous breeders and homozygous offspring were genotyped before use. 
C57BL/6 mice homozygous for the H-2Db-restricted TCR- transgene, F5, which 
recognises NP-68, a nonameric peptide derived from influenza virus A/NT/60/68 
nucleoprotein were a kind gift from Dr James Matthews [Cardiff; Wales] and 
housed under controlled conditions at the Biomedical Services Unit, University of 
Liverpool. Mice were given free access to food and water and housed at a 
temperature of between 19°C - 23°C under 12 h light/dark cycles. All animals were 
bred under pathogen free conditions. Protocols described herein were undertaken 
in accordance with criteria outlined in licenses granted under the Animals (Scientific 
Procedures) Act 1986 (PPL 40/2937 and PPL 40/2544) and approved by the Animal 
Ethics Committee of the University of Liverpool. The NP68 peptide 
(366ASNENMDAM374) used to stimulate F5 CD8 T cells was synthesised by Peptide 
Protein Research Ltd [Hampshire, UK]. 
 
2.5 Generation of mouse bone marrow-derived dendritic cells (DCs)  
Bone marrow cells were flushed from femora and tibiae of wild type and Nrf2-/- 
mice. Cells were washed and cultured in complete medium (Roswell Park Memorial 
Institute-1640 (RPMI-1640) medium supplemented with 10% FBS, 50 M 2-ME, 2 
mM HEPES buffer, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 IU/ ml 
streptomycin and 100 g/ ml penicillin) in the presence of 20 ng/ml GM-CSF at a 
density of 3 x 106 cells/ plate in 10cm microbiological petri dishes. Cultures were 
kept in a fully humidified incubator at 37C under 5% CO2, media was then 
replenished on day 3 with the addition of 20 ng/ ml GM-CSF and differentiated DCs 
55 
 
were used between days 6 or 7. An exception is for DC proliferation assay, as 
explained in 2.13, where DCs on day 3 were harvested from cell culture petri dishes, 
counted and re-seeded in 96-well round-bottom microtitre plates at different cell 
densities with20 ng/ml GM-CSF. 
 
2.6 Viable cell count by Trypan Blue exclusion 
Cell suspensions were mixed with an equal volume of 0.2% w/v Trypan Blue in 
HBSS. The samples were then pipetted into the counting chambers of a 
haemocytometer [Weber Scientific International Ltd.; Lancing, UK] and counted at 
100X magnification. Dead cells absorb the Trypan Blue dye and appear blue, 
whereas viable cells exclude the dye and appear clear. 
 
2.7 Immunomagnetic separation of CD11c+ve DCs (For ELISA only) 
Purified CD11c positive wild type and Nrf2-/- bone marrow derived DCs were 
isolated using MACS LS+ immunomagnetic separation columns [Miltenyi Biotec, 
Germany]. Cells were washed and resuspended at a density of in 1 x 108 cells per 
400 µl of ice cold MACS Buffer (HBSS without phenol red supplemented with 2 mM 
EDTA and 0.5% bovine serum albumin (BSA)). Cells were magnetically labelled using 
anti-CD11c conjugated magnetic microbeads [Miltenyi Biotec, Germany] 20 µl per 1 
x 106 cells, and refrigerated for 15 minutes. Cells were washed with MACS buffer (2 
ml per 1 x 106 cells), centrifuged at 300 g for 10 minutes and resuspended in 500 µl 
MACS buffer. MACS LS+ Separation Columns were attached to MidiMACS magnets 
and set up on a MidiMACS stand. The columns were washed three times with 3 ml 
of MACS buffer. The magnetically labelled cell suspensions were pipetted onto the 
column. Unlabelled cells were collected as the negative fraction whereas labelled 
cells were retained within the column. A thorough elution of the negative fraction 
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was facilitated by washing the columns three times with 3 ml of MACS buffer. The 
columns were then removed from the magnet and flushed with 5 ml of MACS 
buffer using a column plunger. This procedure yielded positive cell populations of 
approximately 90 % purity (data not shown). 
 
2.8 Co-stimulatory receptor expression by flow cytometry  
For DCs phenotyping, cells were scraped from petri dishes and washed in HBSS, 
counted and dispensed into FACS tubes at a density of 1 x 106 cells/ tube. Cells were 
washed with stain buffer (sheath fluid supplemented with 2% FBS and 2 mM 
ethylene diamine tetra acetic acid (EDTA)). Washed cells were resuspended in 50 l 
stain buffer and incubated in the dark at 4C for 10 minutes. Appropriate amounts 
of antibodies were dispensed to each tube in 50 l stain buffer and tubes were 
incubated for 30 minutes in the dark at 4C. After incubation, cells were washed in 
4 ml sheath fluid and resuspended in 700 l sheath fluid prior to analysing on a BD 
FACSCanto II [BD Biosciences; Oxford, UK]. 
Post acquisition analysis of flow cytometry data (FCS) files were conducted using 
Cyflogic v.1.2.1 software [CyFlo Ltd, Finland]. 
 
2.9 Isolation of F5 CD8 T cells  
Spleens were harvested from from F5 TCR transgenic mice and homogenised using 
Jencons Uniform Grade B-24 Tissue Homogeniser [Jencons Scientific Ltd., Leighton 
Buzzard, UK]. Dispersed tissue was then filtered through 40 m gauge Nylon Cell 
Strainers [Falcon, UK]. Cells were washed in HBSS and spun at 300 g for 5 minutes. 
After centrifugation, pelleted cells were treated with red blood cell (RBC) lysis 
buffer (8.3 g/L ammonium chloride in 0.01 M Tris-HCl buffer) for 6 minutes at RT 
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(25 °C) to remove red blood cells, followed by a final wash/centrifugation cycle. 
Lymphocytes were then resuspended in complete medium. 
2.10 F5 CD8 T cell proliferation assay  
F5 CD8 T cell proliferation was quantified as described in (Johnson et al., 1999). 
Isolated splenocytes from F5 TCR mice were processed and plated out in 
quadruplicate at a density of 1 x 105 cells/ well in 96-well round-bottom microtitre 
plates in complete medium. Dendritic cells were pre-pulsed with a concentration 
range of NP68 for 2 hours at 37C, washed and co-cultured with F5 T cells at a 
density of 5000 cells/ well. Cultures were incubated at 37C under 5% CO2 for 72 
hours and 3H-Thymidine added for the last 16 hours. Cultures were harvested onto 
glass fibre filter mats using a Tomtec Mach III harvester [Tomtec; Connecticut, 
USA]., Dried filter mats sealed with solid scintillant [Perkin Elmer; Cambridge, UK] 
were read on a scintillation counter [MicroBeta Trilux; Perkin Elmer; Cambridge, 
UK]. 
 
2.11 Measurement of reactive oxygen species (ROS) levels  
Intracellular ROS levels were determined by measuring the levels of fluorescence 
generated by the rapid oxidation of DHE to its fluorescent oxidised form, ethidium 
bromide in the presence of ROS (emission: 420nm). Intracellular superoxide levels 
of DCs were determined by labelling DCs with DHE according to (Bindokas et al., 
1996; Burnaugh et al., 2007) with minor modifications. Briefly, 5 x 105 DCs were 
washed and resuspended in serum-free RPMI 1640. Cells were treated with or 
without LPS or H2O2 for 10 minutes. Cells were then washed and resuspended in 
HBSS without red phenol before 10 M of DHE was added and incubated at 37°C 
for 10 minutes. Cells were analysed by flow cytometry (see section 2.8). 
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2.12 Apoptosis assay 
Treated and untreated DCs (1 x 105 cells per FACS tube) were washed with 1X 
binding buffer (contained in the Annexin V kit), and incubated with fluorescently 
labelled FITC-conjugated Annexin V or Propidium iodide (PI) plus 1X binding buffer 
in the dark at RT for 15 minutes. At the end of the incubation, 400 l of 1X Binding 
Buffer was added to each tube and analysed by flow cytometry within 1 h. 
 
2.13 DC proliferation assay 
On day 3, DCs were harvested from cell culture petri dishes, counted and re-plated 
in 96-well round-bottom microtitre plates at different cell density in complete 
medium supplemented with 20 ng/ ml GM-CSF and 3H-Thymidine in a total volume 
of 180 l per well. At day 5, 6 and 7, cultures were harvested onto glass fibre filter 
mats using a Tomtec Mach III harvester and read on a scintillation counter.  
 
2.14 ATP activity assay 
This assay was used to determine the number of viable cells in culture based on the 
quantitation of the ATP present, which reflects the amount of metabolically active 
cells. On day 7, DCs were harvested from cell culture petri dishes, counted and re-
plated in 96-well flat-bottom microtitre plates at a density of 25 x 103 cells per 100 
µl per well in complete medium. According to CellTiter-Glo® Assay instructions, the 
CellTiter-Glo® Buffer was mixed with the CellTiter-Glo®Substrate to reconstitute the 
lyophilised enzyme/substrate mixture. CellTiter-Glo® Reagent (100 µl) was mixed 
into the plate wells and left for 10 minutes prior to quantifying the luminescence 
signal on a Varioskan plate reader [Thermo Scientific; MA, USA]. 
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2.15 Detergent lysis of DCs  
On day 6, DCs were harvested and resuspended in serum free RPMI 1640 at a 
density of 10-20 x 106 cells/ condition. They were either stimulated with 1 g/ ml 
LPS for indicated time points at 37C; or left unstimulated on ice with or without 
kinase inhibitors. Cold complete media was added to quench the reaction and the 
cells were then centrifuged and lysed in 1 ml cold 0.5% Nonidet P-40 lysis buffer 
(0.5% Nonidet-P40, 1 mM Na3VO4, 25 mM NaF, 150 mM NaCl, 50 mM Tris-HCl pH 
8.0, 1 mM EDTA) supplemented with protease inhibitors (1 mM PMSF, 10 g/ ml 
Aprotinin, 10 g/ ml Leupeptin and 10 g/ ml Pepstatin A) which were added to the 
lysis buffer immediately prior to cell lysis. Cells were left in the lysis buffer on ice for 
30 minutes and then centrifuged at 16000 g for 15 minutes at 4°C. Supernatants 
were removed and transferred into new pre-cooled eppendorfs, aliquoted into 
small volumes and kept in -80°C until further use.  
 
2.16 Nuclear extraction of DCs 
Nuclear Lysates were generated from cell samples using NE-PER nuclear and 
cytoplasmic extraction kit [Fischer Scientific, Loughborough, UK] via strict 
adherence to manufacturer’s instructions. Briefly, 10 x 106 DCs/condition were 
centrifuged, supernatant was removed and pellets resuspended in 100 l 
cytoplasmic extraction reagent I (CER I) plus protease inhibitors. Cells were left on 
ice for 10 minutes after which 5.5 l CER II was added to each eppendorf, vortexed 
and left on ice for a further 1 minute. Samples were then spun at 16,000 g at 4°C for 
5 minutes and the supernatant containing cytoplasmic fractions were removed and 
stored at -80°C for future use. The remaining pellets were resuspended in 50 l 
nuclear extraction reagent (NER) and left on ice for 45 minutes with intermittent 
vortexing every 15 minutes. Cells were then spun at 16,000 g at 4°C for 10 minutes 
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and the supernatant containing nuclear fractions was carefully removed and stored 
at -80°C for future use. 
 
2.17 Protein content determination via Bradford assay 
Whole cell lysates and/or nuclear extracts from cell samples were generated as 
appropriate to each experimental requirement. The total protein content of 
samples was determined using Protein Assay Dye Reagent,] according to the 
manufacturer’s instructions. Based on the method of Bradford (Bradford, 1976), 
this assay relies on the binding of Coomassie Brilliant Blue G-250 dye to basic and 
aromatic amino acids, resulting in a change in colour of the dye (red to blue). This 
change in the dye colour is proportional to the amount of bound dye and can be 
measured in the absorbance at 570 nm with a MRX plate reader [Dynex; Sussex, 
UK]. Total protein content of samples can be calculated from the absorbance values 
of a 0.25-5 g BSA standard curve prepared for each assay. 
 
2.18 Western blotting analysis 
Whole cell lysates (5-10 μg of protein determined by Bradford assay) were 
denatured via the addition of 5 L loading buffer (70% (v/v) NuPAGE sample loading 
buffer, 30% (v/v) NuPAGE reducing agent) and incubated at 90°C for 5 minutes. 
Samples were loaded onto NuPAGE Novex bis-tris polyacrylamide gels, alongside 
PrecisionPlus protein Kaleidoscope standards. Samples were resolved by 
electrophoresis in a XCell Surelock mini-cell from Invitrogen [Paisley, UK], using a 3-
(N-morpholino) propanesulphonic acid (MOPS) running buffer (50 mM MOPS, 50 
mM Tris base, 3.5 mM sodium dodecyl sulphate, 1mM EDTA, 0.25% (v/v) NuPAGE 
antioxidant), at 90 Volts for 10 minutes, followed by 60 minutes at 170 Volts. 
Resolved proteins were transferred to polyvinylidene difluoride (PVDF) membranes 
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[Bio-rad; Hemel Hempstead, UK] at 200 mA for 90 minutes with ice. To check 
whethere the transfer process was successful, membranes were stained for 30 
seconds with Ponceau S solution. Membranes were blocked for 1 h at RT in tris-
buffered saline (TBS; 150 mM NaCl, 50 mM Tris base, pH 7.6) containing 0.1% (v/v) 
Tween-20 and 10% (weight/volume; w/v) non-fat dry milk. Blocked membranes 
were washed in TBS-0.1% Tween-20 and probed overnight at 4°C with appropriate 
primary antibodies (1:1000 to 1:20000 in TBS-0.1% Tween-20 containing 2% (w/v) 
BSA). Following several washes in TBS-0.1%Tween-20 for 1 h, membranes were 
probed for 1 h with goat anti-rabbit (1:5000 to 1:20000 in TBS-0.1% Tween 
containing 2% (w/v) BSA) horseradish peroxidise (HRP)-conjugated secondary goat 
anti-rabbit or anti-mouse IgG peroxidase conjugate. Immunoblots were visualised 
with Western Lightning chemiluminescence reagents [Perkin Elmer, Cambridge, UK] 
and exposed to Hyperfilm ECL [GE healthcare Life Sciences, Chalfont St Giles, UK] 
under darkroom conditions, using a Kodak BioMax MS intensifying screen 
[Healthcare Amersham; Thermo Fisher Scientific; MA, USA]. Blots were developed 
using Kodak developer and fixer solutions (Kodak; Hemel Hempstead, UK). 
In order to ensure equal loading across gels, membranes were probed with mouse 
anti-β-actin primary antibody (1:10000 in TBS-0.1% Tween containing 2% (w/v) BSA) 
or mouse anti-tubulin primary antibody (1:5000 in TBS-0.1% Tween containing 2% 
(w/v) BSA) and goat IgG anti-mouse or anti-rabbit HRP-conjugated secondary 
antisera. 
Films were scanned using a GS-710 calibrated imaging densitometer [Bio-rad; 
Hemel Hempstead, UK] and immunoreactive band volumes were quantified using 
TotalLab 100 software, in accordance with the manufacturer’s instructions, and 
normalised to total protein. 
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Table 2.1 Summary of Western blotting antibodies used in the study.                  
o/n= over night. 
 
2.19 Reprobing of blotted membranes 
Reprobing of membranes for other proteins following initial immunoblotting and 
ECL developing was done by firstly stripping the membrane of antibodies. For this 
purpose, membranes were incubated in Stripping Buffer (100 mM 2-ME, 2% SDS, 
62.5 mM Tris-HCl pH6.8) for 30 minutes at 55°C. The membranes were transferred 
into TBS-0.1% Tween-20, washed three times for 10 minutes each and blocked in 
blocking buffer (10% non-fat dry milk in TBS-0.1% Tween-20) for 30 minutes. The 
membranes were subsequently immunoblotted for specific proteins and developed 
as described earlier. 
 
 
 
Target protein Primary antibody 
concentrations 
Secondary antibody type and 
concentrations 
Bcl-2 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
IB  1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
Actin 1:20000, 37°C 30 mins Rabbit 1:20000, 37°C 30 mins 
p-p65 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
p65 1:1000, 4°C o/n Mouse 1:5000, 37°C 45 mins 
p-ERK1/2 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
ERK1/2 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
p-JNK 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
JNK 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
p-p38 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
p38 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
Tubulin 1:1000, 4°C o/n Mouse 1:5000, 37°C 45 mins 
p-CREB/p-ATF1 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
CREB 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
HO-1 1:1000, 4°C o/n Rabbit 1:5000, 37°C 45 mins 
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2.20 Measurement of NF-B activity 
NF-B activity was determined using the EZ-DetectTM NF-κB p65 Transcription 
Factor Kit [Pierce Biotechnology; Thermo Fisher Scientific; MA, USA] following the 
manufacturer’s instructions. This is an ELISA based technique using nuclear lysates 
and it is provided with a 96-well in multi-strips format with the bound biotinylated-
consensus sequence for the p65 subunit. The biotinylated-consensus duplexes will 
bind only to the active form of the transcription factor subunit p65. This system is 
designed to improve result specificity.  Nuclear extracts (20 g) were added to the 
pre-coated wells and incubated at RT for 1 h. The plate was then washed using 
wash buffer and the anti-p65 primary antibody was added to the wells and 
incubated for 1 h on a shaker at RT. This is followed by another round of washing 
and incubation with HRP conjugated secondary antibody for another 1 h at room 
temperature without shaking. After washing, a luminol based chemiluminescent 
substrate provided with the kit was added to the wells and the signals were 
detected using Varioskan plate reader. Results were expressed as relative 
luminescence units (RLU). 
2.21 Histone deacetylase (HDAC) activity assay 
HDAC activity of DC nuclear extracts was determined using the HDAC Assay Kit 
[Millipore; Massachusetts, USA] following the manufacturer’s instructions. HDAC 
assay buffer x 2 (10l) was dispensed into each well of the 96-well round-bottom 
microtitre plate followed by the addition of 10 l  DC nuclear extracts samples  into 
the wells which were allowed to equilibrate at 37°C. Subsequently, 10 l of 4 mM 
HDAC Assay Substrate was added to the wells and mixed thoroughly and incubated 
at 37°C for 60 minutes. At the end of the incubation, 20 l of the diluted activator 
solution was added to each well, mixed thoroughly and incubated for 10 minutes at 
room temperature, and then absorbance read at 405 nm (OD 405) using Varioskan. 
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 2.22 Enzyme-Linked Immunosorbent Assay (ELISA)  
On day 6, DCs were harvested, washed with HBSS and CD11c+ve DCs were 
magnetically isolated using CD11c beads. These DCs were then seeded onto 24-well 
plates in duplicate at a density of 8 x 105 DCs per ml with a total volume of 2 ml/ 
well. After 48 h, cell-free cultures supernatants from untreated and treated groups 
were collected for measuring cytokines concentrations by Quantikine ELISA (R&D 
system; Abingdon, UK) according to manufacturer’s protocol. 
Briefly, 100 μl of standard and samples solutions was added to a 96-well 
polystyrene microplate pre-coated with polyclonal antibody specific for mouse 
cytokine. Solutions were mixed by gently tapping the plate frame for 1 minute and 
then cover with the adhesive strip provided and incubated for 2 h at room 
temperature with mild agitation. After that, each well was aspirated and washed 
with wash buffer (0.5% Tween-20 in 1x PBS), the process was repeated four times 
for a total of five washes. After the last wash, 100 μL of mouse cytokine conjugate 
was added to each well and incubated for 2 h at RT. When the incubation time 
finished, the wash steps were repeated as above and then 100 μL of substrate 
solution was added to each well and the wells incubated for 30 minutes at RT with 
protection from light. At the end of the 30 minutes, 100 μL of stop solution was 
added to each well and the plate gently tapped to ensure thorough mixing and then 
the optical density of each well was determined within 30 minutes using a 
microplate reader Varioskan set to 450 nm. Based on the raw OD data obtained, a 
standard curve was plotted and the concentrations of each cytokine were then 
calculated. 
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2.23 DC endocytosis assay 
Endocytic ability of iDCs was determined using DextranFITC as previously described 
(Sallusto et al., 1995b). Briefly, iDCs were harvested and resuspended at a density 
of 1 x 106 cells in 100 l complete medium. DCs were incubated with 0.5 g/ l 
DextranFITC [40,000 MW]  for indicated time points at 37C. Cells were washed twice 
in stain buffer (2% FBS, 2 mM EDTA in PBS), stained with anti-CD11cTC for surface 
expression of CD11c as described above and analysed by flow cytometry.  
 
2.24 DC phagocytosis assays 
Apoptotic thymocytes were generated by harvesting thymi from C57BL/6 mice 
followed by tissue homogenisiation, washing and cell resuspension in complete 
media (3 x 106 cells/ ml). Cells were incubated with 1 M dexamethasone at 37°C 
under 5% CO2 for 18 h. The proportion of apoptotic cells were determined by 
staining with Annexin-V yielding over 90% of apoptotic cells (data not shown). 
Apoptotic thymocytes were labelled with CFSE (4 M) for 20 minutes at 37°C prior 
to washing and co-culturing with 2 x 106 cells/ well (24-well plate) plate adherent 
DCs at a ratio of 2:1 for 2 h at 37°C under 5% CO2 and 4°C as a control. Cells were 
harvested and washed in stain buffer and stained with anti-CD11cTC prior to analysis 
by flow cytometry. 
To assess the phagocytosis of necrotic cells, Jurkat T cells were fluorescently 
labelled with 0.5 M CFSE for 30 minutes and necrosis was induced via snap 
freezing in liquid nitrogen. More than 90% of cells were necrotic as determined by 
trypan blue exclusion (data not shown). Necrotic cells were co-cultured with DCs as 
above. Cells were harvested and washed in stain buffer and stained with anti-
CD11cTC prior to analysis by flow cytometry.  
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2.25 Statistical analysis  
Where appropriate, experiments were performed at least in triplicate, and all 
experiments were replicated on separate occasions. Depending on the results set, 
data are expressed as either mean ± standard deviation of the mean (SD) or mean ± 
standard error of the mean (SEM). One-way analysis of variance (ANOVA) with 
Tukey’s post-test, Mann-Whitney U test, or Student's t-test were used to assess the 
significance of any differences in the data compared to appropriate controls. A two-
sided P value of ≤0.05 was considered to be statistically significant. 
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CHAPTER THREE 
 
 
REGULATION OF DC PHENOTYPE, FUNCTION, 
AND SIGNALLING PATHWAYS BY NRF2  
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3.1 INTRODUCTION 
Dendritic cells (DCs) are potent antigen presenting cells (APCs) that serve as 
sentinels which initiate and modulate immune responses (Cella et al., 1997b; Hart, 
1997). They possess molecular sensors and antigen-processing machinery required 
to recognize pathogens and integrate chemical information ultimately leading to an 
orchestrated immune response that is of appropriate magnitude, quality, and 
specificity (Drozina et al., 2005; Jones, 1997; Steinman et al., 1999). The activation 
of naive T cells by DCs requires both signal 1 (TCR signals via MHC class I and II) and 
signal 2 (co-stimulatory signals via CD80, CD86 and CD40) as well as signal 3 from 
cytokines which help to elicit distinct T cell responses (Bachmann et al., 1999b; 
Banchereau et al., 2000). Up-regulation in the expression of co-stimulatory cell 
surface molecules and increased cytokine secretion are associated with 
transformation of DCs from an immature to a mature state (Banchereau and 
Steinman, 1998; Caux et al., 1994; Inaba et al., 1994). Many signalling pathways are 
involved in DC maturation and these are primarily initiated through the binding of 
Toll-like receptors (TLR) to their ligands, usually bacterial or viral-derived proteins 
and nucleic acids. Engagement of TLRs triggers a complex network of signalling 
molecules and adaptor proteins that will ultimately modulate DC responses. Each 
individual TLR can activate common and unique transcription factors through 
different intracellular signalling pathways (Kawai and Akira, 2005). Of the 13 known 
mammalian TLRs and their ligands, lipopolysaccharide (LPS), which activates TLR4, 
is the most commonly used ligand for the maturation of DCs in vitro. All these 
signalling networks cooperate, integrate, and finally converge onto major pathways 
such as that of the nuclear factor-B (NF-B) and mitogen-activated protein kinases 
(MAPKs) (Agrawal et al., 2003; Zhong et al., 2006). 
The production of reactive oxygen species (ROS) that possess high chemical 
reactivity is due to the incomplete reduction of oxygen during aerobic metabolism 
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and from exposure to some natural and synthetic toxicants (D'Autreaux and 
Toledano, 2007; Davies, 2000; Yu, 1994). ROS include superoxide anion (O2
–), 
hydrogen peroxide (H2O2) and the hydroxyl radical (HO
•). ROS can also function as 
intracellular signalling molecules or serve as diffusible signals that modulate various 
intracellular signalling pathways by chemically reacting with specific atoms of target 
proteins leading to covalent protein modifications (Forman and Torres, 2002; 
Nathan, 2003).  
Intracellular redox homeostasis is maintained through a number of fast, precise, 
and highly dynamic cytoprotective defence measures that counterbalance the 
increment in ROS levels. The functionality of these adaptive cytoprotective cellular 
defence systems are primarily governed by the activity of the redox responsive 
transcription factor Nrf2 (D'Autreaux and Toledano, 2007). Under conditions of 
chemical/oxidative stress, Nrf2 is able to evade Keap1-mediated repression, 
accumulate within the nucleus and mediate transactivation of ARE-dependent 
genes (Copple et al., 2008). Therefore, Nrf2 may serve as a master regulator of the 
ARE-driven cellular defence system against oxidative stress. In addition, Nrf2 can 
regulate the balance between cell quiescence and proliferation and self-renewal 
and differentiation (Lee et al., 2005). 
In the context of DC biology, Nrf2 has been found to regulate co-stimulatory 
molecule expression and modulate cytokine secretion (Rangasamy et al., 2010). In 
addition to that, Nrf2-mediated signalling mechanisms alter the DCs response to 
common environmental allergens, which may contribute to susceptibility to allergic 
diseases (Williams et al., 2008). 
However, intracellular signalling mechanisms that are involved in Nrf2-mediated 
regulation of DC phenotype and function have not been defined. In addition, the 
relevance of altered ROS levels arising as a result of Nrf2 deficiency, in the context 
of DC activation and function has not been investigated. 
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The hypothesis of the work described in this chapter is that Nrf2 affects DC biology 
through its effects on the key intracellular signalling pathways, NF-B and MAPK 
pathways. Through utilisation of the Nrf2 experimental mouse model, we also 
aimed to define the requirement of ROS dysregulation in Nrf2-mediated effects on 
DC phenotype, function, and signalling. 
3.2 RESULTS 
3.2.1 Loss of Nrf2 has variable effects on DC proliferation depending on culture 
conditions 
Dendritic cells (DCs) develop from bone marrow precursors and are distributed in 
limited numbers throughout peripheral tissues and lymphoid organs (Steinman, 
1991). Despite the fact that DCs represent only a small percentage of mononuclear 
leukocytes, they play a major role in initiating and regulating immune responses 
(Banchereau et al., 2000). Generation and distribution of sufficient numbers of DCs 
is required for optimal immune functions. 
Previous studies have shown that Nrf2 controls mechanisms which regulates stem 
cell proliferation in high-turnover tissues such as bone marrow and intestine, and is 
apparent by the excessive expansion of haematopoietic progenitors from Nrf2-/-
bone marrow precursors (Hochmuth et al., 2011; Tsai et al., 2013). However the 
impact of loss of Nrf2 on DC proliferation and differentiation from bone marrow 
progenitors has not been evaluated. In the current study, we tested the hypothesis 
that loss of Nrf2 results in increased DC proliferation. In order to examine this, 
murine Nrf2-/- and Nrf2+/+ bone marrow progenitor cells were initially seeded in 
culture medium at increasing cell densities and cultured in GM-CSF over various 
time points. The final differentiated DC numbers for both genotypes were then  
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Figure 3.1. Nrf2 modulation of DC proliferation depends on culture conditions. 
Nrf2+/+ and Nrf2-/- iDCs were plated at indicated cell densities. [3H]Thymidine (3H-
Thy) was added at day 4. Proliferation of iDCs was determined by scintillation 
counting of incorporated [3H]Thymidine at day 5 (A), day 6 (B) and day 7 (C). Data 
are presented as average [3H]Thymidine scintillation counts ± S.D. Statistical 
significance was tested by one-way analysis of variance (*, p<0.05). Data are 
derived from three independent experiments. 
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compared at each time point. At day 5, Nrf2-/- iDCs proliferate more than Nrf2+/+ 
iDCs at most cell densities (10, 25, 50, 75, and 100 x 103 cells/ml, Figure 3.1A). 
However on day 6, Nrf2-/- iDCs proliferate more than Nrf2+/+ iDCs only at 10 x 103 
cells/ml while other cell densities showed no differences as shown in Figure 3.1B. 
This difference continues on day 7 at the same cell density (10 x 103 cells/ml) but 
other cell densities showed opposite effects where Nrf2+/+ iDCs proliferate more 
than Nrf2-/- iDCs as in Figure 3.1C. These results demonstrated that, depending on 
cell density, Nrf2 has the potential to affect DC proliferative capacity.  
 
3.2.2 Loss of Nrf2 is associated with increased levels of anti-apoptotic protein, Bcl-
2, but does not increase DC survival  
Altered proliferative capacity of Nrf2-/- iDCs could also be accompanied by altered 
survival of these iDCs. The Bcl-2 protein serves as a critical regulator of pathways 
involved in apoptosis and increased Bcl-2 expression is associated with increased 
cell survival (Chao and Korsmeyer, 1998). Therefore we sought to examine the level 
of Bcl-2 by Western immunoblotting. The result revealed an increase in the 
expression of Bcl-2 in Nrf2-/- iDCs basally in comparison to Nrf2+/+ iDCs (Figure 3.2A). 
In order to test whether increased Bcl-2 expression leads to increased survival (or 
reduced cell death) of Nrf2-/- DC, we examined cell apoptosis using FITC Annexin V 
staining which binds to phophatidyl serine (PS) molecules. Phosphatidyl serine is 
exposed on the inverted phospholipid bilayer cell membrane in one of the early 
events involved in apoptosis (Fadok et al., 1992; Vermes et al., 1995). While loss of 
Nrf2 resulted in a reduction in the proportion of Annexin V positive DCs (apoptotic 
DCs) in relation to the wild type control, this was not statistically significant (Figure 
3.2B 8.6 ± 2.1% in Nrf2-/- iDCs versus 11.4 ± 2.0% in Nrf2+/+ iDCs, p > 0.05).  
Since Annexin V staining positivity precedes the loss of membrane integrity (which 
accompanies the later stages of cell death) resulting from either apoptotic or 
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necrotic processes, staining with Annexin V-FITC is typically used in conjunction 
with a live/dead cell-differentiating dye such as propidium iodide (PI) to allow the 
investigator to identify early apoptotic cells (PI negative, Annexin V-FITC positive) 
and dead cells (PI positive, AnnexinV-FITC positive). 
DC necrosis measured by propidium iodide (PI) staining (Sawai and Domae, 2011) 
revealed a reduction in the proportion of necrotic cells in Nrf2-/- iDCs when 
compared with Nrf2+/+ iDCs, but again this was not statistically significant (Figure 
3.2C 8.6 ± 1.4% in Nrf2-/- iDCs versus 11.8 ± 2.3% in Nrf2+/+ iDCs, p > 0.05). To test 
how these DCs respond to the apoptosis inducing drug e.g. dexamethasone (Abe 
and Thomson, 2006; Cifone et al., 1999), Nrf2-/- and Nrf2+/+ iDCs were treated with 1 
μM dexamethasone for 18 h and cell apoptosis and necrosis were measured. 
Results revealed that dexamethasone induced a significant increase in cell 
apoptosis and necrosis in both genotypes as shown in Figure 3.2D for apoptosis 
(Nrf2-/- iDCs 8.6 ± 2.5% in untreated and 20.7 ± 1.4% in dexamethasone treated DCs 
while in Nrf2+/+ iDCs 13.8 ± 2.1% in untreated and 23.2 ± 2.9% in dexamethasone 
treated DCs). The same apply for cell necrosis as in Figure 3.2E (Nrf2-/- iDCs 8.4 ± 
1.3% in untreated and 17.8 ± 1.8% in dexamethasone treated DCs while in Nrf2+/+ 
iDCs 11.8 ± 1.9% in untreated and 17.3 ± 1.7% in dexamethasone treated DCs). 
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Figure 3.2. Loss of Nrf2 is associated with increased Bcl-2 expression but not DC 
survival. A, Whole cell lysates from Nrf2+/+ and Nrf2-/- iDCs were subjected to SDS-
PAGE. Western immunoblotting was used to determine the levels of Bcl-2. Actin 
was assessed for equal loading of lanes. Data are representative of four 
independent experiments. On day 7, Nrf2+/+ and Nrf2-/- iDCs were stained with 
Annexin VFITC (B) and PIPE-Cy®5.5 (C) and analysed by flow cytometry. Percentages of 
Annexin V+ and PI+ iDCs are indicated as percentage represented (Bi) and (Ci) and 
quantified in (Bii) and (Cii). On day 6, Nrf2+/+ and Nrf2-/- iDCs were treated with 
dexamethasone (DEX) 1μM for 18 h or left untreated (basal) and then cells were 
stained with Annexin VFITC (D) and PIPE-Cy®5.5 (E) and analysed by flow cytometry. 
Percentages of Annexin V+ and PI+ iDCs are indicated as percentage represented 
D (i) D (ii) 
E (i) E (ii) 
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(Di) and (Ei) and quantified in (Dii) and (Eii). Data are representative of 4 
independent experiments. (*, p < 0.05; NS- NS-Not Significant).  
 
3.2.3 Loss of Nrf2 results in increased ROS levels without increase in ATP 
production in immature DCs 
Nrf2 signalling increases transcription of antioxidant genes that counter elevations 
in intracellular ROS (Reddy et al., 2007b). The maintenance of DC intracellular redox 
status is imperative for appropriate DC immune functioning (Williams et al., 2008). 
However, the potential effect caused by the loss of Nrf2 on DC ROS levels has not 
yet been clearly defined. We therefore examined ROS levels using the fluorescent 
ROS indicator, dihydroethidium, in Nrf2-/- and Nrf2+/+ iDCs basally and in response 
to the oxidative stress inducer, hydrogen peroxide (H2O2) and the TLR agonist, LPS. 
As demonstrated in Figure 3.3A, Nrf2-/- iDCs had significantly higher basal ROS 
levels in comparison with Nrf2+/+ iDCs (mean fluorescence intensity 1341 ± 98 
versus 833 ± 112, p < 0.05). Furthermore, Nrf2-/- iDC ROS levels were significantly 
increased in comparison with their wild type counterpart following treatment with 
H2O2 (mean fluorescence intensity 2159 ± 116 versus 1482 ± 102, p < 0.05) and LPS 
(mean fluorescence intensity 1557 ± 137 versus 1026 ± 102, p < 0.05). Increased 
ROS levels may result from enhanced cell oxidative phosphorylation due to increase 
adenosine triphosphate (ATP) production (Del Prete et al., 2008; Minet and Gaster, 
2012). To test this possibility, we measured ATP production by DCs. Results show 
that Nrf2-/- iDCs produce more ATP than Nrf2+/+ iDCs, but this was not statistically 
significant as shown in Figure 3.3B ( 251 ± 39 x 103 versus 210 ± 26.5 x 103, p > 
0.05).  
Taken together, these results suggest that loss of Nrf2 impairs the capacity of iDCs 
to maintain redox homeostasis.  
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Figure 3.3. Loss of Nrf2 results in increased DC intracellular ROS Levels but is not 
accompanied by increased oxidative metabolism. A, Nrf2+/+ and Nrf2-/- iDCs were 
untreated or treated with LPS (1 µg/ml) or H2O2 (1 mM) for 10 minutes at 37
°C. Cells 
were then incubated with the ROS-indicator DHE before analysis by flow cytometry. 
Data-points represent mean fluorescence intensity of six separate measurements 
from 2 independent experiments. Horizontal line represents mean. Statistical 
significance was tested by unpaired Student’s t-test (*, p<0.05). B, Nrf2+/+ and Nrf2-
/- iDCs harvested and replated at 30x103 cell/ 100 μl/ well in 96-well flat-bottom 
plate and ATP was measured using a luminescence assay expressed as Relative 
luminescence unit (RLU). Statistical significance was tested by unpaired Student’s t-
test (NS- NS-Not Significant). Data are representative of three independent 
experiments. 
 
 
A 
B 
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3.2.4 Reduction of cellular glutathione levels leads to increased ROS 
Nrf2 is a critical biosynthetic regulator of the antioxidant glutathione (GSH) (Reddy 
et al., 2007a). Our lab has shown that Nrf2-deficient DCs exhibit diminished GSH 
levels and reduction of GSH levels by buthionine sulfoximine (BSO) in wild type iDCs 
did not recapitulate the Nrf2-/- iDCs altered phenotype and function (Aw Yeang et 
al., 2012). We therefore sought to test a possible link between GSH and ROS, and 
found that Nrf2+/+ iDCs treated with BSO exhibited high levels of ROS that are 
comparable with Nrf2-/- iDCs (Figure 3.4). This further supports the assumption that 
altered DC phenotype and function may potentially be ROS derived. 
 
Figure 3.4. Reduction of cellular glutathione leads to increased ROS. Nrf2+/+ iDCs 
untreated or treated with BSO (100 M) for 24h with Nrf2-/- iDCs used as control. 
Then cells were incubated with the ROS indicator dihydroethidium and analysed by 
flow cytometry. Data are presented as average mean fluorescence intensity ± S.D. 
Statistical significance was assessed using unpaired Student’s t test. Data are 
representative of three independent experiments. (*, p<0.05; NS-Not Significant).  
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3.2.5 Loss of Nrf2 results in altered iDCs phenotype  
Elevated ROS levels have been shown to enhance DC co-stimulatory molecule 
expression and maturation (Kantengwa et al., 2003; Matsue et al., 2003b). To 
evaluate the role of Nrf2 in regulating the phenotype of iDCs, we compared the 
maturation states of Nrf2-/- and Nrf2+/+ iDCs. Maturation is accompanied by an 
increase in the proportion of DCs that express higher levels of co-stimulatory 
molecules (Steinman, 2003). Immature DCs are composed of subpopulations that 
express either high or low levels of co-stimulatory molecules (Figure 3.5A). Flow 
cytometric analysis of iDCs demonstrated that the proportion of iDCs that express 
high levels of MHC class II, CD86, and CD40 was significantly increased in the Nrf2-/- 
iDCs in comparison with the Nrf2+/+ iDCs as shown in Figure 3.5A for MHC class II 
(Nrf2-/- 44.0 ± 2.0% versus Nrf2+/+ 19.3 ± 2.5%, p < 0.05); 3.5B for CD86 (Nrf2-/- 37.1 
± 2.8% versus Nrf2+/+ 17.2 ± 1.0%, p < 0.05); and 3.5C for CD40 (Nrf2-/- 31.9 ± 3.9% 
versus Nrf2+/+ 19.7 ± 1.4%, p < 0.05). 
These results showed that loss of Nrf2 enhances co-stimulatory molecule 
expression in iDCs 
  
A (i) 
A (ii) 
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Figure 3.5. Loss of Nrf2 results in enhanced co-stimulatory molecule expression in 
immature DCs. Nrf2+/+ and Nrf2-/- iDCs labelled with antibodies against (A) MHC 
class II, (B) CD86 and (C) CD40. Co-stimulatory receptor expression was determined 
by flow cytometry and presented as representative histograms and percentage of 
cells expressing high MHC class II, CD86 or CD40 indicated above the marker with 
Bar charts for the percentages of cells expression high MHC class II (Aii), CD86 (Bii) 
and CD40 (Cii). Data derived from three independent experiments are presented as 
average percentage ± SD. Statistical significance was assessed using unpaired 
Student’s t test (*, p<0.05). 
B (i) 
B (ii) 
C (i) 
C (ii) 
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3.2.6 Loss of Nrf2 does not alter LPS responsiveness of DCs  
To test whether loss of Nrf2 could affect the DC responsiveness to LPS stimulation, 
we examined the effect of LPS-induced maturation in Nrf2+/+ and Nrf2-/- DC. We 
found that DCs from Nrf2-/- show higher expression of MHC class II and CD86 in 
response to all concentrations of LPS (Figure 3.6A panel (i) and 3.6B panel (i)), but 
for CD40 the higher expression only observed at low concentrations of LPS (Figure 
3.6C panel (i)). However, normalising of the raw data reveals a similar degree of 
responsiveness to LPS in both genotypes for MHC class II (Figure 3.6A panel (ii)), 
CD86 (Figure 3.6B panel (ii)) and CD40 Figure 3.6C panel (ii)). 
These results showed DC responsiveness to LPS is not affected by loss of Nrf2. 
  A (i) A (ii) 
B (i) B (ii) 
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Figure 3.6. Responsiveness of DCs to LPS is unaffected by loss of Nrf2. Nrf2+/+ and 
Nrf2-/- iDCs treated with or without indicated doses of LPS for 18 h. MHC class II 
(Ai), CD86 (Bi) and CD40 (Ci) expression was determined by flow cytometry and 
presented as percentage of cells expressing high MHC class II or CD86. Raw data 
have been normalised for both genotype by subtracting the response percentages 
of (0 g/ml LPS) from themselves and all the other response percentages so that they 
have same starting point of 0% and highest percentage of receptor expression 
exhibited by each genotype was set at 100% maximal response and all other were 
relative to it as shown in MHC class II (Aii), CD86 (Bii) and CD40 (Cii). Data derived 
from three independent experiments are presented as average percentage ± SD. 
Statistical significance was assessed using unpaired Student’s t test  (*, p<0.05; NS-
Not Significant).  
 
3.2.7 Increased co-stimulatory receptor expression of Nrf2-/- iDCs is associated 
with enhanced antigen-specific CD8 T cell stimulatory capacity 
The response of CD8 cytotoxic T cells to intracellular pathogens and tumours is 
generally attributed to T cell receptor (TCR)-mediated signalling events triggered by 
speciﬁc interaction of peptide–major histocompatibility complex (MHC) presented 
C (i) 
C (ii) 
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on DCs with the CD8 TCRs (Berg and Forman, 2006; Guermonprez et al., 2002). 
However, full CD8 T cell activation requires co-stimulatory inputs provided through 
DC receptors such as CD86 (Chai et al., 1999). Immature DCs expressing low levels 
of co-stimulatory molecules are unable to stimulate a fully competent antigen-
specific CD8 T cell response (Bachmann et al., 1999b). Therefore, maturation of DCs 
is crucial for the initiation of CD8 cytotoxic T cell dependent immunity. Given that 
Nrf2-/- iDCs have elevated expression of CD86, CD40, and MHC class II, we 
postulated that these iDCs would be capable of inducing an antigen-specific CD8 T 
cell response. To address this, we utilized a TCR transgenic mouse model wherein 
the CD8 T cells express a T cell receptor (F5 TCR) that recognizes an antigenic 
peptide, NP68, when presented by DCs (Mamalaki et al., 1992). The functional 
consequence of changes in DC co-stimulatory molecule expression can be assessed 
by the ability of NP68-bearing DCs to stimulate F5 CD8 T cell proliferation. 
Nrf2+/+ iDCs pulsed with increasing concentrations of NP68 did not induce specific 
F5 CD8 T cell proliferation until 10 nM NP68 (Figure 3.7), with a greater 
proliferation seen at higher concentrations of NP68 (100 nM). In contrast, Nrf2-/- 
iDCs were able to induce significant F5 CD8 T cell proliferation even at 1 nM NP68 
and a 3-to-10-fold higher degree of T cell proliferation when compared with Nrf2+/+ 
iDCs at all NP68 concentrations (Figure 3.7, p < 0.05). 
These data demonstrate that the enhanced maturation phenotype of Nrf2-/- iDC is 
associated with an increased capacity to induce antigen-specific CD8 T cell 
stimulation. 
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Figure 3.7. Increased T cell stimulatory capacities of Nrf2-/- iDCs. Nrf2+/+ and Nrf2-/- 
iDCs were pulsed with increasing concentrations of NP68 antigenic peptide, and 
DCs were then co-cultured with F5 CD8 T cells for 72 h.[3H]Thymidine (3H-Thy) was 
added for the last 16 h. Proliferation of T cells was determined by scintillation 
counting of incorporated [3H] Thymidine. Data are presented as average 
[3H]Thymidine scintillation counts ± S.D. Statistical significance was tested by one-
way analysis of variance (*, p<0.05). Data are derived from three independent 
experiments.  
  
3.2.8 Altered immature DC function due to the loss of Nrf2 is not dependent on 
elevated ROS 
Loss of Nrf2 in iDCs leads to elevated ROS levels (Figure 3.3A), increased co-
stimulatory molecule expression (Figure 3.5A), and enhanced T cell stimulatory 
potential (Figure 3.7) (Aw Yeang et al., 2012). We investigated whether the 
elevated ROS contributed to increased co-stimulatory molecule expression by 
reducing ROS to normal levels using antioxidants in these cells. Vitamins C and E 
possess antioxidant activity and are known to reduce ROS levels (Jeong et al., 2011; 
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Roche et al., 2009). Nrf2+/+ and Nrf2-/- iDCs were treated with vitamins C and E for 
48 h, and ROS levels measured by flow cytometry. A significant reduction in ROS 
levels was observed in vitamin-treated Nrf2-/- iDCs compared with untreated 
controls (Figure 3.8A, mean fluorescence intensity, vitamin-treated Nrf2-/- iDCs 
2079 ± 132 versus untreated Nrf2-/- iDCs 938 ± 213, p < 0.05). A slight reduction in 
the ROS levels was also seen in vitamin-treated Nrf2+/+ iDCs, which was not 
statistically significant (Figure 3.8A, mean fluorescence intensity, vitamin-treated 
Nrf2+/+ iDCs 1230 ± 209 versus untreated Nrf2+/+ iDCs 878 ± 148, p > 0.05). It is 
important to note that the ROS levels in vitamin-treated Nrf2-/- iDCs was equivalent 
to that in untreated Nrf2+/+ iDCs (Figure 3.8A). To test whether elevated 
intracellular redox levels is responsible for increased DC co-stimulatory molecule 
expression, we measured MHC class II and CD86 expression in Nrf2-/- iDCs following 
vitamins treatment. As shown in Figure 3.8B, there was no significant difference in 
the co-stimulatory molecules expression between untreated controls and vitamins 
treatment groups in both MHC class II (23.1 ± 4.7% versus 21.2 ± 4.2%, p > 0.05 in 
Nrf2+/+ iDCs; 43.2 ± 2.1% versus 42.6 ± 2.7% p > 0.05 in Nrf2-/- iDCs, panel (i)) and 
CD86 (18.4 ± 1.9% versus 17.2 ± 2.3%, p > 0.05 in Nrf2+/+ iDCs; 34.8 ± 3.5% versus 
35.2 ± 4.1%, p > 0.05 in Nrf2-/- iDCs, panel (ii)). These results indicate that restoring 
ROS levels in Nrf2-/- DC to Nrf2+/+ DC status does not reverse co-stimulatory 
molecule expression. 
We further investigated whether the lack of changes in co-stimulatory molecule 
expression in Nrf2-/- iDCs upon ROS reset is also reflected in its ability to induce 
antigen-specific T cell activation. Consistent with our previous findings, lowering of 
ROS levels by vitamin treatment did not reduce the potential of NP68-bearing Nrf2-
/- iDCs to stimulate F5 CD8 T cell proliferation (Figure 3.8C). 
These results demonstrate that altered ROS status associated with loss of Nrf2 does 
not contribute to increased co-stimulatory molecules expression and T cell 
stimulatory potential of DCs. 
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Figure 3.8. Reducing ROS levels does not restore altered phenotype and function 
of Nrf2-deficient iDCs. A, Nrf2+/+ and Nrf2-/- iDCs were treated with or without 
vitamins C (1 mM) and E (100 µM) for 48 h. then were incubated with the ROS 
indicator dihydroethidium and analysed by flow cytometry. Data are presented as 
average mean fluorescence intensity ± S.D. Statistical significance was assessed 
using unpaired Student’s t test. Data are representative of three independent 
experiments. (*, p<0.05; NS-Not Significant). B, Nrf2+/+ and Nrf2-/- iDCs were treated 
with or without vitamins C (1 mM) and E (100 µM) for 48 h. then were labelled with 
fluorescent conjugated antibodies against MHC class II and CD86 co-stimulatory 
molecules. Co-stimulatory molecule expression was determined by flow cytometry. 
The percentages of iDCs expressing high levels MHC class II (i) and CD86 (ii) are 
presented as average percentage ± SD. Statistical significance was assessed using 
unpaired Student’s t test. Data are representative of three independent 
experiments. (NS-Not Significant). Data are derived from three independent 
experiments. C, Nrf2+/+ (i) and Nrf2-/- (ii) iDCs were treated with or without vitamins 
C (1 mM) and E (100 µM) for 48 h. then were pulsed with increasing concentrations 
of NP68 antigenic peptide, then co-cultured with F5 CD8 T cells for 72 h. [3H]-
Thymidine (3H-Thy) was added for the last 16 h. Proliferation of T cells was 
determined by scintillation counting of incorporated [3H]-thymidine. Data are 
presented as average [3H]-thymidine scintillation counts ± S.D. Statistical 
significance was assessed using one-way ANOVA. Data are representative of three 
independent experiments. (NS-Not Significant).  
   
C (i) C (ii) 
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3.2.9 The NF-B pathway does not contribute to altered phenotype and function 
observed in Nrf2-deficient DC 
The transcription factor NF-B has been implicated in driving transcription of genes 
for the expression of MHC molecules, co-stimulatory receptors (CD40 and CD86) 
and cytokines in DCs (Yoshimura et al., 2001). Elevated ROS levels in DCs were 
found to be associated with alterations in NF-B signalling (Sheng et al., 2010). 
Upon activation, upstream IB kinase (IKK) complexes are activated, which in turn 
phosphorylate IB, resulting in its ubiquitination and subsequent proteasomal 
degradation. This facilitates NF-B translocation into the nucleus, where it can 
transcribe genes involved in the immune response (Oeckinghaus and Ghosh, 2009). 
It is unknown whether changes observed in the DC phenotype and function in the 
absence of Nrf2 was due to alterations in the NF-B signalling pathway. We 
therefore first examined the degradation of IB upon LPS stimulation in Nrf2+/+ 
iDCs and Nrf2-/- iDCs via western blot. Figure 3.9A revealed that the kinetics of LPS-
triggered IBdegradation is altered in Nrf2-/- iDCs. While, basally (at 0 min) the 
levels of IBwere comparable in both genotypes, upon stimulation with LPS, 
IBdegradation could be seen as early as 10 min, progressing to total loss of 
IBat 60 min in Nrf2+/+ iDCs, whereas in Nrf2-/- iDCs IBdegradation was 
delayed in onset (at 15 min) and incomplete in extent with residual IBbeing 
detected at 90 min after stimulation. Subsequently, we examined basal and LPS-
induced phosphorylation of p65. Although there were no basal differences in 
phosphorylated NF-B subunit p65, LPS-induced phosphorylation of p65 was 
impeded in the Nrf2-/- iDCs when compared with the Nrf2+/+ iDCs (Figure 3.9B panel 
(i)). In Nrf2+/+ iDCs, an increase in p65 phosphorylation could be detected at 10 min, 
peaking at 30 min, followed by a decrease to basal levels at 120 min after LPS 
stimulation (Figure 3.9B panel (i)). In contrast, no increases in p65 phosphorylation 
were detected in Nrf2-/- iDCs (Figure 3.9B panel (i)) at any of the time points. 
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Densitometry analysis of p65 phosphorylation normalised to total p65 protein 
expression is depicted in Figure 3.9B panel (ii).  
Since there was no change in the basal phosphorylation of p65, we next examined 
the basal nuclear NF-B (p65) activity by chemiluminescent transcription factor 
assay and demonstrated that there were no significant basal differences in NF-B 
activity between Nrf2-/- and Nrf2+/+ iDCs (Figure 3.9C). 
To investigate whether inhibition of NF-B could reverse the enhanced co-
stimulatory molecule expression in Nrf2-/- iDCs, we treated Nrf2-/- and Nrf2+/+ iDCs 
with the p65 inhibitor, Bay 11-7082 (Mori et al., 2002) and assessed its effect on iDC 
co-stimulatory molecule expression. As expected, p65 inhibition did not reverse the 
enhanced expression of MHC class II and CD86 in Nrf2-/- iDCs as shown in Figure 
3.9D panel (i) and (ii) (MHC class II 40.8 ± 1.6% versus 43.8 ± 1.4%, p > 0.05; CD86 
30.3 ± 0.6% versus 33.3 ± 5.5%, p > 0.05) and also no changes were observed in 
treated Nrf2+/+ iDCs (MHC class II 13.1 ± 0.2% versus 12.3 ± 1.4%, p > 0.05; CD86 9.7 
± 0.6% versus 11.0 ± 2.6%, p > 0.05). 
Additionally, the iDC-mediated antigen-specific CD8 T cell proliferation also 
remained unaltered following p65 inhibition in Nrf2+/+ and Nrf2-/- iDCs (Figure 3.9E 
(i) and (ii)). 
Taken together, these results suggest that although loss Nrf2 in iDCs may affect 
upstream elements of the NF-B pathway (phosphorylation of p65 and IB 
degradation), it did not affect basal NF-B activity and thus the enhanced co-
stimulatory molecule expression exhibited in Nrf2-/- iDCs is not dependent on NF-B 
activity. 
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Figure 3.9. The NF-B pathway does not contribute to altered phenotype and 
function of Nrf2-deficient iDCs. A and B, Nrf2+/+ and Nrf2-/- iDCs were treated with 
LPS (1 μg/ml) for indicated times and whole cell lysates were subjected to SDS-
PAGE. The levels of IBa and actin (A) and the phosphorylation levels of p65 and 
total p65 (B i) were assessed by Western blotting and p-p65 protein bands were 
blotted by densitometry against total p65 (B ii). Data are representative of 3 
independent experiments. C, NF-B activity in the nuclear lysates of Nrf2+/+ and 
Nrf2-/- iDCs was measured and presented as dot plots with each dot representing 
mean RLUs (from triplicates).  Data are from 6 independent experiments. Horizontal 
lines indicate means for each group. D, Nrf2+/+ and Nrf2-/- iDCs treated with or 
without 10 µM BAY 11-7082 (BAY) for 48 h. MHC class II (i) and CD86 (ii) expression 
was determined by flow cytometry and presented as percentage of cells expressing 
high MHC class II or CD86. Data derived from three independent experiments are 
presented as average percentage ± SD. (NS-Not Significant). E, Nrf2+/+ (i) and Nrf2-/- 
(ii) iDCs treated with or without 10 µM BAY 11-7082 (BAY) for 48 h. then were 
pulsed with increasing concentrations of NP68 antigenic peptide, and co-cultured 
with F5 CD8 T cells for 72 h. [3H]-Thymidine (3H-Thy) was added for the last 16 h. 
Proliferation of T cells was determined by scintillation counting of incorporated 
[3H]-thymidine. Data are presented as average [3H]-thymidine scintillation counts ± 
S.D. Statistical significance was assessed using unpaired Student’s t test or one-way 
ANOVA. Data are representative of three independent experiments. (NS-Not 
Significant). 
E (i) E (ii) 
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3.2.10 ERK1/2 MAPK is not involved in mediating Nrf2-dependent modulation of 
DC function 
Redox alterations in DCs have been found to be associated with changes in ERK1/2 
MAPK signalling pathway (Aiba et al., 2003). Activation of MAPK pathways by 
stimuli such as LPS results in phosphorylation of ERK1/2 (Rescigno et al., 1999). We 
therefore investigated whether loss of Nrf2 in DCs affected ERK1/2 signalling. In 
order to test that we examined the phosphorylation levels of ERK1/2 via Western 
blot. Results revealed that the level of phosphorylated ERK1/2 was slightly higher in 
Nrf2-/- iDCs in comparison with Nrf2+/+ iDCs both basally and upon LPS stimulation 
(Figure 3.10A panel (i)). Furthermore, Nrf2-/- iDCs exhibited enhanced 
phosphorylation kinetics of ERK1/2 in response to LPS in comparison with their wild 
type counterpart. The onset of LPS-induced phosphorylation of ERK1/2 was 
observed at 10 min in Nrf2-/- iDCs when compared with 15 min for Nrf2+/+ iDCs. 
These changes were more obvious when observed in densitometry analysis of 
phosphorylated ERK1 normalised to total ERK1 protein expression (3.10A panel (ii)) 
and phosphorylated ERK2 normalised to total ERK2 protein expression (3.10A panel 
(iii)). 
To assess whether this change in basal ERK1/2 phosphorylation contributes to the 
enhanced co-stimulatory molecule expression in Nrf2-/- iDCs, we treated Nrf2-/- and 
Nrf2+/+ iDCs with the ERK inhibitor, PD98059 (Yanagawa et al., 2002), and assessed 
its effect on iDC co-stimulatory molecule expression. ERK inhibition did not reverse 
the enhanced expression of MHC class II and CD86 in Nrf2-/- iDCs but rather caused 
a slight but insignificant increase (MHC class II 43.8 ± 1.8% versus 48.9 ± 3.2%, p > 
0.05; CD86 37.7 ± 2.3% versus 43.5 ± 3.5%, p > 0.05) (Figure 3.10B panel (i) and (ii)). 
As reported previously for human DCs (Aiba et al., 2003), similar findings were 
found in Nrf2+/+ iDCs (MHC class II 19.3 ± 1.2% versus 21.1 ± 1.0%, p > 0.05; CD86 
13.3 ± 0.2% versus 14.8 ± 0.9%, p > 0.05). 
94 
 
Consistent with the lack in the changes in co-stimulatory molecule expression, 
inhibition of ERK1/2 MAPK did not result in reduced DC-mediated antigen-specific 
CD8 T cell proliferation in Nrf2-/- iDCs as shown in Figure 3.10C panel (i) and (ii).  
From these findings we conclude that enhanced co-stimulatory molecule 
expression in Nrf2-/- iDCs is not dependent on ERK1/2 activity. 
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Figure 3.10. ERK1/2 does not contribute to the altered DC phenotype and function 
in Nrf2-/- iDCs. A, Nrf2+/+ and Nrf2-/- iDCs were treated with LPS (1 μg/ml) for 
indicated time points and whole cell lysates were subjected to SDS-PAGE. The 
phosphorylation levels of ERK1/2 and total ERK1/2 were assessed by Western 
blotting (i) and p-ERK1 (ii) and p-ERK2 (iii) protein bands were analysed by 
densitometry and normalised to total ERK1 and ERK2 respectively. Data are 
representative of 3 independent experiments. B, Nrf2+/+ and Nrf2-/- iDCs were 
treated with or without 50 µM of ERK1/2 inhibitor (PD98059) for 48 h. MHC class II 
(i) and CD86 (ii) expression was determined by flow cytometry and presented as 
percentage of cells expressing high MHC class II or CD86. Data derived from three 
independent experiments are presented as average percentage ± SD. Statistical 
significance was assessed using unpaired Student’s t test. (NS-Not Significant). C, (i) 
Nrf2+/+ and (ii) Nrf2-/- iDCs treated with or without 50 µM of ERK1/2 inhibitor 
(PD98059) for 48 h. then were pulsed with increasing concentrations of NP68 
antigenic peptide, and co-cultured with F5 CD8 T cells for 72 h. [3H]-Thymidine (3H-
Thy) was added for the last 16 h. Proliferation of T cells was determined by 
scintillation counting of incorporated [3H]-thymidine. Data are presented as average 
[3H]-thymidine scintillation counts ± S.D. Statistical significance was assessed using 
unpaired Student’s t test or one-way ANOVA. Data are representative of three 
independent experiments. (NS-Not Significant). 
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3.2.11 c-Jun N-terminal kinase (JNK) is not involved in mediating Nrf2-dependent 
modulation of DC function 
JNK signalling pathway play a vital role in the process of DCs maturation that is 
distinct from those of the p38MAPK and ERK cascades (Nakahara et al., 2004). It is 
known to be phosphorylated during the DC maturation process induced by LPS 
(Arrighi et al., 2001). 
In order to examine the contribution of JNK pathway to the altered phenotype and 
function in Nrf2-deficient DC, we assessed the level of phosphorylated JNK by 
Western blotting. JNK was found to be basally hyperphosphorylated in Nrf2-/- iDCs 
compared to Nrf2+/+ iDCs Figure 3.11A panel (i), and JNK inhibitor SP600125 
inhibited the phosphorylation of JNK in Nrf2-/- iDCs as shown in Figure 3.11A panel 
(ii). 
To verify whether this difference in basal phosphorylation of JNK contributed to the 
enhanced co-stimulatory molecule expression in Nrf2-/- iDCs, we treated Nrf2-/- and 
Nrf2+/+ iDCs with the JNK inhibitor, SP600125 (Bennett et al., 2001), and assessed its 
effect on iDCs co-stimulatory molecule expression. JNK inhibition did not reverse 
the enhanced co-stimulatory molecule expression in Nrf2-/- iDCs to that of the wild 
type levels (MHC class II 42.8 ± 2.3% versus 47.0 ± 7.6%, p > 0.05; CD86 44.0 ± 0.6% 
versus 51.8 ± 8.1%, p > 0.05 in Nrf2-/- iDCs; and MHC class II 21.3 ± 1.8% versus 20.5 
± 1.5%, p > 0.05; CD86 20.0 ± 2.1% versus 21.0 ± 0.6%, p > 0.05 in Nrf2+/+ iDCs) as 
indicated in Figure 3.11B panel (i) and panel (ii). 
Moreover, the iDC-mediated antigen specific CD8 T cell proliferation also remained 
unaltered following JNK inhibition in Nrf2+/+ and Nrf2-/- iDCs (Figure 3.11C panel (i) 
and panel (ii)). 
These findings indicate that JNK is not the main MAPK that is involved in Nrf2-
mediated regulation of DC function. 
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Figure 3.11. Basally activated JNK is not involved in mediating altered phenotype 
and function in Nrf2- deficient DCs. A (i), Whole cell lysates from Nrf2+/+ and Nrf2-/- 
iDCs were subjected to SDS-PAGE. (ii), Nrf2+/+ and Nrf2-/- iDCs were treated with JNK 
inhibitor (SP600125) for 1 h or left untreated and whole cell lysates were subjected 
to SDS-PAGE. The phosphorylation levels of JNK were assessed by Western blotting. 
Total JNK and actin were assessed as loading control. Data are representative of 3 
independent experiments. B, Nrf2+/+ and Nrf2-/- iDCs treated with or without 10 µM 
SP600125 (SP) for 48 h. MHC class II (i) and CD86 (ii) expression was determined by 
flow cytometry and presented as percentage of cells expressing high MHC class II or 
CD86. Data derived from three independent experiments are presented as average 
percentage ± SD. (NS-Not Significant). C, Nrf2+/+ (i) and Nrf2-/- (ii) iDCs treated with 
or without 10 µM SP600125 (SP) for 48 h. then were pulsed with increasing 
concentrations of NP68 antigenic peptide, and co-cultured with F5 CD8 T cells for 
72 h. [3H]-Thymidine (3H-Thy) was added for the last 16 h. Proliferation of T cells 
was determined by scintillation counting of incorporated [3H]-thymidine. Data are 
presented as average [3H]-thymidine scintillation counts ± S.D. Statistical 
significance was assessed using unpaired Student’s t test or one-way ANOVA. Data 
are representative of three independent experiments. (NS-Not Significant).  
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3.2.12 Contribution of p38MAPK activity to Nrf2-dependent regulation of DC 
immune function 
The p38MAPK pathway coordinates DC co-stimulatory molecule expression and DC-
mediated T cell activation (Arrighi et al., 2001). As the activity of p38MAPK is 
regulated by phosphorylation, we assessed the phosphorylation status of 
p38MAPK. Western blotting analysis revealed marginal differences in p38MAPK 
phosphorylation between Nrf2-/- and Nrf2+/+ iDCs (Figure 3.12A). 
Next we further dissected the role of p38MAPK in the altered phenotype and 
function observed in Nrf2-/- iDCs using pharmacological approaches. Inhibition of 
p38MAPK activity with SB203580 (English and Cobb, 2002) caused a significant 
reduction in co-stimulatory molecule expression in Nrf2-/- iDCs (Figure 3.12B panel 
(i) and panel (ii) ) (MHC class II 41.0 ± 2.5% versus 32.3 ± 3.8%, p < 0.05; CD86 38.6 
± 3.9% versus 27.8 ± 1.2%, p < 0.05). Inhibition of p38MAPK in Nrf2+/+ iDCs resulted 
in only a slight, statistically insignificant reduction in co-stimulatory molecule 
expression (MHC class II 17.2 ± 3.5% versus 13.0 ± 2.0%, p > 0.05; CD86 17.2 ± 3.2% 
versus 14.0 ± 4.6%, p > 0.05). 
Consistent with the changes in co-stimulatory molecule expression, inhibition of 
p38MAPK resulted in significant reductions in DC-mediated antigen-specific CD8 T 
cell proliferation in Nrf2-/- iDCs with less pronounced effects on Nrf2+/+ iDCs (Figure 
3.12C panel (i) and panel (ii)). 
These observations suggest that p38MAPK plays a role in the Nrf2-dependent 
modulation of DC immune functions. 
100 
 
   
A 
B (i) B (ii) 
101 
 
 
Figure 3.12. Requirement for p38MAPK activity in Nrf2-dependent regulation of 
DC phenotype and function. A, Whole cell lysates from Nrf2+/+ and Nrf2-/- iDCs were 
subjected to SDS-PAGE. Western immunoblotting was used to determine the levels 
of phospho-p38 (p-p38) and total p38 (p38). Tubulin was assessed for equal 
loading. B, Nrf2+/+ and Nrf2-/- iDCs treated with or without 20 µM SB203580 (SB) for 
48 h. MHC class II (i) and CD86 (ii) expression was determined by flow cytometry 
and presented as percentage of cells expressing high MHC class II or CD86. Data 
derived from three independent experiments are presented as average percentage 
± SD. Statistical significance was assessed using unpaired Student’s t test (*, p<0.05; 
NS-Not Significant). C, Nrf2+/+ (i) and Nrf2-/- (ii) iDCs treated with or without 20 µM 
SB203580 (SB) for 48 h. Then, DCs were pulsed with increasing concentrations of 
NP68 antigenic peptide, and co-cultured with F5 CD8 T cells for 72 h. [3H]-
Thymidine (3H-Thy) was added for the last 16 h. Proliferation of T cells was 
determined by scintillation counting of incorporated [3H]-thymidine. Data are 
presented as average [3H]-thymidine scintillation counts ± S.D. Statistical 
significance was assessed using one-way ANOVA. Data are representative of three 
independent experiments. (*, p<0.05; NS-Not Significant).  
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3.2.13 Contribution of the p38MAPK-CREB/ATF1 signalling pathway to Nrf2-
dependent regulation of DC immune function 
Major downstream effectors of p38MAPK are the transcription factors, CREB and 
ATF1 (Ardeshna et al., 2000). Serine phosphorylation of CREB and ATF1 by 
upstream MAPKs is required for their activation. As p38MAPK was found to be 
hyperphosphorylated in Nrf2-/- iDCs (Figure 3.13A), we measured the 
phosphorylation state of CREB and ATF1. Results revealed that CREB and ATF1 were 
hyperphosphorylated under basal conditions in Nrf2-/- iDCs (Figure 3.13B). A 
significant reduction in the phosphorylation of CREB and ATF1 was observed upon 
inhibiting p38MAPK activity using a pharmacological inhibitor (SB203580) as seen in 
Figure 3.13C. This suggests that CREB and ATF1 phosphorylation in DCs are 
dependent on p38MAPK activity. There is evidence in other cell types that in 
addition to p38MAPK, ERK1/2 can also mediate CREB/ATF1 phosphorylation. We 
tested the requirement of ERK1/2 for phosphorylation of CREB and ATF1 in the DCs 
under basal and LPS-stimulated conditions using ERK1/2 inhibitor (PD98059) 
(Yanagawa et al., 2002). As seen in Figure 3.13D, inhibition of ERK1/2 did not 
reduce the level of phosphorylated-CREB/ATF1 under basal conditions. LPS 
stimulation markedly increased the phosphorylation of CREB/ATF1 in Nrf2+/+ and 
Nrf2-/- iDCs (Figure 3.13D) and inhibition of ERK1/2 did not reduce the 
phosphorylation of CREB/ATF1 under LPS-stimulated conditions in both Nrf2+/+ and 
Nrf2-/- iDCs (Figure 3.13D). Consistent with the previous result (Figure 3.13C), 
p38MAPK inhibition reduced CREB/ ATF1 phosphorylation levels both basally and 
upon LPS stimulation. To test whether the basal hyperphosphorylation of 
CREB/ATF1 in Nrf2-/- iDCs could be the result of elevated ROS (Kim et al., 2012), we 
treated the DCs with vitamins and showed that decreasing elevated ROS did not 
reverse the increased CREB/ATF1 phosphorylation (Figure 3.13E). 
These results indicate that Nrf2 is required for controlling the activity of the 
p38MAPK-CREB/ ATF1 signalling axis in DCs. 
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Figure 3.13. Loss of Nrf2 perturbs p38MAPK-CREB/ATF1 signalling in DCs. Whole 
cell lysates from Nrf2+/+ and Nrf2-/- iDCs were subjected to SDS-PAGE. Western 
immunoblotting was used to determine the levels of A, Phospho-p38 (p-p38) and 
total p38 (p38); B, Phospho-CREB (p-CREB), phospho-ATF1 (p-ATF1) and total CREB 
(CREB). C, Whole cell lysates from Nrf2+/+ and Nrf2-/- iDCs treated with or without  
20 µM of p38 activity inhibitor SB203580 (SB) for 1 h were subjected to SDS-PAGE. 
Phosphorylation of CREB and ATF1 (p-CREB and p-ATF1) and total CREB (CREB) were 
assessed. D, Whole cell lysates from Nrf2+/+ and Nrf2-/- iDCs treated with or without 
50 µM of ERK1/2 inhibitor, PD98059 (PD) or 20 µM of SB203580 (SB) for 1 h in the 
presence or absence of LPS (1 µg/ml) for the last 30 min were subjected to SDS-
PAGE. Phosphorylation of CREB and ATF1 (p-CREB and p-ATF1) and tubulin were 
assessed. E, Whole cell lysates from Nrf2+/+ and Nrf2-/- iDCs treated with or without 
vitamins C (1 mM) and E (100 µM) for 48 h were subjected to SDS-PAGE. 
Phosphorylation of CREB (p-CREB) and ATF1 (p-ATF1) and total CREB (CREB) were 
assessed. Data are representative of three independent experiments.  
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 3.2.14 Loss of Nrf2 leads to the dysregulated IL-10 production in DCs 
Transcription of the anti-inflammatory cytokine IL-10 is regulated by CREB/ATF1 
activity (Platzer et al., 1999). We therefore measured the levels of IL-10 secreted by 
the iDCs as readout of CREB/ATF1 transcriptional activity. As shown in Figure 3.14A, 
Nrf2-/- iDCs produced higher levels of IL-10 in comparison to Nrf2+/+ iDCs under 
basal conditions (40.1 pg/ml versus 25.7 pg/ml, p < 0.05). Furthermore, upon LPS 
stimulation, Nrf2-/- iDCs produced levels of IL-10, which was greater than that 
produced by LPS-stimulated Nrf2+/+ iDCs (96.3 pg/ml versus 73.3 pg/ml, p < 0.05). 
Although basal production of IL-10 was not sensitive to p38MAPK inhibition, a 
significant reduction in LPS-induced IL-10 production (Nrf2+/+ 73.3 pg/ml versus 31.3 
pg/ml, p < 0.05; Nrf2-/- 96.3 pg/ml versus 41.2 pg/ml, p < 0.05) was observed in both 
Nrf2+/+ and Nrf2-/- iDCs treated with SB203580 (Figure 3.14B). This result suggests 
that LPS-stimulated but not basal IL-10 production in iDCs is dependent on 
p38MAPK-CREB activity. 
Taken together, our findings suggest that the p38MAPK-CREB/ATF1 signalling axis 
contributes to the Nrf2-mediated regulation of DC immune function. 
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Figure 3.14. Loss of Nrf2 results in elevated IL-10 production by DCs. Nrf2+/+ and 
Nrf2-/- DCs were incubated with or without (A) LPS (1 µg/ml) and/or (B) 20 µM 
SB203580 (SB) for 48 h. Levels of IL-10 in supernatants were measured by ELISA. 
Data are derived from two independent experiments and presented as average 
pg/ml ± S.D. Statistical significance was tested by one-way ANOVA (*, p<0.05; NS-
Not Significant).  
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3.2.15 Increased DC co-stimulatory receptor expression due to the loss of Nrf2 is 
not dependent on PKA activity 
In addition to p38MAPK and ERK1/2, CREB activity is also subject to regulation by 
PKA signalling in DCs (Kocieda et al., 2012; Mayr and Montminy, 2001). Therefore, 
we determined the contribution of PKA signalling to the aberrant DCs function 
associated with the absence of Nrf2 by utilising a pharmacological inhibitor of PKA 
(cAMPS-Rp) (Murray, 2008). Figure 3.15A and B, showed that cAMPS-Rp treatment 
did not induce significant changes to co-stimulatory molecule expression in both 
Nrf2+/+ (MHC class II 20.7 ± 2.4% versus 18.3 ± 2.6%, p > 0.05; CD86 17.4 ± 2.1% 
versus 19.4 ± 2.3%, p > 0.05) and Nrf2-/- (MHC class II 43.5 ± 1.9% versus 44.5 ± 
1.8%, p > 0.05; CD86 45.3 ± 3.1% versus 47.7 ± 2.1%, p > 0.05) iDCs. This set of 
findings indicates that PKA activity is not required for DC co-stimulatory molecule 
expression. 
Figure 3.15. PKA is not required for Nrf2-dependent regulation of DC phenotype. 
Nrf2+/+ and Nrf2-/- iDCs were treated with or without 15 µM of PKA inhibitor 
(cAMPS-Rp) for 48 h. MHC class II (A) and CD86 (B) expression was determined by 
flow cytometry and presented as percentage of cells expressing high MHC class II or 
CD86. Data derived from three independent experiments are presented as average 
percentage ± SD. Statistical significance was assessed using unpaired Student’s t 
test. (NS-Not Significant).  
A 
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3.2.16 Enhanced co-stimulatory receptor expression of Nrf2-/- iDCs is dependent 
on histone deacetylase activity 
As the enhanced co-stimulatory molecule expression in Nrf2-/- iDCs was found to be 
regulated by transcription factors CREB and ATF1, we therefore explored whether 
other transcription regulators may also contribute. Histone deacetylases (HDACs) 
have multiple regulatory roles and originally identified as regulators of transcription 
(Woan et al., 2012). HDAC is involved in regulating DC differentiation, maturation, 
cytokine production, and immune function (Nencioni et al., 2007; Reddy et al., 
2008). To investigate whether enhanced co-stimulatory molecule expression of 
Nrf2-/- iDCs was dependent on HDAC activity, valproic acid (VPA), an HDAC inhibitor 
(Minucci and Pelicci, 2006) was used. VPA at a concentration of 100 µg/ ml reduced 
iDC HDAC activity by around 50% (data not shown). As shown in Figure 3.16A, VPA 
caused a reduction in MHC class II panel (i) and CD86 panel (ii) co-stimulatory 
molecule expression levels in the Nrf2-/- iDCs (MHC class II 35.2 ± 3.9% versus 18.7 ± 
5.1%, p < 0.05; CD86 33.7 ± 2.3% versus 19.4 ± 2.2%, p < 0.05). In addition to altered 
co-stimulatory molecule expression, it has been previously shown that secretion of 
TNF- is also dysregulated in Nrf2-/- iDCs (Rangasamy et al., 2010). We therefore 
were interested in whether TNF- secretion is subject to modulation by HDAC 
inhibition in Nrf2-/- iDCs. Untreated Nrf2-/- iDCs secreted measurable quantities of 
TNF-. However, inhibition of HDAC with VPA did not significantly alter TNF- 
secretion (Figure 3.16B). To examine whether the increased co-stimulatory 
molecule expression is accompanied by changes in HDAC activity, we measured 
HDAC activity in the nuclear lysates of Nrf2+/+ and Nrf2-/- iDCs. Although there was a 
marginal increase in HDAC activity in the Nrf2-/- iDCs when compared with Nrf2+/+ 
iDCs (0.80 ± 0.08 versus 0.74 ± 0.09 respectively), this was not statistically 
significant (Figure 3.16C). Despite the absence of a marked increase in the HDAC 
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activity in the Nrf2-/- iDCs, our results suggest that the enhanced co-stimulatory 
molecule expression of Nrf2-/- iDCs is nevertheless dependent on HDAC activity. 
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Figure 3.16. Histone deacetylase function is required for Nrf2-dependent 
regulation of DC phenotype. A, Nrf2-/- iDCs were treated with the HDAC inhibitor, 
valproic acid – 100 μg/ml (+VPA) for 72 hours, labelled with antibodies against MHC 
class II (i) and CD86 (ii) co-stimulatory receptors. The percentage of DCs expressing 
high levels of co-stimulatory receptors is indicated within the marker. 
Representative histograms are presented and average percentage ± SD is indicated 
above the markers. Data were derived from 4 independent experiments. B, Nrf2-/- 
iDCs were treated with VPA for 24 hours, supernatants collected and levels of TNF-
 measured. Data are presented as average pg/ml ± SD and derived from 3 
independent experiments. C, HDAC activity was measured in nuclear lysates from 
Nrf2+/+ and Nrf2-/- iDCs. Data are presented as average absorbance at 405 nm ± SD 
and derived from 3 independent experiments   
C 
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3.3 DISCUSSION 
The work presented in this chapter investigated the role of the redox responsive 
transcription factor Nrf2 in DC immune function and intracellular signalling 
pathways. Dendritic cells are key antigen presenting cells that detect pathogens, 
process antigens and stimulate T cells to initiate and control a variety of immune 
outcomes. 
DC immune functions can be potentially influenced by a variety of mechanisms 
including alterations of intracellular redox, induction of cytokine genes and 
modulation of intracellular signalling molecules. Nrf2 is central to redox 
homeostasis and understanding its role in DC biology requires the definition of 
critical molecular pathways that are subject to modulation by Nrf2 activity. 
The lifespan of DCs can potentially influence immune responses by affecting the 
duration of lymphocytes stimulated by DCs (Chen et al., 2007; Izawa et al., 2007). 
After interacting with antigen-specific T cells, DCs may undergo accelerated 
clearance from the lymphoid organs. Failure to do so results in increase duration of 
T cells stimulation (Ingulli et al., 1997). Various DC subsets showed significant 
differences in their lifespan, however the molecular mechanisms that regulate such 
differences between DC subsets remain unclear (Chen et al., 2007). Increased 
susceptibility to infection was observed in conditions demonstrating reduced DC 
numbers (O'Shea et al., 2013) whilst on the other hand increased DC population 
was found in asthmatic and allergic respiratory diseases (Holt and Stumbles, 2000; 
Veres et al., 2013). This might contribute to Nrf2 related immune based diseases. 
Nrf2 serves as a master regulator of stem cell integrity and longevity in adult tissues 
(Tsai et al., 2013). Additionally, another study has demonstrated a negative 
regulatory role for Nrf2 in intestinal stem cell proliferation where Nrf2 maintains 
homeostatic quiescence of intestinal stem cells in Drosophila. High ROS levels due 
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to faulty antioxidant mechanisms were linked to increased cell proliferation rates 
(Fiorani et al., 1995; Klaunig et al., 2010). 
Our findings of increasing DC proliferation may highlight the role of Nrf2 in T cell 
tolerance and in preventing inappropriate adaptive immune response that could be 
responsible for developing autoimmune diseases. 
Studies have shown that the co-stimulatory molecules MHC class II and CD86 are 
elevated in Nrf2-/- iDCs and our results support these findings (Rangasamy et al., 
2010; Williams et al., 2008). We also found a marked increase in CD40 expression in 
the Nrf2-/- iDCs, which has not been documented previously. The difference in 
findings between the two studies could be due to some differences in DC culture 
methods and different strains of mice (C57BL6/SV129 versus CD1:ICR). 
Immature DCs silence T cells either by deleting them or by expanding regulatory T 
cells. This minimizes the development of autoimmunity that may be triggered after 
infection or by self antigens captured from dying infected cells and harmless 
environmental proteins. However, when immature DCs express high levels of co-
stimulatory molecules, this could lead to induction of autoimmunity and chronic 
immune-based diseases (Cools et al., 2007; Decker et al., 2006; Steinman and 
Nussenzweig, 2002). 
Generation of functional cytotoxic T lymphocytes from naive CD8 T cells requires 
co-stimulatory and T cell receptor signals (Celluzzi and Falo, 1998; Chai et al., 1999; 
Kemball et al., 2006). CD8 T cells cannot be fully stimulated by immature DCs that 
normally express low amounts of co-stimulatory molecules (Bachmann et al., 
1999b). 
The potential ability of Nrf2-/- iDCs to stimulate enhanced CD8 T cell activation 
suggests that these DCs may not be tolerogenic. This suggests that Nrf2 is a 
potential immunoregulatory molecule involved in preventing inappropriate CD8 T 
cell immune activation by iDCs. It would be interesting to examine the effector 
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function of these CD8 T cells by looking at IFN- production to see whether CD8 T 
cells stimulated by Nrf2 deficient DCs had enhanced effector function. This would 
reaffirm that theses iDCs are not tolerogenic. 
We have also shown in our lab that the increased DC co-stimulatory molecule 
expression was associated with impaired antigen acquisition capacity through 
endocytosis of dextran and phagocytosis of apoptotic and necrotic cells. This 
further reaffirms the enhanced maturation phenotype of the DCs as decreases in 
endo/phagocytosis capacity is associated with the maturation process (Aw Yeang et 
al., 2012). 
In addition to the antigen surveying functions of immature DCs, iDCs also play a 
critical role in the T cell activation/tolerance balance in order to produce a closely 
tuned immune response with the clearance of infection or maintaining self-
tolerance (Banchereau et al., 2000; Kurts et al., 1997a). 
The implications of the enhanced co-stimulatory molecule expression by Nrf2-/- iDCs 
on antigen-specific T cell outcomes have not been explored. In this study, we have 
clearly demonstrated that Nrf2-/- iDCs presenting the antigenic peptides can induce 
substantial CD8 T cell proliferation in the absence of any further maturation or co-
stimulatory signalling. Under normal conditions, presentation of self-peptides on 
MHC molecules to T cells by iDCs that express low levels of co-stimulatory 
molecules leads to the induction of T cell tolerance (Kurts et al., 1997a). 
Experiments conducted in our lab showed that NP34 (which is a partial agonist of 
NP68 and hence can mimic, to a degree the nature of a self-peptide) can induce F5 
CD8 T cell activation by Nrf2-/- iDCs (Aw Yeang et al., 2012). 
We and others have shown that in the absence of Nrf2, there is elevated ROS in DCs 
(Figure 3.3) (Aw Yeang et al., 2012; Rangasamy et al., 2010). Changes in ROS levels 
in DCs have been implicated in altering DC co-stimulatory molecule expression, 
maturation, and subsequent immune responses (Kantengwa et al., 2003; Kim et al., 
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2008; Williams et al., 2008). Testing whether antioxidants could dampen ROS levels 
and reverse changes in function and co-stimulatory molecule expression of Nrf2-/- 
iDCs would clarify the role of ROS. Although there is evidence suggesting that 
increased ROS is associated with elevated co-stimulatory molecule expression 
(Kantengwa et al., 2003; Rutault et al., 1999), our results demonstrate that in the 
context of Nrf2 deficiency, ROS does not directly underlie these changes in 
immature DCs. A possible explanation for this is that increased co-stimulatory 
molecule expression in response to physiological stimuli is usually due to transient 
and not persistent elevation of ROS (Bergamo et al., 2008). The effect of chronic 
elevated basal levels of ROS in the intracellular environment of Nrf2-deficient DCs 
could be different from transient ROS elevations induced by chemical sensitizers. 
Sustained elevations of ROS levels as seen in Nrf2-/- iDCs are therefore likely to 
result in cellular adaptive changes that cannot be simply reversed by rebalancing 
ROS levels but require more complex cellular reprogramming (Boonstra and Post, 
2004; Trachootham et al., 2009). Our findings suggest that Nrf2-mediated 
regulation of DC function is not solely dependent on its role in redox homeostasis. 
This is consistent with our previous results wherein lowering the levels of the 
redox-regulating molecule, GSH in Nrf2+/+ iDCs does not recapitulate the altered 
phenotype and function of Nrf2-/- iDCs (Aw Yeang et al., 2012). 
The transcription factor NF-B is involved in DC development, survival, and 
maturation (Kim et al., 2010; Ouaaz et al., 2002; van de Laar et al., 2010). NF-B is 
activated by a variety of stimuli such as LPS and oxidative stress (Rescigno et al., 
1998). In unstimulated cells, NF-B dimers remain inactive in the cytosol by the 
inhibitor of NF-B proteins (IB) and upon activation, upstream IB kinase (IKK) 
complexes are activated, which results in phosphorylation-induced proteosomal 
degradation of IBα, leading to its ubiquitination. These events are essential 
upstream events required for NF-B activation and this facilitates NF-B 
translocation into the nucleus where it can transcribe genes involved in the immune 
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response (Basseres and Baldwin, 2006; Shih et al., 2011; van de Laar et al., 2010). 
ROS levels have been shown to both induce and repress NF-B signalling depending 
on the cell type (Morgan and Liu, 2011; Zmijewski et al., 2007). Interestingly, our 
results revealed delayed kinetics of LPS-induced phosphorylation of p65 in Nrf2-/- 
iDCs. Elevated ROS levels in Nrf2-/- iDCs could induce modifications in the cysteine 
residues in upstream kinases, namely IKK β, resulting in its inactivation and inability 
to phosphorylate phospho-65 (Reynaert et al., 2006). However, we did not find any 
difference in basal NF-B activation and it appears that changes to upstream 
elements of the NF-B pathway in Nrf2-/- iDCs do not translate to alterations in 
nuclear NF-B levels. This is consistent with previous studies in Nrf2-deficient mice 
whereby no differences in basal NF-B activation in lung lysates were observed 
between Nrf2-/- and wild type mice (Rangasamy et al., 2005; Thimmulappa et al., 
2006). Furthermore, IL-10 was found to block NF-B activity through the 
suppression of IKK activity and inhibition of NF-B DNA binding activity (Schottelius 
et al., 1999). Therefore, this might be the cause for the delayed degradation of IB 
in Nrf2-deficient DCs as they produced more IL-10. Additionally, inhibiting NF-B 
could not reverse the enhanced co-stimulatory molecule expression and CD8 T cell 
stimulation capacity in the Nrf2-deficient DCs. This further reaffirms that NF-B 
pathway does not contribute to the altered Nrf2-/- iDC immune function. 
Increased intracellular ROS and other extracellular stimuli such as LPS also induce 
activation of MAPKs, resulting in increased DC co-stimulatory molecule expression, 
cytokine production, and capacity to stimulate T cells in secondary lymphoid organs 
(Nakahara et al., 2006). Previous inhibitor studies have implicated ERKs and 
p38MAPK in CD86 and MHC class II expression in human DCs under conditions 
where changes in ROS have been induced by chemical sensitizers (Aiba et al., 2003). 
Our results showed that, by using pharmacological inhibitors, ERK and JNK were not 
responsible for the altered phenotype and function in the Nrf2-deficient DCs 
despite the enhanced basal phosphorylation status of both MAPKs. 
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Our observations suggest that the p38MAPK but not ERK1/2 or JNK is the main 
MAPK that is involved in Nrf2-mediated regulation of immature DC function. 
Consistent with our findings, enhanced Nrf2 activity through the use of 
sulforaphane has been shown to suppress p38MAPK pathway in endothelial cells 
(Zakkar et al., 2009). The inhibition of p38MAPK causes a significant but incomplete 
reversal of DC function in Nrf2-deficient DCs, indicating that other pathways or 
factors are also involved. Indeed, histone deacetylases have also been implicated in 
the Nrf2-associated changes in phenotype (Aw Yeang et al., 2012). Increased and/or 
prolonged stimulation of MAPKs signalling pathways is linked to autoimmune 
diseases such as rheumatoid arthritis and psoriasis, and inhibitors of these 
pathways represent new therapeutic strategies (Cohen, 2009; Huang et al., 2012). It 
will be interesting to examine the levels of Nrf2 in these conditions. 
The downstream target of p38MAPK, CREB, has been associated with the regulation 
of key DC immune functions, including the expression of co-stimulatory molecules 
(Ardeshna et al., 2000). Our findings of constitutive basal hyperphosphorylation of 
CREB and ATF1 in Nrf2-/- iDCs highlight the requirement of Nrf2 in maintaining the 
integrity of the p38MAPK-CREB/ATF1 pathway in iDCs. Using pharmacological 
inhibitors, we confirmed that CREB and ATF1 hyperphosphorylation was selectively 
mediated by p38MAPK and not ERK1/2. The other MAPK, JNK was not involved in 
CREB/ATF1 phosphorylation (Vaishnav et al., 2003) and hence was not further 
examined in this study. In keeping with the lack of involvement of ROS in altered co-
stimulatory molecule expression, reducing ROS did not alter CREB/ATF1 
phosphorylation levels. These observations confirm the selective involvement of 
p38MAPK-CREB/ATF1 axis in Nrf2-mediated regulation of DC function. 
We also discounted another major activator of CREB, PKA, in mediating the changes 
in co-stimulatory molecule expression that accompanies loss of Nrf2. The cAMP-
dependent protein kinase signalling transduction cascade is highly conserved 
among a wide variety of organisms. The major targets of PKA are the transcription 
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factors of the cAMP response element binding (CREB) family and this represents 
cross-talk between intracellular signalling pathways (Naviglio et al., 2009). In DCs, 
cAMP/PKA pathway is involved in promoting DC maturation via upregulation of co-
stimulatory molecules and increasing IL-10 with inhibiting IL-12 and TNF- 
production (Schillace et al., 2009). Therefore, it would be important to identify its 
contribution to increase co-stimulatory molecule expression via aberrant 
CREB/ATF1 phosphorylation. Our results using selective inhibitors suggest that 
cAMP-PKA had no effect on the increased co-stimulatory molecules seen in Nrf2-/- 
iDCs. 
The phosphorylation state of p38MAPK-CREB/ATF1 axis can be regulated by protein 
phosphatases (Chi et al., 2006; Johannessen et al., 2004). Key phosphatases that act 
on p38MAPK-CREB/ATF1 axis and regulate their phosphorylation are MKP-1, PP1 
(Hagiwara et al., 1992) and PP2A (Shanware et al., 2010). It is possible that changes 
in MKP-1, PP1, and PP2A activity could also contribute to the increased 
phosphorylation of p38MAPK-CREB/ATF1 axis in Nrf2-/- iDCs. It will be interesting to 
measure MKP-1, PP1 and PP2A activity in these DCs to test this possibility. 
Nrf2-/-iDCs produce higher levels of IL-10 in comparison to Nrf2+/+ iDCs. IL-10 has a 
crucial effect as a feedback regulator of diverse immune responses for both Th1 as 
well as Th2 cell responses and this evidence links overproduction of IL-10 to many 
pathological conditions like systemic lupus erythematosus (SLE) (Liu et al., 2011). It 
is already established that aged Nrf2 deficient female mice develop SLE like disease 
and this could be in part due to high circulating levels of IL-10 (Lee et al., 2009). 
There is evidence that stimuli-induced IL-10 production requires CREB/ATF1 
activation (Platzer et al., 1999). Surprisingly, we found that the basal IL-10 
production could not be reduced by inhibition of the p38MAPK-CREB/ATF1 
pathway. However, LPS-induced IL-10 secretion was sensitive to inhibition of this 
pathway. This suggests that there are differential requirements for p38MAPK-
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CREB/ATF1 in the transcriptional regulation of IL-10 under basal versus stimulated 
conditions. It is pertinent to note that although the level of CREB/ATF1 
phosphorylation in Nrf2-/- iDCs under basal conditions was comparable with that in 
LPS-stimulated iDCs, the amount of IL-10 secreted basally was only half of that in 
LPS-stimulated iDCs. This indicates that CREB/ATF1 phosphorylation alone was not 
sufficient for IL-10 synthesis. A direct functional consequence of increased 
CREB/ATF1 phosphorylation in Nrf2-/- iDCs include increased expression of certain 
target genes like levels of Bcl-2 (Sakamoto and Frank, 2009). This explains the 
increased expression of Bcl-2 observed in this study. Transactivation by CREB/ATF1 
requires its association with cofactors such as CREB binding protein (CBP) 
(Cardinaux et al., 2000). There are data demonstrating that availability of cellular 
CBP is limited and that CBP is also utilized by other transcription factors, including 
Nrf2 and NF-B (Alvarez et al., 2009). It is therefore suggested that Nrf2 and NF-B 
(in addition to CREB) compete for the available CBP (Gerritsen et al., 1997; Katoh et 
al., 2001; Vo and Goodman, 2001). In the absence of Nrf2, more CBP is available for 
use by NF-B and CREB. This could partly explain the increased levels of a number 
of genes transcribed by these transcription factors in Nrf2-/- iDCs (Jin et al., 2008; 
Thimmulappa et al., 2006). This duration of a CREB-dependent transcriptional event 
may be determined, at least in part, by the nature of the dimer bound to the target 
promoter cAMP responsive element (CRE) (Shaywitz and Greenberg, 1999). 
As a transcription factor, CREB, is a challenging target for inhibition by small 
molecules, however various small molecules have been studied as CREB inhibitors 
either to inhibit CREB phosphorylation, CREB-CBP interaction, or CREB-DNA binding. 
These approaches are associated with off-target effects probably because CREB is a 
focal point of many different signalling pathways and there is a risk of DNA damage 
(Xiao et al., 2010). 
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Our data, in conjunction with other studies, suggest that Nrf2 activity can affect cell 
signalling both at the level of p38MAPK-CREB/ATF1 and at the level of 
transcriptional cofactors. 
HDAC has been associated with modulating DC differentiation, co-stimulatory 
molecule expression, cytokine production, and immunogenicity (Nencioni et al., 
2007). Our finding that the Nrf2-deficient co-stimulatory molecule expression can 
be reversed by HDAC inhibition places HDACs as potential targets of Nrf2 function. 
Although the HDAC activity in Nrf2-/- iDCs tended to be higher than in the wild type 
DCs, this difference was not statistically significant. However, it is possible that such 
small differences could lead to significant biological outcomes. In particular, a 
marginally higher HDAC function can lead to cumulative effects over time and may 
drive epigenetic changes, thus altering co-stimulatory molecule expression on DCs. 
Interestingly, dysregulation of HDAC functions has been associated with diseases 
such as cancer, chronic obstructive pulmonary disease, and asthma in which the 
pathology is associated with redox disequilibrium, implicating the link between 
redox status and HDAC (Chung and Marwick, 2010; Minucci and Pelicci, 2006). 
Further investigation into the molecular pathways that lead from Nrf2 activity to 
ROS through to HDAC is merited. The availability of pharmaceuticals that target 
HDACs for therapeutic indications opens up the possibility of using such therapeutic 
strategies to modulate DC functions (Faraco et al., 2011; Reddy et al., 2008; 
Vojinovic and Damjanov, 2011) in diseases that are associated with altered Nrf2 
function. 
In summary, our findings indicate the importance of the transcription factor Nrf2 in 
maintaining the integrity of key intracellular signalling pathways important for 
normal DC function and implicates p38MAPK-CREB/ATF1 axis as a key signalling 
pathway that is regulated by Nrf2 in DCs. The molecules within this pathway could 
represent targets for pharmacological intervention in disease states that arise from 
dysregulated Nrf2 function. 
119 
 
For these reasons, shaping of the adaptive immune responses by manipulating DC 
biology has been gaining huge research interests for translational therapeutic 
purposes. 
 
  
120 
 
 
 
 
 
 
 
 
CHAPTER FOUR 
 
 
REGULATION OF DC PHENOTYPE, FUNCTION, 
AND SIGNALLING PATHWAYS BY HEME 
OXYGENASE-1  
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4.1 INTRODUCTION 
Heme oxygenases (HOs) are intracellular rate-limiting enzymes which catalyse the 
degradation of cellular heme into biliverdin (BV), carbon monoxide (CO), and free 
iron. Three distinct HO enzymes have been identiﬁed: HO-1, HO-2, and HO-3 (Siow 
et al., 1999). HO-1 is an inducible stress-response protein whose expression is 
induced mainly by heme in addition to a variety of oxidative stimuli including heavy 
metals, ultraviolet irradiation, hyperthermia, hydrogen peroxide, inﬂammatory 
cytokines, and nitric oxide (Naito et al., 2011; Ryter and Choi, 2009; Takahashi et al., 
2009). The role of heme is a double-edged sword; on one hand it is required for 
vital biological functions and enzymatic reaction of many heme-containing 
apoproteins such as hemoglobin, myoglobin and cytochrome-c oxidase 
(Padmanaban et al., 1989; Wijayanti et al., 2004). While on the other hand free 
heme catalyzes the formation of reactive oxygen species (ROS) leading to oxidative 
stress-induced cellular and tissue damage. Therefore, intracellular generation of 
heme is required to be tightly regulated (Ponka, 1999; Sassa, 2004). Cells use 
multiple signalling pathways and transcription factors to fine-tune intracellular 
levels of heme. Among these factors, the Nrf2 transcription factor is the most 
important for transcription of HO-1 and the repressor factor Bach1 acts as a 
negative regulator (Alam and Cook, 2007). 
HO-1 has a cytoprotective effect against oxidative insults and inﬂammation. The 
induction of HO-1 expression through gene transfer or pharmacological activations 
has had therapeutic efficacy in a variety of conditions or disorders involving the 
immune system like animal models of organ transplantation and inﬂammatory 
disorders (Ryter et al., 2006). 
Dendritic cells (DCs) are potent antigen presenting cells that play a major role in the 
initiation and regulation of the immune response (Steinman, 2003). Depending on 
their maturation state, DCs can modulate immune functions via changes in its 
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migratory capacity, co-stimulatory molecule expression, and antigen presentation 
abilities (Banchereau and Steinman, 1998). Dendritic cell maturation and function is 
influenced by changes in cellular levels of reactive oxygen species (ROS) (Rutault et 
al., 1999). Alterations in intracellular ROS can also impact on the activity of the 
p38MAPK pathway (Matos et al., 2005). Heme is a product of catabolism of heme-
containing metalloproteins that has the potential to induce the generation of ROS 
(Jeney et al., 2002). 
HO-1 has been shown to inhibit lipopolysaccharide (LPS)-induced DC maturation 
and expression of pro-inﬂammatory cytokines (Chauveau et al., 2005; Cheng et al., 
2010). Furthermore, lack of HO-1 results in profound immune dysregulation and 
induces DC maturation while induction of HO-1 expression renders DCs to be in an 
immature state (Chauveau et al., 2005; Cheng et al., 2010; Park et al., 2010). Given 
what is known about the role of HO-1 in DCs, it is unclear whether HO-1 utilises the 
p38MAPK pathway to mediate regulation of DC maturation and subsequent 
immune functions. Furthermore, it is not known whether the primary effect of HO-
1 in regulating DC maturation is by preventing elevation of intracellular ROS levels. 
Finally, it is unknown whether the HO-1 substrate, heme is directly involved in 
regulating DC maturation and function through activation of the p38MAPK-
CREB/ATF1 pathway. The objective for this segment of research was to address the 
above mentioned gaps in knowledge. 
 
4.2 RESULTS 
4.2.1 Loss of Nrf2 results in decreased expression of HO-1 
We previously noted that the loss of Nrf2 results in the dysregulation of DC immune 
functions (Aw Yeang et al., 2012). We were interested in indentifying downstream 
products that were modulated by Nrf2 in these DCs. Nrf2 regulates a group of 
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HO-1
Tubulin
Nrf2+/+ Nrf2-/-
stress-inducible protein genes including HO-1 genes (Alam et al., 1999). To 
investigate the capacity of DCs to express HO-1 in the absence of Nrf2, we assessed 
the basal level of HO-1 in iDCs from wild type and Nrf2-/- mice by Western blotting. 
Loss of Nrf2 is found to reduce the expression HO-1 in comparison to its wild type 
counterpart as shown in Figure 4.1. 
 
 
 
 
 
Figure 4.1. Loss of Nrf2 results in reduced expression of HO-1. Whole cell lysates 
from Nrf2+/+ and Nrf2-/- iDCs were subjected to SDS-PAGE. Expression of HO-1 was 
assessed by Western blotting. Tubulin was used as loading control. Data are 
representative of three independent experiments. 
 
4.2.2 HO-1 expression decreases during DC maturation 
Human and rat DC maturation was associated with decreased expression of HO-1 
(Chauveau et al., 2005). Given the inducible and dual nature of HO-1 we next asked 
the question if HO-1 can be self-modulated during normal physiological processes 
within bone marrow-derived DCs. One basic physiologic action of DCs is the process 
of maturation and this process has been shown to be metabolically taxing to the 
cells (Banchereau and Steinman, 1998; Rangasamy et al., 2010) which may invoke 
the transcription of HO-1 (via Nrf2). Western immunoblotting of bone marrow-DCs 
shows that murine iDCs expressed HO-1 and this expression was decreased when 
DCs matured by inﬂammatory stimuli (LPS) (Figure 4.2). 
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Figure 4.2. DC maturation is associated with reduction in HO-1 expression. Whole 
cell lysates were generated from untreated (iDC) or treated with LPS 1 μg/ml (mDC) 
for 18 h and subjected to SDS-PAGE. Expression of HO-1 was assessed by Western 
blotting. Tubulin was used as loading control. Data are representative of three 
independent experiments.  
 
4.2.3 Inhibition of HO-1 activity alters immature DC phenotype and function 
To investigate the effect of HO-1 activity on DC immune function, we treated DCs 
with tin protoporphryin-IX dichloride (SnPP-IX), a HO-1 inhibitor (Kappas et al., 
1988) and then evaluated DC phenotype and function. Figure 4.3A showed that 
iDCs treated with (SnPP-IX) showed high levels of cell surface co-stimulatory 
molecule expression when compared to untreated iDCs (MHC class II, 58.2 ± 3.7% 
versus 18.5 ± 0.8%, p<0.05, panel i; CD86, 64.3 ± 4.5% versus 12.0 ± 1.6%, p<0.05, 
panel ii). Furthermore, MHC class II and CD86 levels on SnPP-IX-treated iDCs were 
comparable to LPS-treated iDCs (MHC class II 61.9 ± 4.1% and CD86 67.4 ± 3.2%). 
These findings suggest that inhibition of HO-1 activity results in the DC maturation 
when induced by LPS. Following maturation, DCs have reduced phagocytic and 
endocytic capabilities (Banchereau et al., 2000; Rescigno et al., 1999). As HO-1 
inhibition resulted in DC maturation, we examined the antigen acquisition capacity 
of SnPP-IX-treated iDCs. Our results revealed that SnPP-IX-treated iDCs had a 
reduced capacity to phagocytose both necrotic (Figure 4.3B panel i, 4.9 ± 0.7 versus 
3.4 ± 0.6 -fold increase over baseline, p < 0.05) and apoptotic cells (Figure 4.3B 
HO-1
Tubulin
iDC mDC
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panel ii, 6.9 ± 1.7 versus 4.0 ± 0.5 -fold increase over baseline, p < 0.05) compared 
to their untreated control. Results also demonstrated that SnPP-IX-treated iDCs had 
a diminished capacity to endocytose dextran in comparison to their untreated 
controls (Figure 4.3C, 46.0 ± 1.0% versus 75.0 ± 2.6% at 15 min, 65.7 ± 1.5% versus 
84.0 ± 2.0% at 30 min, and 70.7 ± 2.1% versus 88.7 ± 1.2% at 60 min, p < 0.05). Low 
levels of co-stimulatory molecule expression in iDCs render them unable to 
stimulate a fully competent antigen-specific CD8 T cell response (Bachmann et al., 
1999b). However, up-regulation of these surface molecules in mature DCs enhances 
their ability to induce T cell activation (Lanzavecchia and Sallusto, 2001). As SnPP-IX-
treated iDCs exhibit a mature phenotype, we expected that this would be 
associated with an enhanced capacity to induce DC-mediated antigen-specific CD8 
T cell activation. To test this, we utilised a TCR transgenic mouse model, wherein 
the CD8 T cells exclusively express the F5 T cell receptor (F5 TCR) that specifically 
recognise the MHC class I (H2-Db) restricted antigenic peptide, NP68, when 
presented by DCs (Mamalaki et al., 1992). Functional consequences of altered DC 
co-stimulatory receptor expression were assessed by the ability of NP68 bearing 
DCs to stimulate antigen-specific F5 CD8 T cell proliferation. We observed that 
SnPP-IX-treated iDCs elicited enhanced DC-mediated antigen-specific F5 CD8 T cell 
proliferation in relation to the untreated control at all NP68 concentrations as 
shown in Figure 4.3D (2.5 fold at 1 and 10 nM to 1.4 fold at 100 nM, p < 0.05). 
Taken together, these findings indicate that inhibition of HO-1 activity affects DC 
phenotypic maturation, antigen acquisition ability, and antigen-specific CD8 T cell 
stimulatory capacity. 
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Figure 4.3. Inhibiting HO-1 activity alters dendritic cell phenotype and function. A, 
Immature DCs untreated or treated with HO-1 inhibitor (SnPP-IX, 5 µM) or (1 µg/ml) 
LPS for 14 h. Cells were labelled with fluorescent conjugated antibodies against 
MHC class II and CD86 co-stimulatory molecules. Co-stimulatory molecule 
expression was determined by flow cytometry. The percentages of iDCs expressing 
high levels of MHC class II (i) and CD86 (ii) are indicated above the marker. 
Representative histograms are presented with average percentage ± SD. (*, p < 
0.05). Data are derived from three independent experiments. B, Immature DCs 
untreated or treated with SnPP-IX (5 µM) for 14 h were co-cultured with CFSE-
labelled necrotic Jurkat cells (i) or apoptotic thymocytes (ii) at 37 °C for 2 h. DC 
phagocytic capacity was measured by flow cytometry as an increase in CFSE levels 
when compared with corresponding 4°C baseline control samples. Data derived 
from four independent experiments are presented as average-fold changes ± S.E.M. 
Statistical significance was tested by Mann-Whitney U test (*, p < 0.05). C, 
Endocytic capacity was measured by incubating iDCs untreated or treated with 
SnPP-IX (5 µM) for 14 h with DextranFITC for the indicated time points at 37°C. 
DextranFITC uptake by iDCs was assessed by flow cytometry. Data derived from 
three independent experiments are presented as average percentage of uptake ± 
S.D. Statistical significance was tested by unpaired Student’s t test (*, p <0.05). D, 
Immature DCs untreated or treated with SnPP-IX (5 µM) for 14 h were pulsed with 
increasing concentrations of NP68 antigenic peptide, and co-cultured with F5 CD8 T 
cells for 72 h. [3H]-Thymidine (3H-Thy) was added for the last 16 h. Proliferation of T 
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cells was determined by scintillation counting of incorporated 3H-Thy. Data are 
presented as average scintillation counts ± S.D. Statistical significance was assessed 
using one-way ANOVA. Data are representative of three independent experiments 
(*, p <0.05).  
 
 
4.2.4 HO-1 inhibition in DCs results in elevated intracellular ROS levels 
Dendritic cell maturation and function is influenced by intracellular ROS levels 
(Kantengwa et al., 2003). Heme, substrate for HO-1 activity, can enhance ROS 
generation (Figueiredo et al., 2007). In order to test whether HO-1 activity is 
required for regulation of ROS levels in DCs, we treated iDCs with SnPP-IX and 
measured the ROS levels by flow cytometry. We found that HO-1 inhibition for 14 
hours resulted in a significant increase in intracellular ROS levels in iDCs as shown in 
Figure 4.4A (mean fluorescence intensity (MFI) 449.6 ± 16.2 versus 178.2 ± 2.9, p < 
0.05). However, this increment in ROS levels was less than that observed in the LPS-
treated DCs (MFI 615.2 ± 24.2). Intracellular ROS can be lowered by the ROS 
scavengers vitamins C and E (Al-Huseini et al., 2013; Cachia et al., 1998; Tan et al., 
2005) and indeed co-treatment with vitamins C and E resulted in significant 
reduction in ROS levels in SnPP-IX-treated iDCs (Figure 4.4B, MFI 254.2 ± 2.9 versus 
449.6 ± 16.2, p < 0.05). These findings implicate HO-1 activity in preventing 
elevation of intracellular ROS levels in iDCs. 
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Figure 4.4. Inhibiting HO-1 activity increases ROS levels in DCs that can be 
restored by vitamin treatment. A, Immature DCs untreated or treated with tin 
protoporphyrin IX dichloride (SnPP-IX, 5 µM), or LPS (1 µg/ml) for indicated time 
points. Cells were incubated with the ROS indicator dihydroethidium and analysed 
by flow cytometry. Data are presented as average mean fluorescence intensity ± 
S.D and derived from three independent experiments (*, p <0.05; NS, not 
significant). B, Immature DCs untreated or treated with SnPP-IX (5 µM) for 14 h or 
with a combination of vitamins C (1 mM) and E (100 µM) for 48 h and SnPP-IX (5 
µM) for 14 h, or with LPS (1 µg/ml) for 2 h. DCs were incubated with the fluorescent 
ROS indicator, dihydroethidium and analysed by flow cytometry. Data derived from 
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three independent experiments are presented as average mean fluorescence 
intensity ± S.D (*, p <0.05).  
 
4.2.5 Altered immature DC function by HO-1 inhibition is not dependent on 
elevated ROS 
To test whether DC maturation induced by HO-1 inhibition was a result of increased 
intracellular ROS levels, we treated HO-1 inhibited iDCs with vitamins C and E and 
examined MHC class II and CD86 expression. Our results revealed that there were 
no significant differences between SnPP-IX treatment alone or in combination with 
vitamins C and E in iDC expression of MHC class II (Figure 4.5A panel i, 43.6 ± 0.8 
versus 40.7 ± 1.3, p > 0.05) and CD86 (Figure 4.5A panel ii, 44.5 ± 1.4 versus 45.7 ± 
4.1, p > 0.05). Similarly, there were no differences observed in iDC-mediated 
antigen-specific F5 CD8 T cell proliferation upon SnPP-IX treatment alone or in 
combination with vitamins C and E (Figure 4.5B). These observations demonstrate 
that the altered iDC phenotype and function induced by HO-1 inhibition is not a 
result of elevated ROS in these iDCs. 
  
132 
 
  
0
20
40
60
iDC SnPP-IX SnPP-IX+
Vitamins C&E
P
er
ce
n
ta
ge
 o
f 
 c
el
ls
 w
it
h
 h
ig
h
 M
H
C
 II
 E
xp
re
ss
io
n
* NS
P
er
ce
n
ta
ge
 o
f 
 c
el
ls
 w
it
h
 h
ig
h
 C
D
8
6
  E
xp
re
ss
io
n
0
20
40
60
iDC SnPP-IX SnPP-IX + 
Vitamins C&E
* NS
A (i) 
A (ii) 
133 
 
 
Figure 4.5. Altered immature DC function by HO-1 inhibition is not dependent on 
elevated ROS. A, Immature DCs untreated or treated with SnPP-IX (5 µM) for 14 h 
alone, or with a combination of vitamins C (1 mM) and E (100 µM) for 48 h plus 
SnPP-IX (5 µM) for 14 h. MHC class II (i) and CD86 (ii) expression were determined 
by flow cytometry and presented as percentage of cells expressing high MHC class II 
or CD86. Data derived from three independent experiments are presented as 
average percentage ±S.D. (*, p <0.05; NS, not significant). B, Immature DCs 
untreated or treated with SnPP-IX (5 µM) for 14 h alone, or treated with vitamins C 
(1 mM) and E (100 µM) for 48 h along with SnPP-IX (5 µM) for the last 14 h. Cells 
were pulsed with increasing concentrations of NP68 antigenic peptide, and co-
cultured with F5 CD8 T cells for 72 h. [3H]-Thymidine (3H-Thy) was added for the last 
16 h. Proliferation of T cells was determined by scintillation counting of 
incorporated 3H-Thy. Data are presented as average scintillation counts ± S.D. 
Statistical significance was assessed using one-way ANOVA. Data are representative 
of three independent experiments (*, p <0.05; NS, not significant).  
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4.2.6 HO-1 regulates DC phenotype and function through the p38MAPK-
CREB/ATF1 pathway 
Activation of the p38MAPK-CREB/ATF1 signalling pathway has been shown to be 
involved in DC maturation (Arrighi et al., 2001). Activation of this pathway is 
accompanied by an increase in the serine phosphorylation status of p38MAPK 
(Ardeshna et al., 2000; Shanware et al., 2010). In order to investigate whether 
p38MAPK is involved in the HO-1 mediated regulation of DC function, we first 
examined the phosphorylation status of p38MAPK upon SnPP-IX treatment. As 
demonstrated in Figure 4.6A, HO-1 inhibition resulted in a marked increase in 
p38MAPK phosphorylation. We then assessed the requirement of the p38MAK 
pathway for the induction of DC maturation elicited by HO-1 inhibition using the 
pharmacological inhibitor of p38MAPK (SB203580) (English and Cobb, 2002) and 
examined its effects on SnPP-IX-treated iDC phenotype and function. As shown in 
Figure 4.6B, inhibition of p38MAPK activity prevented the increase in co-
stimulatory molecule expression induced by SnPP-IX treatment of iDCs (MHC class II 
43.5 ± 1.0 versus 15.9 ± 0.6%, p <0.05, panel i; CD86 40.4 ± 0.9% versus 14.8 ± 2.3%, 
p <0.05, panel ii). Furthermore, p38MAPK inhibition also prevented the enhanced 
antigen-specific F5 CD8 T cell proliferation mediated by SnPP-IX-treated iDCs 
(Figure 4.6C, reduction of 2.5-fold at 1 nM NP68, p <0.05; 2-fold at 10 nM NP68, p 
<0.05; and 1.4-fold at 100 nM, p <0.05, which are comparable to iDCs). To test 
whether inhibition of p38MAPK activity in SnPP-IX-treated iDCs which resulted in 
reduced DC maturation phenotype is manifested through altered CREB/ATF1 
signalling, DCs were treated with SnPP-IX and SB203580. Western immunoblotting 
revealed that SnPP-IX treatment resulted in increased CREB/ATF1 phosphorylation 
(Figure 4.6D). Furthermore, the enhanced CREB/ATF1 phosphorylation was 
markedly reduced by p38MAPK inhibition. Collectively, these results suggest that 
HO-1 regulates DC phenotype and function through modulation of the p38MAPK-
CREB/ATF1 signalling axis. 
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Figure 4.6. Modulation of dendritic cell phenotype and function by HO-1 is 
mediated through the p38MAPK-CREB/ATF1 pathway. A, Cell lysates generated 
from iDCs untreated or treated with SnPP-IX (5µM) for 2 h. or with LPS (1 µg/ml) for 
30 min, were subjected to SDS-PAGE and levels of phosphorylated p38MAPK (p-
p38) and tubulin assessed by Western blotting. B, Immature DCs untreated or 
treated with SnPP-IX (5 µM) for 14 h alone, or treated with p38MAPK activity 
inhibitor SB203580 (SB, 20 µM) for 48 h along with SnPP-IX (5 µM) for the last 14 h. 
MHC class II (i) and CD86 (ii) expression were determined by flow cytometry and 
presented as percentage of cells expressing high MHC class II or CD86. Data derived 
from three independent experiments are presented as average percentage ±S.D. (*, 
p <0.05). C, Immature DCs were untreated or treated with SnPP-IX (5 µM) for 14 h, 
or treated with SB (20 µM) for 48 h along with SnPP-IX (5 µM) for the last 14 h. DCs 
were then pulsed with increasing concentrations of NP68 antigenic peptide, and co-
cultured with F5 CD8 T cells for 72 h. [3H]-Thymidine (3H-Thy) was added for the last 
16 h. Proliferation of T cells was determined by scintillation counting of 
incorporated (3H-Thy). Data are presented as average scintillation counts ± S.D. 
Statistical significance was assessed using one-way ANOVA. Data are representative 
of three independent experiments (*, p <0.05). D, Cell lysates were generated from 
iDCs untreated or treated with SnPP-IX (5µM) for 2 h in the presence or absence of 
SB (20 µM) for 1 h prior to SnPP-IX treatment. These iDCs were subjected to SDS-
PAGE and phosphorylation status of CREB and ATF1 (p-CREB and p-ATF1) assessed 
by Western blotting. Lysates from iDCs treated with SB (20 µM) for 1 h in the 
presence or absence of LPS (1 µg/ml) for the last 30 min were also included. Tubulin 
was assessed for equal loading of lanes.  
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4.2.7 Up-regulation of HO-1 renders DCs refractory to LPS-induced DC signalling 
and maturation 
In order to further test the involvement of HO-1 in the regulation of DC phenotype 
and function through p38MAPK-CREB/ATF1, we investigated the effect of HO-1 up-
regulation on LPS-triggered DC maturation and CREB/ATF1 phosphorylation. Cobalt 
protoporphyrin (CoPP) can be used to up- regulate the expression of HO-1 (Rosa et 
al., 2008) and we used it to treat iDCs (at concentrations of 10 µM and 20 µM). We 
demonstrated that both basal and LPS-induced up-regulation of MHC class II 
molecules expression was significantly reduced (Figure 4.7A panel i). HO-1 
induction also causes significant reduction in LPS-induced up-regulation of CD86 
(Figure 4.7A panel ii). Furthermore, CoPP treatment resulted in a significant 
reduction in LPS-treated DC-mediated antigen-specific F5 CD8 T cell proliferation 
(Figure 4.7B). In order to evaluate the influence of CoPP treatment on LPS-induced 
phosphorylation of CREB and ATF1, iDCs were treated with CoPP and stimulated 
with LPS. Cobalt protoporphyrin treatment markedly reduced CREB/ATF1 
phosphorylation in LPS-treated DCs as shown in Figure 4.7C. These results 
strengthen the evidence for the regulation of DC function by HO-1.
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Figure 4.7. Upregulation of HO-1 activity inhibits LPS-induced signalling, 
phenotypic and functional changes in DCs. A, Immature DCs untreated or treated 
with HO-1 inducer CoPP (10 µM and 20 µM) for 24 h with or without LPS at 
indicated concentrations for 18 h. MHC class II (i) and CD86 (ii) expression were 
determined by flow cytometry and presented as percentage of cells expressing high 
MHC class II or CD86. Data derived from three independent experiments are 
presented as average percentage ±S.D (*, p <0.05; NS, not significant). B, Immature 
DCs were untreated or treated with CoPP (10 µM and 20 µM) for 24 h along with or 
without LPS (1 µg/ml) for the last 18 h. DCs were then pulsed with increasing 
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concentrations of NP68 antigenic peptide, and co-cultured with F5 CD8 T cells for 
72 h. [3H]-Thymidine (3H-Thy) was added for the last 16 h. Proliferation of T cells 
was determined by scintillation counting of incorporated (3H-Thy). Data are 
presented as average scintillation counts ± S.D. Statistical significance was assessed 
using one-way ANOVA. Data are representative of three independent experiments 
(*, p <0.05). C, Cell lysates generated from iDCs untreated or treated with CoPP (10 
µM and 20 µM) for 4 h in combination with LPS (1 µg/ml) for 30 min. Lysates were 
subjected to SDS-PAGE and phosphorylation status of CREB and ATF1 (p-CREB and 
p-ATF1) assessed by Western blotting. Lysate from iDCs treated with LPS (1 µg/ml) 
for 30 min was used as positive control. Tubulin was assessed for equal loading of 
lanes.  
 
4.2.8 The HO-1 substrate, heme, induces DC functional maturation through 
p38MAPK-CREB/ATF1 pathway  
Inhibition of HO-1 results in intracellular accumulation of the HO-1 substrate, heme 
(Wagener et al., 2003). When heme (as hemin, the oxidised form of heme), is added 
to innate immune cells, it can accumulate within the cells (Dang et al., 2011; Hualin 
et al., 2012). We therefore used hemin to test whether heme can recapitulate the 
effects of HO-1 inhibition on DC phenotype and function. When iDCs were treated 
with hemin, the expression of MHC class II and CD86 were up-regulated compared 
to untreated iDCs (Figure 4.8A, MHC class II 17.7 ± 3.5% (untreated) versus 46.4 ± 
9.1% (at 5 µM) and 53.7 ± 5.4% (at 10 µM), p < 0.05 panel i; CD86, 12.5 ± 0.6% 
(untreated) versus 37.7 ± 9.6% (at 5 µM) and 50.6 ± 4.4% (at 10 µM), p < 0.05 panel 
ii). The mature phenotype observed in hemin-treated DCs was comparable to that 
of LPS-treated DCs (MHC class II 61.6 ± 0.7%, and CD86 67.2 ± 2.0%). Next we 
investigated the effect of hemin on DC phago- and endocytic function. Our results 
revealed that DCs treated with hemin exhibited a reduction in their ability to 
phagocytose necrotic cells (1.93 ± 0.31 for 5 μM hemin and 1.53 ± 0.41 for 10 μM 
hemin compared with 3.42 ± 0.21 -fold increase over the baseline for untreated 
iDCs, p < 0.05, Figure 4.8B panel i) and apoptotic cells (2.07 ± 0.61 for 5 μM hemin 
and 1.55 ± 0.09 for 10 μM hemin compared with 3.54 ± 0.52 -fold increase over the 
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baseline for untreated iDCs, p < 0.05, Figure 4.8B panel ii). A similar reduction was 
observed in the endocytic capacity of hemin-treated iDCs (Figure 4.8C, 27.5 ± 3.3% 
for 5 μM hemin and 31.5 ± 7.4% for 10 μM hemin versus 62.5 ± 2.7% for iDCs at 15 
min, 47.9 ± 3.5% for 5 μM hemin and 49.2 ± 3.2% for 10 μM hemin versus 73.1 ± 
3.4% for iDCs at 30 min and 60.6 ± 6.1% for 5 μM hemin and 64.7 ± 2.7% for 10 μM 
hemin versus 78.4 ± 1.6% for iDCs at 60 min, p < 0.05). Furthermore, hemin-treated 
iDCs demonstrated an enhanced capacity to stimulate antigen-specific F5 CD8 T cell 
proliferation compared to untreated iDCs (Figure 4.8D). Finally, we investigated the 
effects of hemin on the p38MAPK signalling pathway in iDCs. We demonstrated 
that p38MAPK (Figure 4.8E), CREB, and ATF1 (Figure 4.8F) were 
hyperphosphorylated in hemin-treated DCs. Taken together, these results suggest 
that the changes in DC phenotype, function and signalling induced by HO-1 
inhibition could be attributable to the effects of the HO-1 substrate, heme. 
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Figure 4.8. HO-1 substrate, heme, induces iDC signalling, phenotypic and 
functional changes in DCs. A, Immature DCs untreated or treated with hemin (0.1, 
1, 5 and 10 µM) or LPS (1 µg/ml) for 14 h. MHC class II (i) and CD86 (ii) expression 
were determined by flow cytometry and presented as percentage of cells 
expressing high MHC class II or CD86. Data derived from three independent 
experiments are presented as average percentage ±S.D. (*, p <0.05; NS, not 
significant). B, Immature DCs untreated or treated with hemin (5 and 10 µM) for 14 
h were co-cultured with CFSE-labelled necrotic Jurkat cells (i) or apoptotic 
thymocytes (ii) at 37 °C for 2 h. DC phagocytic capacity was measured by flow 
cytometry as an increase in CFSE levels when compared with corresponding 4°C 
baseline control samples. Data derived from four independent experiments are 
presented as average fold changes ± S.E.M. Statistical significance was tested by 
Mann-Whitney U test (*, p < 0.05). C, Endocytic capacity was measured by 
incubating iDCs with DextranFITC for the indicated time points at 37°C. DextranFITC 
uptake by iDCs was assessed by flow cytometry. Data derived from three 
independent experiments are presented as average percentage of uptake ± S.D. 
Statistical significance was tested by unpaired Student’s t test (*, p <0.05). D, 
Immature DCs were untreated or treated with hemin (5 and 10 µM) or with LPS (1 
µg/ml) for 14 h. DCs were then pulsed with increasing concentrations of NP68 
antigenic peptide, and co-cultured with F5 CD8 T cells for 72 h. [3H]-Thymidine (3H-
Thy) was added for the last 16 h. Proliferation of T cells was determined by 
scintillation counting of incorporated (3H-Thy). Data are presented as average 
scintillation counts ± S.D. Statistical significance was assessed using one-way 
ANOVA. Data are representative of three independent experiments (*, p <0.05). E, 
Cell lysates were generated from iDCs untreated or treated with hemin (5 and 10 
µM) or LPS (1 µg/ml) for 30 min. Lysates were subjected to SDS-PAGE and 
phosphorylation status of p38MAPK (p-p38) assessed by Western blotting. Tubulin 
was assessed for equal loading of lanes. F, Cell lysates were generated from iDCs 
untreated or treated with (5 and 10 µM) hemin or LPS (1 µg/ml) for 30 min, 
subjected to SDS-PAGE and phosphorylation status of CREB and ATF1 (p-CREB and 
p-p38
Tubulin
p-CREB
Tubulin
p-ATF1
E  F  
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p-ATF1) assessed by Western blotting. Tubulin was assessed for equal loading of 
lanes.  
4.3 DISCUSSION 
Heme oxygenase-1 is an Nrf2-inducible gene product that mediates antioxidant and 
cytoprotective effects resulting in maintenance of cellular redox homeostasis and 
protects cells from oxidative stress (Abraham et al., 1995; Lee et al., 1996). 
In this chapter, we have shown the contribution of HO-1 in the regulation of DC 
phenotype and immune function. First, we showed that Nrf2-/- iDCs express less 
HO-1 levels in unstimulated cells. This confirms the requirement for Nrf2 
transcriptional activity in for the production of HO-1 protein. Of note, mature DCs 
express lower levels of HO-1 than immature DCs. Interestingly, Nrf2-/- iDCs which 
have a reduced expression of HO-1 exhibit a more mature phenotype (as shown in 
Chapter 3). It is tempting to speculate that reduction in HO-1 is a necessary 
accompaniment to DC maturation. Furthermore, the presence of significant HO-1 
activity may impede the DC maturation signals induced by agents such as LPS. 
Indeed, inhibition of HO-1 activity in iDCs caused an enhanced maturation 
phenotype in terms of increased levels of MHC class II and CD86 expression 
consistent with previous reports (Al-Huseini et al., 2013; Cheng et al., 2010; 
Figueiredo et al., 2007; Schumacher et al., 2012). 
 
To further delineate the precise role of HO-1 in iDC immune function, we examined 
the impact of HO-1 inhibition on antigen acquisition. HO-1 inhibition resulted in 
impaired phagocytic and endocytic function in iDCs. This is most likely to be a 
consequence of the enhanced maturation status of these DCs rather than direct 
regulation by HO-1 of these biological processes. A major function of iDCs is to take 
up antigens via phagocytic and endocytic processes, critical for initiation of T cell 
immune response and for induction of T cell tolerance (Albert et al., 1998; 
Steinman, 2003). DCs utilise phagocytic and endocytic mechanisms to acquire 
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antigens from the extracellular environment and from cells that die (by apoptosis or 
necrosis) due to infection or normal tissue homeostasis. This is an exceptional 
function of iDCs and they start to lose such qualities when they mature (Inaba et al., 
1993; Sallusto et al., 1995a). As DCs mature, they lose their endocytic and 
phagocytic capacity, which correlates closely with higher expression of co-
stimulatory molecules. Defects in endocytic/ phagocytic function of DCs are 
associated with systemic lupus erythematosus and Gaucher’s disease (Micheva et 
al., 2006; Monrad et al., 2008).  
Both endocytic and phagocytic functions were impaired in SnPP-IX-treated iDCs. It 
is however unclear whether this effect is due to direct contribution of HO-1 to these 
biological processes or just due to enhanced maturation status of the cells. It is 
interesting to note that interference of endocytosis during HO-1 inhibition is much 
higher in the early phase than the late phase which may suggest a blocking in the 
initiating step in the dephosphorylation of a group of proteins implicated in 
endocytosis (Zhao et al., 2010). Examples of these proteins are dephosphins that 
stimulating the assembly of several large essential endocytic protein complexes 
(Cousin and Robinson, 2001). Rearrangement of the actin cytoskeleton is involved 
in the endocytic and phagocytic pathways in DCs (Jutras and Desjardins, 2005; West 
et al., 2004a) and it is possible that actin polymerisation is impaired in SnPP-IX-
treated iDCs. Signalling molecules such as Rho GTPases (Rac, Cdc42 and RhoA) are 
key players in the regulation of the actin cytoskeleton (Hall, 1998b; Kobayashi et al., 
2001). Previous studies have shown that hemin potentiates actin polymerisation 
and subsequent migration in intestinal epithelial cells and neutrophils (Barcellos-de-
Souza et al., 2013; Graca-Souza et al., 2002). Measurement of actin polymerisation 
(F-actin) and assessing the phosphorylation status of these molecules in bone 
marrow derived-DCs could shed more light on this issue. 
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To further explore the role of HO-1 in modulating DC functions, our next approach 
was to examine iDC-mediated antigen-specific CD8 T cell stimulatory capacity which 
reflects the DC maturation state. Effector cytotoxic T lymphocyte generation, from 
naive CD8 T cells, requires strong co-stimulatory signals in addition to TCR signals 
provided by mature DCs (Chai et al., 1999; Gett et al., 2003; Kemball et al., 2006). 
Consequently the mature phenotype exhibited by the SnPP-IX-treated iDCs was 
associated with increased CD8 T cell stimulation capacity. In addition to increased 
co-stimulation, it is possible that HO-1-inhibited DCs may secrete proinflammatory 
cytokines that would further influence the quality and magnitude of the CD8 T cell 
response. Cytokine analysis of the supernatants from HO-1-inhibited iDCs should 
provide data on this aspect. Immature DCs that have low levels of co-stimulatory 
molecule expression contribute to immune tolerance by engaging with self-reactive 
CD8 T cells and causes CD8 T cell anergy or deletion (Kurts et al., 1997a). This 
implicates HO-1, through its effect on DC co-stimulatory molecule expression, in the 
maintenance of immune tolerance mediated by iDCs. Interestingly, there is 
evidence for the requirement of HO-1 function for the expansion of a CD4 subset of 
immunosuppressive T cells, regulatory T cells (Tregs), the generation of which is 
dependent on iDCs (Schumacher et al., 2012). 
 
The induction of HO-1 is dependent on the activity of the transcription factor, Nrf2 
(Alam et al., 1999). We have previously shown that iDCs which lack Nrf2, display an 
enhanced maturation phenotype and increased T cell stimulatory capacity that is 
remarkably similar to DCs treated with SnPP-IX (Aw Yeang et al., 2012) and we 
showed earlier in this chapter that loss of Nrf2 causes reduction in HO-1 expression. 
This suggests that lowered HO-1 activity due to loss of Nrf2 underlies the 
phenotypic and functional changes observed in the Nrf2 deficient iDCs. Our results 
highlighted the effects of HO-1 induction on counteracting DC phenotypic 
maturation induced by LPS which is consistent with earlier publications (Listopad et 
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al., 2007). Up-regulation of HO-1 mRNA and protein by cobalt protoporphyrin was 
known to be time and dose related (Shan et al., 2006). However, the p38MAPK 
pathway may mediate this effect as we demonstrated a reduction in CREB and ATF1 
phosphorylation upon cobalt protoporphyrin treatment. The mechanism by which 
HO-1 activity contributes to the maintenance of DCs in an immature state merits 
further investigation. 
One possible mechanism through which HO-1 regulates DC function is through 
generation of CO and BV by its enzymatic action on its substrate heme (Siow et al., 
1999). We hypothesise that upon inhibition of HO-1 activity in iDCs, deprivation of 
HO-1 products CO and BV in iDCs leads to enhanced maturation and consequently 
increased T cell stimulatory function. In support of this, previous studies have 
shown that CO inhibited DC maturation through TLR3 and TLR4 pathways as well as 
inhibition of secretion of proinﬂammatory cytokines and induction of alloreactive T 
cell proliferation (Remy et al., 2009). A recent study on fibroblasts focussing on 
inducible CO releasing molecules found that CO augments fibroblast survival in 
hypoxic conditions (Zobi et al., 2013). BV administration reduced neutrophil activity 
(Freitas et al., 2006) and also protected against LPS-induced shock (Sarady-Andrews 
et al., 2005), suppressed T cell proliferation, and induced tolerance to cardiac 
allografts in mice (Yamashita et al., 2004).  
 
In keeping with these findings, we have also demonstrated that induction of HO-1 
in DCs using CoPP was associated with lower sensitivity to LPS-induced DC 
maturation. The potential increase in CO production as a result of higher HO-1 
activity in iDCs treated with CoPP may underlie the resistance to TLR4 signalling by 
LPS. This could be brought about through the interaction of CO with caveolin-1 
(cav-1), a structural component of the plasma membrane that when bound to TLR4 
in the presence of CO results in inhibition of LPS-induced signalling (Chidlow and 
Sessa, 2010). Additionally, CO treatment on LPS-treated DCs inhibited CD4 and CD8 
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T cell activation in the context of soluble antigens (Tardif et al., 2013). Although this 
effect was not due to altered endocytosis capacity as opposed to our observations, 
it would be interesting to further dissect these different observations. 
 
Another potential mechanism for HO-1 effects on DC maturation could be through 
its role in redox homeostasis. Changes in ROS levels have been implicated in many 
aspects of DC biology including cell maturation and cytokine production 
(Kantengwa et al., 2003). We demonstrated that HO-1 inhibition increased ROS 
levels in iDCs possibly due to build up of intracellular heme. Heme can directly 
induce intracellular ROS generation (Vincent, 1989) and induction of HO-1 was able 
to reduce high ROS levels in LPS-stimulated DCs (Chauveau et al., 2005). However, 
lowering ROS levels through vitamin treatment did not alter DC maturation levels 
induced by HO-1 inhibition, indicating that these changes in DC phenotype and 
function are not ROS mediated. Consistent with the lack of ROS involvement in 
mediating these changes in iDCs, similar findings were observed in the previous 
chapter which demonstrated that resetting  elevated ROS levels in Nrf2-deficient 
DCs did not reverse the dysregulated DC phenotype and function (Al-Huseini et al., 
2013).  
 
The molecular pathways that are utilised by HO-1 to modulate DC function, was a 
focus of our investigations. We provide evidence for the involvement of the 
p38MAPK-CREB/ATF1 signalling axis in mediating the effects of HO-1 on DC 
function. Studies that used pharmacological inhibition of p38MAPK activity, have 
demonstrated the importance of this pathway in DC co-stimulatory molecules up-
regulation induced by LPS (Nakahara et al., 2006). 
This suggests that in iDCs, HO-1 may exert anti-inﬂammatory and tolerogenic 
effects. An inﬂammatory stimulus like LPS should switch off HO-1 expression to fully 
initiate effective immune responses. However, this effect might be limited to DCs 
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due to their particular role in responding to pathogens while other parenchymal 
cells require an increased expression of HO-1 in order to protect against 
inﬂammation (Wiesel et al., 2000). As LPS signals through the TLR4 receptor and 
subsequently activates the p38MAPK signalling pathway (An et al., 2002), 
elucidating the effects HO-1 has on this pathway may highlight functional changes 
when HO-1 levels or its metabolites are altered. 
 
In the current study, p38MAPK activity inhibition prevented the mature DC 
phenotype in SnPP-IX-treated iDCs. Furthermore, p38MAPK activity inhibition also 
produced a marked reversal in the enhanced DC-mediated antigen-specific CD8 T 
cell proliferation observed in SnPP-IX-treated iDCs. In addition, the downstream 
effectors of p38MAPK, CREB and ATF1 were also activated in SnPP-IX-treated iDCs 
as revealed by their hyperphosphorylated state, which could be reduced by the 
p38MAPK activity inhibitor. These results highlight the role for p38MAPK-
CREB/ATF1 activity in mediating HO-1 effects on DC function. The exact molecular 
basis for p38MAPK-CREB/ATF1 activation in HO-1 inhibited DCs is not known but 
one possibility could be due to interaction of intracellular heme with receptors that 
signal through this pathway. We tested this possibility by treating DCs with heme 
and demonstrated that not only did heme activate the p38MAPK-CREB/ATF1 
pathway but also recapitulated the other phenotypic and functional effects of HO-1 
inhibition in DCs (enhanced co-stimulatory receptor expression, enhanced CD8 T 
cell stimulatory capacity and reduced endo- and phagocytic capability).  
 
Heme is synthesised in all human nucleated cells and its levels are regulated 
through synthesis of heme which is counterbalanced via degradation of heme by 
HO-1. Synthesis and degradation of heme are thus closely linked (Abraham and 
Kappas, 2008). Heme synthesis involves a series of enzymatic reactions localised in 
the mitochondrion and cytoplasm of cells. Depending on cell and tissue types, 
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heme requirements can vary significantly. The most rapid rates of heme synthesis 
occur in bone marrow erythroid cells and in liver hepatocytes. Due to the 
incorporation of heme into the heme proteins hemoglobin and cytochrome P450, 
heme is synthesized in very high quantities in these respective organs. It has been 
postulated that most mammalian cells contain a “free” or “uncommitted” heme 
pool, serving both precursor and regulatory functions in the synthesis and 
regulation of heme levels.  
Heme derived from denatured heme proteins other than hemoglobin is probably 
degraded locally by HO while heme derived from hemoglobin degradation is reused 
for re-synthesis of haemoglobin (Abraham et al., 1988; Ponka, 1999; Wagener et al., 
2003). Increased heme levels leads to a potential amplifier of the inflammatory 
response and is a characteristic feature of diseases with increased hemolysis or 
widespread cell damage (Jeney et al., 2002). Heme is quite hydrophobic and readily 
enters cell membranes. Brief incubation of immune cells with micromolar 
concentrations of hemin (5-10 μM) triggered the oxidative burst and the production 
of reactive oxygen species was directly proportional to the concentration of hemin 
added to the cells (Graca-Souza et al., 2002). However, prolonged incubation with 
higher concentration of heme will induce stimulation of HO-1 causing increases in 
its cytoprotective activity and subsequent reduction of heme levels (Soares et al., 
2009). 
 
While Nrf2 is a potent positive regulator of the HO-1 gene (Alam et al., 1999), bach1 
is a transcriptional repressor of HO-1 (Kitamuro et al., 2003). Bach1 binds in 
conjunction with a small Maf protein to tandem repeats of the antioxidant 
response element (ARE) and quenches the target gene expression (Ishikawa et al., 
2005). When HO-1 is inhibited, heme will build up leading to increase ROS levels 
which causes redox conformational modification in Bach1 rendering it unable to 
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bind ARE. This will enhance the binding of Nrf2 to the ARE and promote 
transcription of HO-1 (Ishikawa et al., 2005). 
 
In our system we timed the experiment to inhibit HO-1 activity by SnPP-IX but at 
the same time not allowing heme builds up to induce HO-1 expression which could 
subsequently mask the end results. 
 
Heme has been shown to engage and activate TLR4 thereby potentially activating 
signalling pathways including the p38MAPK-CREB/ATF1 axis (Figueiredo et al., 
2007). We therefore speculate that elevated level of heme in HO-1-inhibited DCs 
activates TLR4. However, there is a kinetic difference in the induction of p38MAPK-
CREB/ATF1 pathway between heme build up due to HO-1 inhibition and hemin-
treated DCs. The former condition showed increase phosphorylation of p38MAPK, 
CREB and ATF1 after 2 h while the latter showed that in a much shorter time (30 
min) with decreasing phosphorylation at 2 h. 
It has been shown that macrophages which are pre-exposed to free heme lose their 
ability to respond, and become desensitized to a subsequent challenge by other 
TLR4 agonists like LPS (Otterbein et al., 2003). This immunoregulatory effect could 
be attributed to the induction of HO-1 and in particular to the production of CO. 
Additionally, there is a different activation profile for heme and LPS which might in 
part be related to the association of these molecules at different binding sites of 
the TLR4 receptor complex. Furthermore, heme polymers like hemozoin and -
hematin have been shown to activate the innate immune system through TLR9 
while heme itself wasn’t able to activate TLR9 (Figueiredo et al., 2007).  
This could be tested by examining whether the altered phenotype, function and 
signalling seen in HO-1-inhibited DCs is abolished when HO-1 is inhibited in TLR4 
deficient DCs. 
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Given that multiple DC functions are modulated by HO-1, it would be interesting to 
determine the cytokine expression profile of DCs treated with hemin may shed 
further light in order to examine its role in heme-induced dysregulation in DC 
immune function. Indeed, previous studies in DCs and other cell types have 
implicated the role of HO-1 in modulating cytokine production (Barcellos-de-Souza 
et al., 2013; Graca-Souza et al., 2002; Tardif et al., 2013). 
 
HO-1 is being considered as potential future clinical approach following successful 
therapeutic targeting of a variety of animal models of inﬂammatory conditions or 
disorders involving the immune system, including organ transplantation, 
autoimmunity and allergy (Ryter et al., 2006) as it improves graft survival through 
local anti-inflammatory and modifying T cell functions as well as inducing 
immunosuppressive molecules in transplantation (Blancou et al., 2011; Soares et 
al., 1998). Therefore it is critical to understand the details of HO-1-mediated 
regulation of DC function.  
 
Taken together these findings along with other publications, HO-1 can be 
considered as a promising immunosuppressive molecule in organ transplantation In 
atherosclerotic diseases, modulation of HO-1 induction has been anticipated to be a 
potential therapeutic target and in vitro screening assay for anti-atherosclerotic 
agents (Wu et al., 2006).  
 
Our observations provide further details and insights into the role of HO-1 in DC 
biology and could therefore inform the design of future pharmacological strategies 
that aim to modulate DC function in the therapy of immune diseases. 
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5.1 Introduction 
Dendritic cells have a central role in the immune system and have been recognised 
as key communicating sentinels at the interface between the innate and adaptive 
immune responses. Maturation of DCs is a process that has a significant impact on 
both innate and acquired immune responses, whereby antigen-capturing, poorly 
immunogenic iDCs are transformed into highly immunogenic antigen-presenting 
mDCs which migrate from peripheral tissues to lymphoid organs subsequently 
activating naive T cells. 
Precise regulation of intracellular signalling pathways is vital for normal DC 
maturation and function. Studies have shown that modulation of these pathways 
can modify the immune response elicited by DCs. Stimulation of PRRs on the DC 
surface following pathogen infection or tissue damage results in the activation of 
members of each of the major MAPK subfamilies — p38MAPK, ERK and JNK 
subfamilies. MAPKs activation, in conjunction with the activation of NF-B, induces 
the expression of multiple genes that collectively regulate the inflammatory 
response. 
DC function is subject to the influence of its intracellular redox potential as 
oxidative stress has been shown to be detrimental to normal physiological 
functioning. Generally, mammalian cells have evolved a highly regulated cell 
defence system that affords protection against the harmful effects of exogenous 
and endogenous chemical and oxidant insults. Natural or pharmacological 
manipulation of the activity and levels of cellular antioxidants may have vital effects 
on their functions including regulation of genes that are implicated in the chronic 
inflammatory disease process (Chen and Kunsch, 2004). Redox-sensitive 
transcription factor Nrf2 activity is a principal cellular defence system against 
oxidative stress. 
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It is clear that understanding how the transcription factor Nrf2, and its transcribed 
genes, influence DC function through their effects on redox homeostasis and 
signalling pathways in DCs is required before targeting of this system for 
therapeutic purposes becomes a viable strategy. 
This thesis dissects the role of two major redox regulators; the transcription factor 
Nrf2 and its transcribed protein HO-1 in controlling DC intracellular signalling and 
function. 
5.2 Nrf2 modulates DC immune function through regulation of p38MAPK-
CREB/ATF1 signalling 
 
The first part of this study demonstrated that Nrf2 deficiency in mouse bone 
marrow derived-iDCs resulted in increased DC proliferation, ROS production, 
enhanced iDC co-stimulatory receptor expression, and increased iDC-mediated 
antigen-specific CD8 T cell stimulatory capacity. 
Nrf2 controls the expression of a large number of genes that enable a coordinated 
protective response to oxidative stress. These Nrf2-responsive genes regulate the 
transcriptional induction of a battery of drug-detoxifying enzymes and proteins 
include glutathione, heme oxygenases, -Glutamylcysteine synthetase, thioredoxin, 
Glutamate—cysteine ligase catalytic subunit, glutathione reductase, superoxide 
dismutase, catalase, UDP-glucuronyl transferases, and quinone reductases. The 
proteins encoded by Nrf2-responsive genes function as direct antioxidants, 
conjugate to and detoxify natural and xenobiotic electrophiles, metabolise free 
radicals, recognize DNA damage, drive GSH synthesis, regulate the proteasome and 
molecular chaperones, and inhibit inflammation (Itoh et al., 2010; Slocum and 
Kensler, 2011). The critical role of Nrf2-regulated enzymes in the detoxification of a 
wide range of chemicals, drugs, and toxins has been well-established (Cederbaum, 
2009; Chan et al., 2001; Osburn and Kensler, 2008). 
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Nrf2 is correlated to differentiation, growth, proliferation, apoptosis and it is 
thought that Nrf2 has evolved from an original role in haematopoiesis with the 
regulation of cell differentiation from early lineages (Li et al., 2012). 
Loss of Nrf2 was found to enhance lymphocyte proliferation as well as renal 
mesangial cell proliferation which showing acute and chronic glomerulonephritis is 
consistent with multiple inflammatory episodes similar to that seen in systemic 
lupus erythematosus (SLE) (Li et al., 2004; Ma et al., 2006). In the current study, the 
findings of increase DC proliferation and enhanced expression of anti-apoptotic 
protein Bcl-2 might also contribute to this pathology. Previous publications have 
shown that accelerated proliferation together with poor detoxification exacerbated 
tumor transformation susceptibility in Nrf2 deficient mice (Ma and He, 2012).  
Enhanced co-stimulatory receptor expression in iDCs has been shown to cause a 
break in peripheral T cell tolerance, through the prolongation of T cell activation 
and enhancement of adaptive immune responses (Hawiger et al., 2001). Therefore, 
in the absence of infection, it would be reasonable to propose that Nrf2 deficient 
iDCs (instead of instructing autoreactive T cell deletion or anergy) could present 
self-antigens to CD8 T cells in such a context that may result in the induction of 
inappropriate CD8 T cells activation, adaptive immune responses, and 
autoimmunity. Indeed results from our lab presented evidences that the CD8 T cells 
activated by the Nrf2-/- iDCs develop effector functions (Aw Yeang et al., 2012). The 
role of Nrf2 in the regulation of T cell tolerance and autoimmunity is further 
emphasised by the fact that aged Nrf2 deficient mice manifest enhanced 
lymphoproliferation and autoimmune-like symptoms (Ma et al., 2006). 
Results from our lab demonstrated that T cells from Nrf2-/- mice manifest signs of 
low level T cell activation with a small but consistent reduction in CD62L expression 
when compared with their Nrf2+/+ counterpart presumably through interaction with 
DCs in the lymph nodes (Aw Yeang et al., 2012). These findings raise the possibility 
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that Nrf2 could play an important role in the maintenance of peripheral T cell 
tolerance by iDCs. 
The rationale for targeting the Nrf2 system is therefore a promising strategy for the 
therapy of autoimmune diseases. 
Evidence has shown that the intracellular redox status of the DC has a profound 
impact on its functions such as DC activation, maturation, cytokine production, and 
immunosenescence (Kim et al., 2008; Verhasselt et al., 1999b; Williams et al., 
2008). Therefore, strategies based on therapeutically manipulation of these redox 
balance regulators are achieving enormous consideration. 
Oxidative stress occurs when the production of ROS exceeds their catabolism. 
However, the term stress is an imprecise reference to a restricted range of ROS 
signalling that runs from adaptive to maladaptive cellular changes (Nathan and 
Cunningham-Bussel, 2013). When ROS generation overwhelms the cellular 
buffering capacity as shown in Figure 5.1, this may lead to modulating or utilizing of 
intracellular signalling pathways from cell surface receptors like MAPKs and NF-B, 
in association with direct damage, resulting in cell death or pathological processes 
(Nakamura et al., 1997a). Oxidative damage, caused by defective defences and 
increased generation of ROS, has been implicated in the pathogenesis of both aging 
and of autoimmune disease (Droge, 2002). In the context of DCs, ROS may act as a 
“danger” signal and could induce phenotypic and functional maturation of DCs 
(Kantengwa et al., 2003; Rutault et al., 1999). Consistent with this premise, 
treatment with both vitamins C and E antioxidants results in DC resistance to 
phenotypic and functional changes induced by high ROS levels (Tan et al., 2005). 
Global deletion of Nrf2 in mice lowers the redox potential, impairs induction of 
cellular antioxidant defences, and enhances vulnerability and severity to several 
inﬂammatory disorders including asthma, emphysema, ﬁbrosis and colitis (Kensler 
et al., 2007; Rangasamy et al., 2004; Rangasamy et al., 2005). 
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 Figure 5.1. ROS effect on homeostasis adopted from Nathan & Cunningham, 2013  
 
Glutathione is a cellular buffer for ROS (Kim et al., 2007). Work done by our group 
has shown that GSH was not responsible for altered phenotype and function 
observed in Nrf2-/- iDCs (Aw Yeang et al., 2012). In this study, we demonstrate that 
elevated ROS does not contribute towards the development of altered phenotype 
and function observed in Nrf2-/- DCs (Al-Huseini et al., 2013). This suggests that the 
effects of long term high ROS levels on cellular function may be through 
conformation changes in cell kinases and transcription factors thus potentially 
inﬂuencing their association with other cellular proteins. However, our approach to 
reduce ROS levels using vitamins C and E reduced elevated ROS levels lower than 
Nrf2 sufficient DCs but this was ineffective in reversing the altered DC phenotype 
and function. Other approaches for reducing ROS levels by ROS scavengers other 
than antioxidant vitamins, like edaravone (Mikawa et al., 2005), may be worth 
investigating in future studies for further confirmation of the above results. 
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ROS have various inhibitory or stimulatory roles in NF-B signalling (Morgan and 
Liu, 2011). NF-B proteins are sensitive to oxidation leading to a modification that 
decreases DNA binding; it is therefore possible that modulation of the redox state 
of NF-B could represent a post-translational control mechanism for this factor 
(Toledano and Leonard, 1991). 
Our results showed that loss of Nrf2 did not affect basal NF-B activity but it 
impedes activity of upstream elements of the NF-B pathway (phosphorylation of 
p65 and IB degradation). These results suggest redox modification of upstream 
IB kinases due to prolonged high ROS levels exposure could lead to aberrant NF-
B signalling. This needs to be tested by normalising ROS levels in Nrf2-/- DCs and 
examining NF-B activation. However, inhibiting NF-B pathway did not reverse the 
altered DC phenotype and function in the absence of Nrf2 (Aw Yeang et al., 2012). 
This suggests that any alterations in NF-B signalling in these DCs is not part of the 
mechanism that leads to altered DC phenotype and function in of Nrf2-/- DCs. 
Although the three MAPKs (ERK1/2, JNKs, p38MAPK) are found to be activated i.e. 
hyperphosphorylated in Nrf2-/- iDCs, only inhibition of p38MAPK pathway was able 
to reverse the altered DC phenotype and function. This pathway also contributed to 
HO-1 mediated alteration in DC biology. These findings highlight a pivotal role for 
p38MAPK in the regulation of DC maturation and antigen-specific CD8 T cell 
stimulation. This is consistent with findings in other cells such as endothelial cells 
wherein pharmacological activation of Nrf2 was able to reduce endothelial cell 
activation through inactivation of p38MAPK by suppressing an upstream activator 
MKK3/6 and by enhancing the activity of the negative regulator MKP-1 (Zakkar et 
al., 2009). This may suggest a reciprocal relation between Nrf2 and p38MAPK. 
However, we cannot say for certain that the phenotype exhibited by the Nrf2 
deficient DCs is only mediated through p38MAPK as HDACs has also been shown to 
contribute to DC function dysregulation. 
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5.3 Heme oxygenase-1 regulates dendritic cell function through modulation of 
p38MAPK-CREB/ATF1 signalling  
Nrf2 binds to antioxidant-responsive elements (AREs) and this induces the 
expression of stress-responsive genes that governs the production of a wide range 
of cytoprotective enzymes and proteins, including HO-1 (Alam and Cook, 2003). HO-
1 contributes to defence mechanisms against oxidative stress inducing agents such 
as heme/haemoglobin, metals, various cytokines, and endotoxin. Overexpression of 
HO-1 in cells might, therefore, protect against oxidative stress produced by certain 
of these agents particularly heme and haemoglobin by catalysing their degradation 
to biliverdin/bilirubin and CO which both have antioxidant properties (Abraham, 
2003; Baranano et al., 2002; Otterbein Le Fau - Bach et al.; Sammut et al., 1998). 
In chapter 4, we have shown the contribution of HO-1 to DC phenotype and 
function. We found that interfering with HO-1 activity resulted in increased ROS 
levels and DC phenotypic and functional changes similar to that induced by 
inflammatory stimuli e.g. LPS. It was concluded that this effect was also mediated 
through p38MAPK-CREB/ATF1. The ability of HO-1 to inhibit the maturation state of 
DCs has been linked to the protective effect of Treg cells on pregnancy outcome 
(Schumacher et al., 2012). 
Studies of HO-1 deficiency in humans and knockout mice have revealed a protective 
role for HO-1 in inflammation (Rushworth and O'Connell, 2004). Human HO-1 
deficiency leads to severe growth retardation with spontaneous development of a 
chronic inﬂammatory pathology characterized by increased serum IgM and blood 
leukocyte count, accumulation of polymorphonuclear (PMN) cells, monocytes and 
macrophages in the spleen as well as in non-lymphoid tissues and wide-spread 
oxidative tissue injury (Soares et al., 2009; Yachie et al., 1999). Additionally, HO-1 
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knockout mice showed reduced stress defence capacity and were hypersensitive to 
cytotoxicity caused by hemin and hydrogen peroxide (Poss and Tonegawa, 1997). 
Extensive randomized clinical trials have been done using HO-1 inhibitors to control 
serum bilirubin levels in patients with hereditary porphyria (Dover et al., 1991), liver 
disease (Berglund et al., 1990), Crigler-Najjar type I syndrome (Galbraith et al., 
1992), and in newborns with ABO incompatibility where SnPP-IX can, in appropriate 
doses, moderate the postnatal rate of increase of plasma bilirubin levels and 
diminish the intensity of hyperbilirubinemia in treated babies (Kappas et al., 1988) 
or in glucose 6-dehydrogenase deficiency where HO-1 inhibitor administration 
preventively or therapeutically entirely supplanted the need for phototherapy to 
control hyperbilirubinemia (Valaes et al., 1998). 
 
Cytoprotective effect of HO-1 can be attributed to the end product of its activity 
like CO and BV. It will be interesting to test the effect of CO and BV on Nrf2-/- iDC 
phenotype and function. These DCs may show low levels of CO and BV and their 
supplementation with these molecules might result in restore altered DC 
phenotype and function observed in Nrf2-/- iDCs. 
The release of heme from damaged cells and tissues is believed to be higher in 
trauma and haemorrhage or in diseases such as malaria and autoimmune 
haemolytic anaemia. Hence, heme can be involved in the Danger model concept 
which proposes that endogenous molecules from damaged tissues activate the 
immune system and cause inflammation (Mortensen et al., 2008). These danger 
signals would be able to initiate effective immune responses through DC 
maturation and enabling these DCs to activate naive T cells. Furthermore, heme 
catalyzes the formation of ROS, resulting in oxidative stress (Jeney et al., 2002; 
Vercellotti et al., 1994). 
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We demonstrated, upon hemin treatment, the DCs exhibited increased co-
stimulatory molecule expression with enhanced DC-mediated T cell stimulation.  
However, this effect induced by exogenouse hemin administration is potentially 
time-limited as prolonged exposure to heme will ultimately induce HO-1 activity 
and this will have anti-inflammatory effect by subsequently reducing co-stimulatory 
expression as shown in Figure 5.2. 
 
 
 
  
 
 
 
 
 
 
 
Figure 5.2. Regulation of immune response by the heme/HO-1 system. Initially 
free heme induces a pro-inflammatory response followed by induction of HO-1 
leading to anti-inflammatory response attributable to HO-1. (adopted from Soares 
et al 2009) . 
 Observations from this study are based on in vitro approach as DCs are generated 
from mice bone-marrow progenitors. Therefore DCs from an in vivo model may be 
required to exclude the contribution of the ex vivo culturing environment on DC 
biology. However, this approach is not without limitations, with the most important 
one being the difficulty in getting enough DC numbers (both from peripheral blood 
and spleens) for functional studies. 
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Additionally, it would be best to have a DC specific Nrf2 knockout alone without the 
involvement of other cells especially T cells. Pharmacological and gene silencing of 
Nrf2 or HO-1 through siRNA knockdown in DCs may be another approach that 
would reaffirm our findings. 
In summary, we have studied modulation of multiple aspects of DC phenotype and 
function by two important redox regulators, Nrf2 and HO-1. Figure 5.3 summarises 
the key results from our study and includes key findings from other studies. It 
highlights the contribution of intracellular signalling pathways and molecular 
disruption to altered DC phenotype and function in the absence of these redox 
regulators. From these studies we have identified several pathways that could be 
targeted in order to modulate DC function. However further studies are required to 
convert these discoveries into a viable therapeutic reality. 
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Figure 5.3. Schematic summary of thesis results 
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